

REFINITIV

DELTA REPORT

10-Q

UIS - UNISYS CORP

10-Q - JUNE 30, 2024 COMPARED TO 10-Q - MARCH 31, 2024

The following comparison report has been automatically generated

TOTAL DELTAS	1823
--------------	------

 CHANGES	231
---	-----

 DELETIONS	90
---	----

 ADDITIONS	1502
---	------

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549

FORM 10-Q

(Mark One)

☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the quarterly period ended **March 31, 2024** **June 30, 2024**

or

☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the transition period from _____ to _____.

Commission file number 1-8729

UNISYS CORPORATION

(Exact name of registrant as specified in its charter)

Delaware

(State or other jurisdiction of
incorporation or organization)

38-0387840

(I.R.S. Employer
Identification No.)

801 Lakeview Drive, Suite 100
Blue Bell, Pennsylvania 19422
(215) 986-4011

(Address, zip code and telephone number, including area code, of principal executive offices)

Securities registered pursuant to Section 12(b) of the Act:

Title of each class	Trading Symbol(s)	Name of each exchange on which registered
Common Stock, par value \$.01	UIS	New York Stock Exchange

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes ☒ No ☐

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). Yes ☒ No ☐

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of "large accelerated filer," "accelerated filer," "smaller reporting company," and "emerging growth company" in Rule 12b-2 of the Exchange Act.

Large accelerated filer	<input type="checkbox"/>	Accelerated filer	<input checked="" type="checkbox"/>
Non-accelerated filer	<input type="checkbox"/>	Smaller reporting company	<input type="checkbox"/>
		Emerging growth company	<input type="checkbox"/>

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes ☐ No ☒

Number of shares of Unisys Common Stock, par value \$.01, outstanding as of **March 31, 2024** **June 30, 2024**: **69,228,515** **69,335,500**

UNISYS CORPORATION

TABLE OF CONTENTS

	Page Number
Information Concerning Forward-Looking Statements	2
PART I - FINANCIAL INFORMATION	
Item 1. Consolidated Financial Statements (Unaudited)	
Consolidated Statements of Income (Loss)	3
Consolidated Statements of Comprehensive Income (Loss)	4
Consolidated Balance Sheets	5
Consolidated Statements of Cash Flows	6
Consolidated Statements of Equity (Deficit)	7
Notes to Consolidated Financial Statements	8
Item 2. Management's Discussion and Analysis of Financial Condition and Results of Operations	23 24
Item 3. Quantitative and Qualitative Disclosures about Market Risk	27 30
Item 4. Controls and Procedures	27 30
PART II - OTHER INFORMATION	
Item 1. Legal Proceedings	28 31
Item 1A. Risk Factors	28 31
Item 2 Unregistered Sales of Equity Securities and Use of Proceeds and Issuer Purchases of Equity Securities	28 31
Item 5 Other Information	28 31
Item 6. Exhibits	29 31
Exhibit Index	30 32
Signatures	31 33

INFORMATION CONCERNING FORWARD-LOOKING STATEMENTS

Certain statements contained in this report, including, without limitation, statements as to management expectations, assumptions and beliefs presented in Part I, Item 2. "Management's Discussion and Analysis of Financial Condition and Results of Operations," Part I, Item 3. "Quantitative and Qualitative Disclosures About Market Risk," Part II, Item 1. "Legal Proceedings" and in the notes to the financial statements are forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, Section 21E of the Exchange Act of 1934, as amended, and the Private Securities Litigation Reform Act of 1995. Words such as "anticipates," "estimates," "expects," "projects," "may," "will," "intends," "plans," "believes," "should" and similar expressions may identify forward-looking statements and such forward-looking statements are made based upon management's current expectations, assumptions and beliefs as of this date concerning future developments and their potential effect on us. There can be no assurance that future developments will be in accordance with management's expectations, assumptions or beliefs, or that the effect of future developments on us will be those anticipated by management. Because actual results may differ materially from those expressed or implied by these forward-looking statements, we caution readers not to place undue reliance on these statements. Any forward-looking statement speaks only as of the date on which that statement is made. The company assumes no obligation to update any forward-looking statement to reflect events or circumstances that occur after the date on which the statement is made.

The factors that could cause actual results to differ materially from our expectations, assumptions and beliefs include, but are not limited to, those discussed in Item 1A. Risk Factors of our Annual Report on Form 10-K for the fiscal year ended December 31, 2023, as summarized below:

Business and Operating

- cyber incidents, security breaches and other disruptions in our IT systems;
- our ability to maintain our installed base and sell new solutions and related services;
- our ability to grow revenue, expand margin and generate sufficient cash flows in our businesses;
- the adverse effects of volatile, negative or uncertain economic and political conditions as well as acts of war, terrorism, natural disasters or the widespread outbreak of infectious diseases;
- our ability to effectively anticipate and respond to rapid technological innovation, such as artificial intelligence among others, in our industry;
- our ability to work with government and public sector clients and additional risks inherent in government and public sector contracting;
- our ability to maintain our credit rating or access financing markets;
- our ability to align employees and their skills with client demand and retain and develop employees and management with strong leadership skills;
- our ability to meet our underfunded defined benefit pension plan obligations;
- the potential adverse effects of aggressive competition;
- the performance and capabilities of third parties with whom we have commercial relationships;
- our contracts may not be as profitable as expected or provide the expected level of revenue;
- our ability to protect or enforce our intellectual property rights and defend against infringement claims;
- the business and financial risk in the completion of acquisitions or dispositions;

Legal and Regulatory

- our inability to comply with global legal and regulatory requirements;
- our failure to maintain an effective system of internal controls over financial reporting and disclosure controls and procedures;
- our exposure to legal proceedings, investigations and environmental matters;
- our failure to meet Environmental, Social and Governance (ESG) expectations and standards, achieve our ESG goals, or comply with ESG regulations or laws;

Accounting

- our ability to use our net operating loss carryforwards and certain other tax attributes may be limited; and
- a potential impairment of goodwill or intangible assets.

Other factors discussed in this report, although not listed here, also could materially affect our future results.

Part I - FINANCIAL INFORMATION

Item 1. Financial Statements

UNISYS CORPORATION
CONSOLIDATED STATEMENTS OF INCOME (LOSS) (Unaudited)
(Millions, except per share data)

	Three Months Ended March 31,		Three Months Ended June 30,		Six Months Ended June 30,	
	2024	2023	2024	2023	2024	2023
Revenue						
Services						
Services						
Services						
Technology						
	487.8				478.2	
Costs and expenses						
Cost of revenue						
Cost of revenue						
Cost of revenue						
Services						
Services						
Services						
Technology						
	351.8				348.3	
Selling, general and administrative						
Research and development						
	470.1				454.6	
Operating income						

Postretirement adjustments, net of tax of \$2.8 in 2024 and \$(3.0) in 2023
Total other comprehensive income
Postretirement adjustments, net of tax of \$1.1 and \$3.9 in 2024 and \$(4.4) and \$(7.4) in 2023
Total other comprehensive (loss) income
Comprehensive (loss) income
Less comprehensive income attributable to noncontrolling interests
Less comprehensive (loss) income attributable to noncontrolling interests
Comprehensive (loss) income attributable to Unisys Corporation

See notes to consolidated financial statements

4

UNISYS CORPORATION
CONSOLIDATED BALANCE SHEETS (Unaudited)
(Millions)

	March 31, 2024	December 31, 2023
	June 30, 2024	December 31, 2023
Assets		
Current assets:		
Current assets:		
Current assets:		
Cash and cash equivalents		
Cash and cash equivalents		
Cash and cash equivalents		
Accounts receivable, net		
Contract assets		
Inventories		
Prepaid expenses and other current assets		
Total current assets		
Properties		
Less-accumulated depreciation and amortization		
Properties, net		
Outsourcing assets, net		
Marketable software, net		
Operating lease right-of-use assets		
Prepaid postretirement assets		
Deferred income taxes		

Goodwill		
Intangible assets, net		
Restricted cash		
Assets held-for-sale		
Other long-term assets		
Total assets		
Total liabilities and deficit		
Current liabilities:		
Current liabilities:		
Current liabilities:		
Current maturities of long-term debt		
Current maturities of long-term debt		
Current maturities of long-term debt		
Accounts payable		
Deferred revenue		
Other accrued liabilities		
Total current liabilities		
Total current liabilities		
Total current liabilities		
Long-term debt		
Long-term postretirement liabilities		
Long-term deferred revenue		
Long-term operating lease liabilities		
Other long-term liabilities		
Commitments and contingencies (see Note 14)	Commitments and contingencies (see Note 14)	Commitments and contingencies (see Note 14)
Deficit:		
Common stock, shares issued: 2024; 75.1, 2023; 74.0		
Common stock, shares issued: 2024; 75.1, 2023; 74.0		
Common stock, shares issued: 2024; 75.1, 2023; 74.0		
Common stock, shares issued: 2024; 75.3, 2023; 74.0		
Common stock, shares issued: 2024; 75.3, 2023; 74.0		
Common stock, shares issued: 2024; 75.3, 2023; 74.0		
Accumulated deficit		
Treasury stock, shares at cost: 2024; 5.9, 2023; 5.6		
Treasury stock, shares at cost: 2024; 6.0, 2023; 5.6		
Paid-in capital		
Accumulated other comprehensive loss		
Total Unisys Corporation stockholders' deficit		
Noncontrolling interests		
Total deficit		
Total liabilities and deficit		

UNISYS CORPORATION
CONSOLIDATED STATEMENTS OF CASH FLOWS (Unaudited)
(Millions)

	Three Months Ended March 31,		Six Months Ended June 30,	
	2024	2023	2024	2023
Cash flows from operating activities				
Consolidated net loss				
Consolidated net loss				
Consolidated net loss				
Adjustments to reconcile consolidated net loss to net cash provided by operating activities:				
Adjustments to reconcile consolidated net loss to net cash provided by operating activities:				
Adjustments to reconcile consolidated net loss to net cash provided by operating activities:				
Foreign currency losses (gains)				
Foreign currency losses (gains)				
Foreign currency losses (gains)				
Non-cash interest expense				
Employee stock compensation				
Depreciation and amortization of properties				
Depreciation and amortization of outsourcing assets				
Amortization of marketable software				
Amortization of intangible assets				
Other non-cash operating activities				
Loss on disposal of capital assets				
Pension and postretirement contributions				
Pension and postretirement contributions				
Pension and postretirement contributions				
Postretirement expense				
Pension and postretirement expense				
Deferred income taxes, net				
Changes in operating assets and liabilities, excluding the effect of acquisitions:				
Receivables, net and contract assets				
Receivables, net and contract assets				
Receivables, net and contract assets				
Inventories				
Other assets				

Accounts payable and current liabilities
Other liabilities
Net cash provided by operating activities
Cash flows from investing activities
Proceeds from foreign exchange forward contracts
Proceeds from foreign exchange forward contracts
Proceeds from foreign exchange forward contracts
Purchases of foreign exchange forward contracts
Investment in marketable software
Capital additions of properties
Capital additions of outsourcing assets
Other
Other
Other
Net cash used for investing activities
Cash flows from financing activities
Payments of long-term debt
Payments of long-term debt
Payments of long-term debt
Other
Other
Other
Net cash used for financing activities
Effect of exchange rate changes on cash, cash equivalents and restricted cash
Decrease in cash, cash equivalents and restricted cash
(Decrease) increase in cash, cash equivalents and restricted cash
Cash, cash equivalents and restricted cash, beginning of period
Cash, cash equivalents and restricted cash, end of period

See notes to consolidated financial statements

UNISYS CORPORATION

CONSOLIDATED STATEMENTS OF EQUITY (DEFICIT) (Unaudited)

(Millions)

<div></div>	Unisys Corporation	<div></div>	<div></div>	Unisys Corporation	<div></div>
-------------	--------------------	-------------	-------------	--------------------	-------------

	Total	Total	Total Unisys Corporation	Common Stock Par Value	Accumu- lated Deficit	Treasury Stock At Cost	Paid-in Capital	Accumu- lated Other Compre- hensive Loss	Non- controlling Interests	Total	Total Unisys Corporation	Common Stock Par Value	Accumu- lated Deficit	Treasury Stock At Cost	Paid-in Capital	Accumu- lated Other Compre- hensive Loss	Non- controlling Interests
Balance at December 31, 2022																	
Consolidated net (loss) income																	
Stock-based activity																	
Stock-based activity																	
Stock-based activity																	
Translation adjustments																	
Translation adjustments																	
Translation adjustments																	
Postretirement plans																	
Balance at March 31, 2023																	
Consolidated net (loss) income																	
Stock-based activity																	
Translation adjustments																	
Translation adjustments																	
Translation adjustments																	
Postretirement plans																	
Balance at June 30, 2023																	

UNISYS CORPORATION**NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Unaudited)****(Dollars in millions, except share and per share amounts)****Note 1 - Basis of Presentation**

The unaudited consolidated financial statements included in this Quarterly Report on Form 10-Q have been prepared pursuant to the rules and regulations of the U.S. Securities and Exchange Commission (the SEC) (SEC). These rules and regulations permit some of the information and footnote disclosures normally included in financial statements, prepared in accordance with generally accepted accounting principles in the United States of America (GAAP), to be condensed or omitted. In management's opinion, the unaudited consolidated financial statements contain all adjustments that are of a normal recurring nature, necessary for a fair presentation of the results of operations and financial position of the company for the interim periods presented. These adjustments consist only of normal recurring accruals except as disclosed herein. Because of seasonal and other factors, results for interim periods are not necessarily indicative of the results to be expected for the full year.

These unaudited consolidated financial statements should be read in conjunction with the audited consolidated financial statements for the fiscal year ended December 31, 2023 and the notes thereto included in the company's Annual Report on Form 10-K, filed with the SEC.

Use of Estimates

The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions about future events. These estimates and assumptions affect the amounts of assets and liabilities reported, disclosures about contingent assets and liabilities and the reported amounts of revenue and expenses. Such estimates include the valuation of estimated credit losses, contract assets, operating lease right-of-use assets, outsourcing assets, marketable software, goodwill, purchased intangibles and other long-lived assets, legal and environmental contingencies, assumptions used in the calculation for systems integration projects, income taxes and retirement and other post-employment benefits, among others. These estimates and assumptions are based on management's best estimates and judgment. Management evaluates its estimates and assumptions on an ongoing basis using historical experience and other factors, including the current economic environment, which management believes to be reasonable under the circumstances. Management adjusts such estimates and assumptions when facts and circumstances dictate. As future events and their effects cannot be determined with precision, actual results could differ materially from these estimates. Changes in those estimates resulting from continuing changes in the economic environment such as rising interest rates, inflation, fluctuation in foreign exchange rates and conflicts and other events of geopolitical significance, will be reflected in the financial statements in future periods.

The company's accounting policies are set forth in detail in Note 1 of the Notes to Consolidated Financial Statements in the company's Annual Report on Form 10-K for the year ended December 31, 2023 filed with the SEC. Such Annual Report also contains a discussion of the company's critical accounting policies and estimates. The company believes that these critical accounting policies and estimates affect its more significant estimates and judgments used in the preparation of the company's consolidated financial statements.

Note 2 - Accounting Standards

In November 2023, the Financial Accounting Standards Board (FASB) issued Accounting Standards Update (ASU) No. 2023-07, *Segment Reporting (Topic 280) - Improvements to Reportable Segment Disclosures*, which enhances reportable segment disclosure requirements including disclosures about significant segment expenses on an annual and interim basis. This update is effective for fiscal years beginning after December 15, 2023, and for interim periods within fiscal years beginning after December 15, 2024, with early adoption permitted and requires application on a retrospective basis. This ASU is not expected to have a material effect on the company's consolidated financial statements.

In December 2023, the FASB issued ASU No. 2023-09, *Income Taxes (Topic 740) - Improvements to Income Tax Disclosures*. This ASU enhances disclosures relating to the rate reconciliation and requires income taxes paid disclosures disaggregated by jurisdiction among other amendments. This update is effective for annual periods beginning after December 15, 2024, with early adoption permitted and should be applied a prospective

basis with a retrospective application permitted. This ASU is not expected to have a material effect on the company's consolidated financial statements.

8

Note 3 - Cost-Reduction Actions

The company from time to time initiates cost reduction actions designed to improve operating efficiency, reduce costs and align the company's workforce and facility structures to its overall business plan.

8

During the three months ended March 31, 2024 June 30, 2024, the company recognized net cost-reduction charges and other costs of \$6.3 million \$0.6 million. The net credit related to workforce reductions was \$0.7 million, principally related to severance costs, and was comprised of: (a) a credit of \$1.0 million for changes in estimates and (b) a charge of \$0.3 million. The company recorded charges of \$1.3 million comprised of \$1.2 million for net foreign currency losses related to exiting foreign countries and \$0.1 million for other expenses related to cost reduction efforts.

During the three months ended June 30, 2023, the company recognized net cost-reduction charges and other costs of \$3.5 million. The net charges related to workforce reductions were \$6.6 million \$2.1 million, principally related to severance costs, and were comprised of: (a) a charge of \$9.4 million \$3.9 million and (b) a credit of \$2.8 million \$1.8 million for changes in estimates. The In addition, the company recorded a net credit charges of \$0.3 million \$1.4 million comprised of a net credit of \$0.8 million \$1.3 million for changes in estimates professional fees and other expenses related to other cost-reduction efforts and a charge of \$0.5 million \$0.1 million for net foreign currency losses related to exiting foreign countries.

During the three six months ended March 31, 2023 June 30, 2024, the company recognized net cost-reduction charges and other costs of \$6.9 million. The net charges related to workforce reductions of \$0.7 million. These net charges were \$5.9 million, principally related to severance costs, and were comprised of: (a) a charge of \$2.6 million \$9.7 million and (b) a credit of \$1.9 million \$3.8 million for changes in estimates. The company recorded a net charge of \$1.0 million comprised of a charge of \$1.7 million for net foreign currency losses related to exiting foreign countries and a net credit of \$0.7 million for changes in estimates related to other cost-reduction efforts.

During the six months ended June 30, 2023, the company recognized net cost-reduction charges and other costs of \$0.7 million. The net charges related to workforce reductions were \$2.8 million, principally related to severance costs, and were comprised of: (a) a charge of \$6.5 million and (b) a credit of \$3.7 million for changes in estimates. In addition, the company recorded a net credit of \$3.5 million \$2.1 million comprised of a credit of \$3.4 million for net foreign currency gains related to exiting foreign countries.

countries and a charge of \$1.3 million for professional fees and other expenses related to cost-reduction efforts.

The charges (credits) were recorded in the following statement of income (loss) classifications:

	Three Months Ended March 31,				Three Months Ended June 30, Six Months Ended June 30,							
	Three Months Ended March 31,											
	Three Months Ended March 31,											
	Three Months Ended March 31,											
	2024				2024				2023			
Cost of revenue												
Selling, general and administrative												

Research and development
Other (expense), net
Total

Liabilities and expected future payments related to the company's work-force reduction actions are as follows:

	Total	Total	U.S.	International	Total	U.S.	International
Balance at December 31, 2023							
Additional provisions							
Payments							
Changes in estimates							
Translation adjustments							
Balance at March 31, 2024							
Expected future utilization on balance at March 31, 2024:							
Balance at June 30, 2024							
Expected future utilization on balance at June 30, 2024:							
Short-term							
Short-term							
Short-term							

Note 4 - Pension and Postretirement Benefits

Net periodic pension expense (income) is presented below:

	Three Months Ended March 31, 2024			Three Months Ended March 31, 2023			Three Months Ended June 30, 2024			Three Months Ended June 30, 2023		
	Total	U.S. Plans	International Plans	Total	U.S. Plans	International Plans	Total	U.S. Plans	International Plans	Total	U.S. Plans	International Plans
Service cost ⁽ⁱ⁾												
Interest cost												
Expected return on plan assets												
Amortization of prior service benefit												
Recognized net actuarial loss												
Settlement losses ⁽ⁱⁱ⁾ ⁽ⁱⁱⁱ⁾												
Net periodic pension expense (income)												
Net periodic pension expense (income)												
Net periodic pension expense (income)												

	Six Months Ended June 30, 2024			Six Months Ended June 30, 2023		
	Total	U.S.	International	Total	U.S.	International
		Plans	Plans		Plans	Plans
Service cost ⁽ⁱ⁾	\$ 0.6	\$ —	\$ 0.6	\$ 0.6	\$ —	\$ 0.6
Interest cost	92.9	59.3	33.6	112.2	76.3	35.9
Expected return on plan assets	(108.2)	(64.6)	(43.6)	(131.4)	(89.3)	(42.1)
Amortization of prior service benefit	(2.3)	(1.2)	(1.1)	(2.4)	(1.2)	(1.2)
Recognized net actuarial loss	44.0	33.6	10.4	42.2	37.8	4.4
Settlement losses ⁽ⁱⁱ⁾ ⁽ⁱⁱⁱ⁾	132.3	132.3	—	183.2	183.2	—
Net periodic pension expense (income)	<u>\$ 159.3</u>	<u>\$ 159.4</u>	<u>\$ (0.1)</u>	<u>\$ 204.4</u>	<u>\$ 206.8</u>	<u>\$ (2.4)</u>

⁽ⁱ⁾ Service cost is reported in selling, general and administrative expense. All other components of net periodic pension expense (income) are reported in other (expense), net in the consolidated statements of income (loss).

⁽ⁱⁱ⁾ In March 2024, the company purchased a group annuity contract, with plan assets, for approximately \$195 million to transfer projected benefit obligations related to approximately 3,800 retirees of one of the company's U.S. defined benefit pension plans. This action resulted in a pre-tax settlement loss of \$132.3 million for the **three** **six** months ended **March 31, 2024** **June 30, 2024**.

⁽ⁱⁱⁱ⁾ In March 2023, the company purchased a group annuity contract, with plan assets, for approximately \$265 million to transfer projected benefit obligations related to approximately 8,650 retirees of one of the company's U.S. defined benefit pension plans. This action resulted in a pre-tax settlement loss of \$183.2 million for the **three** **six** months ended **March 31, 2023** **June 30, 2023**.

In 2024, the company expects to make cash contributions of approximately \$20 million primarily for its international defined benefit pension plans. In 2023, the company made cash contributions of \$42.4 million to its worldwide defined benefit pension plans. During the **three** **six** months ended **March 31, 2024** **June 30, 2024** and 2023, the company made cash contributions of **\$6.4 million** **\$10.3 million** and **\$14.5 million** **\$28.4 million**, respectively.

At the end of each year, the company estimates its future cash contributions to its U.S. qualified defined benefit pension plans based on year-end pension data and assumptions. Any material deterioration in the value of the company's U.S. qualified defined benefit pension plan assets, as well as changes in pension legislation, volatility in the capital markets, discount rate changes, asset return changes, or changes in economic or demographic trends, could require the company to make cash contributions to its U.S. defined benefit pension plans in different amounts and on a different schedule than previously contemplated.

10

Net periodic postretirement benefit income is presented below:

	Three Months Ended March 31,		Three Months Ended June 30,		Six Months Ended June 30,	
	2024	2023	2024	2023	2024	2023
Service cost ⁽ⁱ⁾						
Interest cost						
Expected return on assets						
Recognized net actuarial gain						
Amortization of prior service benefit						

Net periodic postretirement benefit income

ⓐ Service cost is reported in selling, general and administrative expense. All other components of net periodic postretirement benefit expense (income) are reported in other (expense), net in the consolidated statements of income (loss).

The company expects to make cash contributions of \$4.0 million to its postretirement benefit plan in 2024. In 2023, the company made cash contributions of \$5.6 million to its postretirement benefit plan. For the **three** **six** months ended **March 31, 2024** **June 30, 2024** and 2023, the company made cash contributions of **\$1.3 million** **\$2.1 million** and **\$1.9 million** **\$2.7 million**, respectively.

Note 5 - Stock Compensation

Under stockholder approved stock-based plans, stock options, stock appreciation rights, restricted stock and restricted stock units may be granted to officers, directors and other key employees.

10

As of **March 31, 2024** **June 30, 2024**, the company has granted restricted stock and restricted stock units under these plans. The company recognizes compensation cost, net of a forfeiture rate, in selling, general and administrative expense, and recognizes compensation cost only for those awards expected to vest. The company estimates the forfeiture rate based on its historical experience and its expectations about future forfeitures.

During the **three** **six** months ended **March 31, 2024** **June 30, 2024** and 2023, the company recorded **\$6.7 million** **\$11.4 million** and **\$4.7 million** **\$8.9 million** of share-based restricted stock and restricted stock unit compensation expense, respectively.

Restricted stock and restricted stock unit awards may contain time-based units, performance-based units, total shareholder return market-based units, or a combination of these units. Each performance-based and market-based unit will vest into zero to two shares depending on the degree to which the performance or market conditions are met. Compensation expense for performance-based awards is recognized as expense ratably for each installment from the date of grant until the date the restrictions lapse and is based on the fair market value at the date of grant and the probability of achievement of the specific performance-related goals. Compensation expense for market-related awards is recognized as expense ratably over the measurement period, regardless of the actual level of achievement, provided the service requirement is met. Restricted stock unit grants for the company's directors vest upon award and compensation expense for such awards is recognized upon grant.

A summary of restricted stock and restricted stock unit (RSU) activity for the **three** **six** months ended **March 31, 2024** **June 30, 2024** follows (shares in thousands):

	Restricted Stock and RSU	Restricted Stock and RSU	Weighted- Average Grant-Date Fair Value	Restricted Stock and RSU	Weighted- Average Grant-Date Fair Value
Outstanding at December 31, 2023					
Granted					
Vested					
Forfeited and expired					
Outstanding at March 31, 2024					
Outstanding at June 30, 2024					

11

The aggregate weighted-average grant-date fair value of restricted stock and restricted stock units granted during the **three** **six** months ended **March 31, 2024** **June 30, 2024** and 2023 was **\$18.6 million** **\$19.3 million** and **\$13.8 million** **\$16.7 million**, respectively. The fair value of restricted stock and restricted stock units with time and performance conditions was determined based on the trading price of the company's common shares on the date of grant. The fair value of awards with market conditions was estimated using a Monte Carlo simulation with the following weighted-average assumptions:

		Three Months Ended March 31,			Six Months Ended June 30,		
		2024	2024		2023	2024	2023
Weighted-average fair value of grant							
Risk-free interest rate ⁽ⁱ⁾	Risk-free interest rate ⁽ⁱ⁾	4.46 %	4.51 %	Risk-free interest rate ⁽ⁱ⁾	4.46 %	4.51 %	
Expected volatility ⁽ⁱⁱ⁾	Expected volatility ⁽ⁱⁱ⁾	76.28 %	63.63 %	Expected volatility ⁽ⁱⁱ⁾	76.28 %	63.63 %	
Expected life of restricted stock units in years ⁽ⁱⁱⁱ⁾	Expected life of restricted stock units in years ⁽ⁱⁱⁱ⁾	2.85	2.84	Expected life of restricted stock units in years ⁽ⁱⁱⁱ⁾	2.85	2.84	
Expected dividend yield	Expected dividend yield	— %	— %	Expected dividend yield	— %	— %	

⁽ⁱ⁾ Represents the continuously compounded semi-annual zero-coupon U.S. treasury rate commensurate with the remaining performance period.

⁽ⁱⁱ⁾ Based on historical volatility for the company that is commensurate with the length of the performance period.

⁽ⁱⁱⁱ⁾ Represents the remaining life of the longest performance period.

As of **March 31, 2024** **June 30, 2024**, there was **\$29.9 million** **\$24.8 million** of total unrecognized compensation cost related to outstanding restricted stock and restricted stock units granted under the company's plans. That cost is expected to be recognized over a weighted-average period of **2.0** **1.9** years. The aggregate weighted-average grant-date fair value of restricted stock and restricted stock units vested during the **three** **six** months ended **March 31, 2024** **June 30, 2024** and 2023 was **\$9.6 million** **\$12.8 million** and **\$6.6 million** **\$7.2 million**, respectively.

Common stock issued upon the lapse of restrictions on restricted stock and restricted stock units are newly issued shares. In light of its tax position, the company is currently not recognizing any tax benefits from the issuance of stock upon lapse of restrictions on restricted stock and restricted stock units.

11

Note 6 - Other (expense), net

Other (expense), net is comprised of the following:

		Three Months Ended March 31,		Three Months Ended March 31,		Three Months Ended March 31,		Three Months Ended June 30,		Six Months Ended June 30,			
	2024	2024	2023	2024	2023	2024	2023	2024	2023	2024	2023	2024	2023
Postretirement expense ⁽ⁱ⁾													
Foreign exchange (losses) gains ⁽ⁱⁱ⁾													

Foreign exchange (losses) gains⁽ⁱⁱ⁾
Foreign exchange (losses) gains⁽ⁱⁱ⁾
Other, net⁽ⁱⁱⁱ⁾
Other, net⁽ⁱⁱⁱ⁾
Other, net⁽ⁱⁱⁱ⁾
Total other (expense), net

⁽ⁱ⁾ Includes \$132.3 million and \$183.2 million of U.S pension settlement losses in the threeSix months ended March 31, 2024 June 30, 2024 and 2023, respectively. See Note 4.

⁽ⁱⁱ⁾ Includes net foreign exchange losses of \$0.5 million \$1.2 million and net foreign currency gains of \$3.5 million \$0.1 million, respectively, in the three months ended March 31, 2024 June 30, 2024 and 2023, related to substantial completion of liquidation of foreign subsidiaries. Includes net foreign currency losses of \$1.7 million and net foreign currency gains of \$3.4 million, respectively, in the six months ended June 30, 2024 and 2023, related to substantial completion of liquidation of foreign subsidiaries.

⁽ⁱⁱⁱ⁾ Other, net in the threeSix months ended March 31, 2024 June 30, 2024 includes a net gain of approximately \$14.9 million related to a favorable judgment received in a Brazilian services tax matter. Additionally, other, net includes environmental costs related to previously disposed businesses.

Note 7 - Income Taxes

Accounting rules governing income taxes require that deferred tax assets and liabilities be recognized using enacted tax rates for the effect of temporary differences between the book and tax bases of recorded assets and liabilities. These rules also require that deferred tax assets be reduced by a valuation allowance if it is more likely than not that some portion or the entire deferred tax asset will not be realized.

The company evaluates the realizability of its deferred tax assets by assessing its valuation allowance and by adjusting such amount, if necessary. The realization of the company's net deferred tax assets as of March 31, 2024 June 30, 2024, is primarily dependent on the ability to generate sustained taxable income in various jurisdictions. Judgment is required to estimate forecasted future taxable income, which may be impacted by future business developments, actual results, strategic operational and tax initiatives, legislative, and other economic factors and developments. Any increase or decrease in the valuation allowance would result in additional or lower income tax expense in that period and could have a significant impact on that period's earnings.

A full valuation allowance is currently maintained for all U.S. and certain foreign deferred tax assets in excess of deferred tax liabilities. The company will record a tax provision or benefit for those international subsidiaries that do not have a full valuation allowance against their net deferred tax assets. Any profit or loss recorded for the company's U.S. operations will have no provision or benefit associated with it due to such valuation allowance, except with respect to withholding taxes not creditable against future taxable income. As a result, the company's provision or benefit for taxes may vary significantly depending on the geographic distribution of income.

A corporation's ability to deduct its federal net operating loss (NOL) carryforwards and utilize certain other available tax attributes can be substantially constrained under the general annual limitation rules of Section 382 of the U.S. Internal Revenue Code (Section 382) if it undergoes an "ownership change" as defined in Section 382 (generally where cumulative stock ownership changes among material shareholders exceed 50 percent during a rolling three-year period). Similar rules may apply under state tax laws. A future tax "ownership change" pursuant to Section 382 or future changes in tax laws that impose tax attribute utilization limitations may severely limit or effectively eliminate the company's ability to utilize its NOL carryforwards and other tax attributes.

Note 8 - Loss Per Share

The following table shows how loss per share attributable to Unisys Corporation was computed (shares in thousands):

	Three Months Ended March 31,		Three Months Ended June 30,		Six Months Ended June 30,	
	2024	2023	2024	2023	2024	2023

Basic loss per common share computation:

Net loss attributable to Unisys Corporation

Net loss attributable to Unisys Corporation

Net loss attributable to Unisys Corporation

Weighted average shares

Basic loss per common share

Basic loss per common share

Basic loss per common share

Diluted loss per common share computation:

Diluted loss per common share computation:

Diluted loss per common share computation:

Net loss attributable to Unisys Corporation

Net loss attributable to Unisys Corporation

Net loss attributable to Unisys Corporation

Weighted average shares

Weighted average shares

Weighted average shares

Plus incremental shares from assumed vesting of employee stock plans

Plus incremental shares from assumed vesting of employee stock plans

Plus incremental shares from assumed vesting of employee stock plans

Adjusted weighted average shares

Adjusted weighted average shares

Adjusted weighted average shares

Diluted loss per common share

Diluted loss per common share

Diluted loss per common share

Anti-dilutive restricted stock units⁽¹⁾

Anti-dilutive restricted stock units⁽¹⁾

Anti-dilutive restricted stock units⁽¹⁾

⁽¹⁾ Amounts represent shares excluded from the computation of diluted loss per share, as their effect, if included, would have been anti-dilutive for the periods presented.

Note 9 - Contract Assets and Deferred Revenue

Contract assets represent rights to consideration in exchange for goods or services transferred to a customer when that right is conditional on something other than the passage of time. Deferred revenue represents contract liabilities.

Net contract assets (liabilities) are as follows:

	March 31, 2024	December 31, 2023
	June 30, 2024	December 31, 2023
Contract assets - current		
Contract assets - long-term ⁽ⁱ⁾		
Deferred revenue - current		
Deferred revenue - long-term		

⁽ⁱ⁾ Reported in other long-term assets on the company's consolidated balance sheets.

Significant changes in the above contract liability balances were as follows:

	Three Months Ended March 31,						
	Three Months Ended March 31,						
	Three Months Ended March 31,						
	Three Months Ended June 30,	Six Months Ended June 30,					
	2024	2024	2023	2024	2023	2024	2023
Revenue recognized that was included in deferred revenue at the beginning of the period							

Note 10 - Capitalized Contract Costs

The company's incremental direct costs of obtaining a contract consist of sales commissions, which are deferred and amortized ratably over the initial contract life. These costs are classified as current or noncurrent based on the timing of when the company expects to recognize the expense. The current and noncurrent portions of deferred commissions are included in prepaid expenses, other current assets and in other long-term assets, respectively, in the company's consolidated balance sheets. At March 31, 2024 June 30, 2024 and December 31, 2023, the company had \$1.8 million \$1.7 million and \$3.7 million, respectively, of deferred commissions.

Amortization expense related to deferred commissions was as follows:

Three Months Ended March 31,

	Three Months Ended March 31,		Three Months Ended March 31,		Three Months Ended June 30,		Six Months Ended June 30,			
	2024		2024		2023		2024	2023	2024	2023

Deferred commissions - amortization expense⁽ⁱ⁾

⁽ⁱ⁾ Reported in selling, general and administrative expense in the company's consolidated statements of income (loss).

Costs on outsourcing contracts are generally expensed as incurred. However, certain costs incurred upon initiation of an outsourcing contract (costs to fulfill a contract), principally initial customer setup, are capitalized and expensed over the initial contract life. These costs are included in outsourcing assets, net in the company's consolidated balance sheets. The amount of such costs at **March 31, 2024**, **June 30, 2024** and December 31, 2023, was **\$15.4 million**, **\$13.1 million** and \$19.2 million, respectively. These costs are amortized over the initial contract life and reported in cost of revenue.

Amortization expense related to costs to fulfill a contract was as follows:

	Three Months Ended March 31,		Three Months Ended March 31,		Three Months Ended March 31,		Three Months Ended June 30,		Six Months Ended June 30,			
	2024		2024		2023		2024	2023	2024	2023	2024	2023

Costs to fulfill a contract - amortization expense

The remaining balance of outsourcing assets, net is comprised of fixed assets and software used in connection with outsourcing contracts. These costs are capitalized and depreciated over the shorter of the initial contract life or in accordance with the company's fixed asset policy.

14

Note 11 - Financial Instruments and Fair Value Measurements

Due to its foreign operations, the company is exposed to the effects of foreign currency exchange rate fluctuations on the U.S. dollar, principally related to intercompany account balances. The company uses derivative financial instruments to reduce its exposure to market risks from changes in foreign currency exchange rates on such balances. The company enters into foreign exchange forward contracts, generally having maturities of three months or less, which have not been designated as hedging instruments. At **March 31, 2024**, **June 30, 2024** and December 31, 2023, the notional amount of these contracts was **\$493.4 million**, **\$509.4 million** and \$488.4 million, respectively. The fair value of these forward contracts is based on quoted prices for similar but not identical financial instruments; as such, the inputs are considered Level 2 inputs.

The following table summarizes the fair value of the company's foreign exchange forward contracts.

Balance Sheet Location	March 31, 2024	December 31, 2023

Prepaid expenses and other current assets	\$	0.1	\$	9.0
Other accrued liabilities		4.2		0.1
Total fair value	\$	(4.1)	\$	8.9

14

	June 30, 2024	December 31, 2023
Balance Sheet Location		
Prepaid expenses and other current assets	\$ 1.3	\$ 9.0
Other accrued liabilities	3.8	0.1
Total fair value	\$ (2.5)	\$ 8.9

The following table summarizes the location and amount of gains (losses) recognized on foreign exchange forward contracts.

	Three Months Ended March 31,	Three Months Ended March 31,	Three Months Ended March 31,	Three Months Ended June 30,	Six Months Ended June 30,				
	2024		2024		2023	2024	2023	2024	2023

Statement of Income Location

Other (expense), net
Other (expense), net
Other (expense), net

Financial assets with carrying values approximating fair value include cash and cash equivalents and accounts receivable. Financial liabilities with carrying values approximating fair value include accounts payable and other liabilities. The carrying amounts of these financial assets and liabilities approximate fair value due to their short maturities. Such financial instruments are not included in the following table that provides information about the estimated fair values of other financial instruments that are not measured at fair value in the consolidated balance sheets as of **March 31, 2024** **June 30, 2024** and December 31, 2023.

March 31, 2024				December 31, 2023					
June 30, 2024				December 31, 2023					
Carrying Amount	Carrying Amount	Fair Value	Carrying Amount	Fair Value	Carrying Amount	Fair Value	Carrying Amount	Fair Value	

Long-term debt:

6.875% senior secured notes due
November 1, 2027
6.875% senior secured notes due
November 1, 2027

6.875% senior secured notes due
November 1, 2027

Long-term debt is carried at amortized cost and its estimated fair value is based on market prices classified as Level 2 in the fair value hierarchy.

Note 12 - Goodwill and Intangible Assets

Goodwill

Changes in the carrying value of goodwill by reporting unit were as follows:

	Total	Total	DWS	CA&I	ECS	Other	Total	DWS	CA&I	ECS	Other
Balance at December 31, 2023											
Translation adjustments											
Translation adjustments											
Translation adjustments											
Balance at March 31, 2024											
Balance at June 30, 2024											

At **March 31, 2024** **June 30, 2024**, the amount of goodwill allocated to reporting units with negative net assets within Other was \$10.3 million.

The company reviews goodwill for impairment annually, as well as whenever there are events or changes in circumstances (triggering events), which indicate that the carrying amount may not be recoverable. Based on the annual impairment analysis

15

performed during the fourth quarter of 2023, the reporting units that were closest to impairment were the Cloud, Applications & Infrastructure Solutions (CA&I) and Digital Workplace Solutions (DWS) reporting units with fair value in excess of book value, including goodwill, of 10% and 16%, respectively. All other reporting units had a fair value substantially in excess of book value.

The company continuously monitors its revenue, gross profit and operating profit growth and evaluates other relevant events and circumstances including changes to U.S. treasury rates and equity risk premiums, tax rates, recent market valuations from transactions by comparable companies, volatility in the company's market capitalization, and general industry, market and macro-economic conditions, that could unfavorably impact the recoverability of the goodwill carrying value. As of June 30, 2024, the company believes that there are no indicators of goodwill impairment as no triggering events were identified during the three and six months ended June 30, 2024. It is possible that future changes in such circumstances or in the inputs and assumptions used in estimating the fair value of the reporting units could require the company to record a non-cash impairment charge.

Intangible Assets, Net

Intangible assets, net at **March 31, 2024** **June 30, 2024**, consists of the following:

	Gross Carrying Amount	Gross Carrying Amount	Accumulated Amortization	Net Carrying Amount	Gross Carrying Amount	Accumulated Amortization	Net Carrying Amount
Technology ⁽ⁱ⁾							
Customer relationships ⁽ⁱⁱ⁾							
Marketing ⁽ⁱⁱ⁾							
Total							

⁽ⁱ⁾ Amortization expense is included within cost of revenue - technology in the consolidated statements of income (loss).

⁽ⁱⁱ⁾ Amortization expense is included within selling, general and administrative expense in the consolidated statements of income (loss).

For the three months ended **March 31, 2024** **June 30, 2024** and 2023, amortization expense was **\$2.4 million** **\$2.2 million** and **\$2.5 million** **\$2.4 million**, respectively.

15

For the six months ended **June 30, 2024** and 2023, amortization expense was **\$4.6 million** and **\$4.9 million**, respectively.

The future amortization relating to acquired intangible assets at **March 31, 2024** **June 30, 2024**, was estimated as follows:

Future Amortization Expense	
Remainder of 2024	
2025	
2026	
2027	
2028	
Thereafter	
Total	

16

Note 13 - Debt

Long-term debt is comprised of the following:

	March 31, 2024	December 31, 2023
6.875% senior secured notes due November 1, 2027 (Face value of \$485.0 million less unamortized issuance costs of \$4.3 and \$4.6 million at March 31, 2024 and at December 31, 2023) ⁽ⁱ⁾		
	June 30, 2024	December 31, 2023
6.875% senior secured notes due November 1, 2027 (Face value of \$485.0 million less unamortized issuance costs of \$4.0 and \$4.6 million at June 30, 2024 and at December 31, 2023, respectively) ⁽ⁱ⁾		
Finance leases		
Other debt		
Total		
Less – current maturities		
Total long-term debt		

⁽ⁱ⁾ See Note 11 for the fair value of the notes.

Senior Secured Notes due 2027

The company has outstanding \$485.0 million aggregate principal amount of its 6.875% Senior Secured Notes due 2027 (the 2027 Notes). The 2027 Notes pay interest semiannually on May 1 and November 1 and will mature on November 1, 2027, unless earlier repurchased or redeemed. The 2027 Notes are fully and unconditionally guaranteed on a senior secured basis by Unisys Holding Corporation, Unisys NPL, Inc. and Unisys AP Investment Company I, each of which is a U.S. corporation that is directly or indirectly owned by the company (the subsidiary guarantors).

The 2027 Notes and the related guarantees rank equally in right of payment with all of the existing and future senior debt of the company and its subsidiary guarantors and senior in right of payment to any future subordinated debt of the company and its subsidiary guarantors. The 2027 Notes and the related guarantees are structurally subordinated to all existing and future liabilities (including preferred stock, trade payables and pension liabilities) of the subsidiaries of the company that are not subsidiary guarantors. The 2027 Notes and the guarantees are secured by liens on substantially all assets of the company and the subsidiary guarantors, other than certain excluded assets (the collateral). The liens securing the 2027 Notes on certain ABL collateral are subordinated to the liens on ABL Asset Based Lending (ABL) collateral in favor of the ABL secured parties and, in the future, the liens securing the 2027 Notes may be subordinated to liens on the collateral securing certain permitted first lien debt, subject to certain limitations and permitted liens.

The company may, on any one or more occasions, redeem all or a part of the 2027 Notes at specified redemption premiums, declining to par for any redemptions on or after November 1, 2025.

The indenture contains covenants that limit the ability of the company and its restricted subsidiaries to, among other things: (i) incur additional indebtedness and guarantee indebtedness; (ii) pay dividends or make other distributions or repurchase or redeem its capital stock; (iii) prepay, redeem or repurchase certain debt; (iv) issue certain preferred stock or similar equity securities; (v) make loans and investments; (vi) sell assets; (vii) create or incur liens; (viii) enter into transactions with affiliates; (ix) enter into agreements restricting its subsidiaries' ability to pay dividends; and (x) consolidate, merge or sell all or substantially all of its assets. These covenants are subject to several important limitations and exceptions.

16

If the company experiences certain kinds of changes of control (as defined in the indenture), it will be required to offer to repurchase the 2027 Notes at 101% of the principal amount of the 2027 Notes, plus accrued and unpaid interest as of the repurchase date, if any. In addition, if the company sells assets, under certain circumstances it must apply the proceeds towards an offer to repurchase the 2027 Notes at a price equal to par plus accrued and unpaid interest, if any.

The indenture also provides for events of default, which, if any of them occur, would permit or require the principal, premium, if any, interest and any other monetary obligations on all the then outstanding 2027 Notes to be due and payable immediately.

17

Interest expense related to the 2027 Notes is comprised of the following:

	Three Months Ended March 31,		Three Months Ended March 31,		Three Months Ended March 31,		Three Months Ended June 30,		Six Months Ended June 30,					
	2024						2024		2023		2024	2023	2024	2023
Contractual interest coupon														
Amortization of issuance costs														
Total														

Asset Based Lending (ABL) Credit Facility

The company has a secured revolving credit facility (the Amended and Restated ABL Credit Facility), which matures on October 29, 2025 and provides for revolving loans and letters of credit up to an aggregate amount of \$145.0 million (with a limit on letters of credit of \$40.0 million), with an accordion feature provision allowing for the aggregate amount available under the credit facility to be increased up to \$175.0 million upon the satisfaction of certain specified conditions. Availability under the credit facility is subject to a borrowing base calculated by reference to the company's receivables. At **March 31, 2024** **June 30, 2024**, the company had no borrowings and \$7.0 million of letters of credit outstanding. Availability under the facility was **\$43.4 million** **\$58.5 million** net of letters of credit issued.

The Amended and Restated ABL Credit Facility is subject to a springing maturity, under which the Amended and Restated ABL Credit Facility will immediately mature 91 days prior to any date on which contributions to pension funds in the United States in an amount in excess of \$100.0 million are required to be paid unless the company is able to meet certain conditions, including that the company has the liquidity (as defined in the Amended and Restated ABL Credit Facility) to cash settle the amount of such pension payments, no default or event of default has occurred under the Amended and Restated ABL Credit Facility, the company's liquidity is above \$130.0 million and the company is in compliance with the then applicable fixed charge coverage ratio on a pro forma basis.

The Amended and Restated ABL Credit Facility is guaranteed by the subsidiary guarantors and any future material domestic subsidiaries. The facility is secured by the assets of the company and the subsidiary guarantors, other than certain excluded assets, under a security agreement entered into by the company and the subsidiary guarantors in favor of JPMorgan Chase Bank, N.A., as agent for the lenders under the credit facility.

The company is required to maintain a minimum fixed charge coverage ratio if the availability under the Amended and Restated ABL Credit Facility falls below the greater of 10% of the lenders' commitments under the facility and \$14.5 million.

The Amended and Restated ABL Credit Facility contains customary representations and warranties, including, but not limited to, that there has been no material adverse change in the company's business, properties, operations or financial condition. The Amended and Restated ABL Credit Facility includes restrictions on the ability of the company and its subsidiaries to, among other things, incur other debt or liens, dispose of assets and make acquisitions, loans and investments, repurchase its equity, and prepay other debt. These restrictions are subject to several important limitations and exceptions. Events of default include non-payment, failure to comply with covenants, materially incorrect representations and warranties, change of control and default under other debt aggregating at least \$50.0 million, subject to relevant cure periods, as applicable.

At **March 31, 2024** **June 30, 2024**, the company has met all covenants and conditions under its various lending and funding agreements. For at least the next 12 months, the company expects to continue to meet these covenants and conditions.

17

Note 14 - Litigation and Contingencies

The company is involved in a wide range of lawsuits, claims, investigations and proceedings, which arise in the ordinary course of business, including actions with respect to commercial and government contracts, labor and employment, employee benefits, environmental matters, intellectual property and non-income tax matters. Further, given the rapidly evolving external landscape of cybersecurity, privacy and data protection laws, regulations and threat actors, the company and its clients have been and will continue to be subject to actions or proceedings in various jurisdictions. These matters can involve a number of different parties, including competitors, clients, current or former employees, government and regulatory agencies, stockholders and representatives of the locations in which the company does business. Many of these matters are also highly complex and may seek recovery on behalf of a class or similarly large number of plaintiffs. It is therefore inherently difficult to predict the size or scope of potential future losses arising from these matters.

The company records a provision for these matters when it is both probable that a liability has been incurred and the amount of the loss can be reasonably estimated. Significant judgment is required in both the determination of probability and the determination as to whether an exposure is reasonably estimable. Because of uncertainties related to these matters, accruals are based only on the best information available at the time. Any provisions are reviewed at least quarterly and are adjusted to

18

reflect the impact and status of settlements, rulings, advice of counsel and other information and events pertinent to a particular matter. These adjustments could have a material impact on our results of operations and financial position.

The company intends to defend itself vigorously with respect to any legal matters. Based on its experience, the company also believes that the damage amounts claimed against it in the matters disclosed below are not a meaningful indicator of the company's potential liability.

Legal proceedings are inherently unpredictable and unfavorable resolutions could occur. Whether any losses, damages or remedies finally determined in any claim, suit, investigation or proceeding could reasonably have a material effect on the company's business, financial condition, results of operations or cash flows will depend on a number of variables, including: the timing and amount of such losses or damages; the structure and type of any such remedies; the significance of the impact any such losses, damages or remedies may have in the company's consolidated financial statements; and the unique facts and circumstances of the particular matter that may give rise to additional factors. Accordingly, it is possible that an adverse outcome from such matters could be material to the company's financial condition, results of operations and cash flows in any particular reporting period.

Notwithstanding that the ultimate results of the lawsuits, claims, investigations and proceedings that have been brought or asserted against the company are not currently determinable, the company believes that at **March 31, 2024** **June 30, 2024**, it has adequate provisions for any such matters.

The following is a summary of the more significant legal proceedings involving the company.

The company's Brazilian operations, along with those of many other companies doing business in Brazil, are involved in various litigation matters, including numerous governmental assessments related to indirect and other taxes, as well as disputes associated with former employees and contract labor. The tax-related matters pertain to value-added taxes, customs, duties, sales and other non-income-related tax exposures. The labor-related matters include claims related to compensation. The company believes that appropriate accruals have been established for such matters based on information currently available. At **March 31, 2024** **June 30, 2024**, excluding those matters that have been assessed by management as being remote as to the likelihood of ultimately resulting in a loss, the amount related to unreserved tax-related matters, inclusive of any related interest, is estimated to be approximately **\$118 million** **\$92 million**.

On November 11, 2022, a purported stockholder of the company filed a putative securities class action complaint in the United States District Court for the Eastern District of Pennsylvania against the company and certain of its current officers, alleging violations of the Securities Exchange Act of 1934, as amended (the Exchange Act). The plaintiff sought an award of compensatory damages, among other relief, and costs and attorneys' and experts' fees. On August 21, 2023, the class action complaint was amended to assert violations of the Exchange Act based on allegedly false or misleading statements related to the efficacy of the company's disclosure controls and procedures, and internal control over financial reporting in certain of the company's 2021 and 2022 filings with the SEC. On October 20, 2023, the company filed a motion to dismiss the amended complaint for plaintiff's failure to state a claim on which relief may be granted. On February 1, 2024, the Court entered an order dismissing plaintiff's amended complaint, permitting the plaintiff to file a second amended complaint on or before March 1, 2024, if the deficiencies found in the amended complaint by the court can be cured. Plaintiffs did not file an amended complaint, resulting in the dismissal of the case with prejudice.

As previously disclosed, the company received voluntary requests for information and documents from the SEC relating to the company's policies, procedures and disclosures in connection with cybersecurity incidents. The company is cooperating with the SEC's investigation of certain of the company's cybersecurity risk disclosures and cybersecurity-related internal controls, including with respect to the material weaknesses that the company identified and disclosed in the company's Annual Report on

Form 10-K for the year ended December 31, 2022. The company is in discussions with the SEC staff regarding a potential non-scienter-based settlement of the alleged issues arising from the investigation but there can be no assurance that the company will be able to resolve the matter on terms acceptable to the company and the SEC. The company believes it has an adequate provision for this matter.

With respect to the specific legal proceedings and claims described above, except as otherwise noted, either (i) the amount or range of possible losses in excess of amounts accrued, if any, is not reasonably estimable or (ii) the company believes that the amount or range of possible losses in

excess of amounts accrued that are estimable would not be material. Nonetheless, the company is unable to predict the outcome from such matters and it is possible that an adverse result could be material to the company's financial conditions, results of operations and cash flows.

Environmental Matters

As of March 31, 2024 June 30, 2024, the company has an estimated environmental liability for a site that its predecessor company previously operated of approximately \$26 million \$25 million, of which \$11 million \$12 million is reported in other accrued liabilities and \$15 million \$13 million in other long-term liabilities on the company's consolidated balance sheet. The company has an agreement related to this site, which provides for a partial reimbursement of certain costs when all cleanup work has been approved and finalized. As of March 31, 2024 June 30, 2024, the company expects to recover approximately \$32 million \$33 million, which is included in other long-term assets on the company's consolidated balance sheet. As the company continues to perform investigation activities and if events and circumstances change, the company may incur future additional costs, which could have a material impact on the company's results of operations, financial condition and cash flows.

Note 15 - Accumulated Other Comprehensive Loss

Accumulated other comprehensive loss is as follows:

	Total	Total	Translation Adjustments	Postretirement Plans	Total	Translation Adjustments	Postretirement Plans
Balance at December 31, 2023							
Other comprehensive (loss) income before reclassifications							
Amounts reclassified from accumulated other comprehensive loss							
Current period other comprehensive income (loss)							
Balance at March 31, 2024							
Balance at June 30, 2024							

Amounts reclassified out of accumulated other comprehensive loss are as follows:

	Three Months Ended March 31, 2024	2023	Three Months Ended June 30, 2024	2023	Six Months Ended June 30, 2024	2023
Translation adjustments:						
Adjustment for substantial completion of liquidation of foreign subsidiaries ⁽ⁱ⁾						
Adjustment for substantial completion of liquidation of foreign subsidiaries ⁽ⁱ⁾						
Adjustment for substantial completion of liquidation of foreign subsidiaries ⁽ⁱ⁾						
Postretirement plans ⁽ⁱⁱ⁾ :						
Amortization of prior service benefit						
Amortization of prior service benefit						
Amortization of prior service benefit						
Amortization of actuarial losses						
Settlement losses						

Total before tax
Income tax
Total reclassifications for the period

- (i) Reported in other (expense), net in the consolidated statements of income (loss).
- (ii) These items are included in net periodic postretirement cost (see Note 4).

Note 16 - Supplemental Cash Flow Information

	Three Months Ended March 31,			Six Months Ended June 30,		
	2024	2024	2023	2024	2023	2023
Cash paid during the period for:						
Income taxes, net of refunds						
Income taxes, net of refunds						
Income taxes, net of refunds						
Interest						

The following table provides a reconciliation of cash and cash equivalents and restricted cash reported within the consolidated balance sheets to the total of the amounts shown in the consolidated statements of cash flows.

	March 31, 2024	December 31, 2023
	June 30, 2024	December 31, 2023
Cash and cash equivalents		
Restricted cash		
Total cash, cash equivalents and restricted cash shown in the consolidated statements of cash flows		

Cash and cash equivalents subject to contractual restrictions and are therefore not readily available are classified as restricted cash.

Note 17 - Segment Information

The company's reportable segments are as follows:

- Digital Workplace Solutions (DWS), which provides modern and traditional workplace solutions;
- Cloud, Applications & Infrastructure Solutions (CA&I), which provides digital platform, applications, and infrastructure solutions; and
- Enterprise Computing Solutions (ECS), which provides solutions that harness secure, continuous high-intensity computing and enable digital services through software-defined operating environments.

The accounting policies of each segment are the same as those followed by the company as a whole. The company evaluates segment performance based on gross profit exclusive of the service cost component of postretirement income or expense, cost reduction charges, amortization of purchased intangibles and unusual and nonrecurring items, which are included in other gross profit.

21

A summary of the company's operations by segment is presented below:

	Total Segments	DWS	CA&I	ECS
Three Months Ended March 31, 2024				
Revenue	\$ 408.3	\$ 132.3	\$ 129.0	\$ 147.0
Gross profit	\$ 125.4	\$ 19.0	\$ 21.4	\$ 85.0
Three Months Ended March 31, 2023				
Revenue	\$ 445.2	\$ 131.0	\$ 126.0	\$ 188.2
Gross profit	\$ 157.5	\$ 15.6	\$ 16.4	\$ 125.5

	Total Segments	DWS	CA&I	ECS
Three Months Ended June 30, 2024				
Revenue	\$ 403.9	\$ 132.1	\$ 134.3	\$ 137.5
Gross profit	\$ 122.2	\$ 21.4	\$ 23.9	\$ 76.9
Three Months Ended June 30, 2023				
Revenue	\$ 402.2	\$ 135.0	\$ 132.6	\$ 134.6
Gross profit	\$ 113.6	\$ 18.4	\$ 22.4	\$ 72.8

	Total Segments	DWS	CA&I	ECS
Six Months Ended June 30, 2024				
Revenue	\$ 812.2	\$ 264.4	\$ 263.3	\$ 284.5
Gross profit	\$ 247.6	\$ 40.4	\$ 45.3	\$ 161.9
Six Months Ended June 30, 2023				
Revenue	\$ 847.4	\$ 266.0	\$ 258.6	\$ 322.8
Gross profit	\$ 271.1	\$ 34.0	\$ 38.8	\$ 198.3

Presented below is a reconciliation of total segment revenue to total consolidated revenue:

	Three Months Ended March 31,			Three Months Ended June 30,			Six Months Ended June 30,		
	2024	2023		2024	2023		2024	2023	
Total segment revenue									
Other revenue									
Total consolidated revenue									
Total consolidated revenue									
Total consolidated revenue									

Presented below is a reconciliation of total segment gross profit to consolidated **loss income (loss)** before income taxes:

	Three Months Ended March 31,			Three Months Ended June 30,			Six Months Ended June 30,		
	2024	2023		2024	2023		2024	2023	
Total segment gross profit									
Other gross profit									
Total gross profit									
Selling, general and administrative expense									
Research and development expense									
Interest expense									
Other (expense), net									
Total loss before income taxes									
Total income (loss) before income taxes									

Other revenue and other gross profit are comprised of an aggregation of a number of immaterial business activities and cost reductions charges. These **businesses activities** principally provide for the management of processes and functions for clients in select industries, helping them improve performance and reduce costs.

22

Geographic information about the company's revenue, which is principally based on location of the selling organization, is presented below:

	Three Months Ended March 31,			Three Months Ended June 30,			Six Months Ended June 30,		
	2024	2023		2024	2023		2024	2023	
United States									
United Kingdom									
Other foreign									
Total									

21

Note 18 - Remaining Performance Obligations

Remaining performance obligations represent the transaction price of firm orders for which work has not been performed and excludes (1) contracts with an original expected length of one year or less and (2) contracts for which the company recognizes revenue at the amount to which it has the right to invoice for services performed. At March 31, 2024 June 30, 2024, the company had approximately \$0.8 billion of remaining performance obligations of which approximately 26% 22% is estimated to be recognized as revenue by the end of 2024, 29% 32% by the end of 2025, 20% 21% by the end of 2026, 16% by the end of 2027 and 9% thereafter.

22 23

Item 2. Management's Discussion and Analysis of Financial Condition and Results of Operations

This management's discussion and analysis of financial condition and results of operations should be read in conjunction with the consolidated financial statements and the related notes included elsewhere in this quarterly report.

Overview

For the three months ended March 31, 2024 June 30, 2024, the company reported net loss attributable to Unisys Corporation of \$149.5 million \$12.0 million, or \$2.18 \$0.17 per diluted share, compared with a loss of \$175.4 million \$40.0 million, or \$2.58 \$0.59 per diluted share, for the three months ended March 31, 2023 June 30, 2023.

For the six months ended June 30, 2024, the company reported net loss attributable to Unisys Corporation of \$161.5 million, or \$2.34 per diluted share, compared with a loss of \$215.4 million, or \$3.16 per diluted share, for the six months ended June 30, 2023. Included in the The loss for the three six months ended March 31, 2024 June 30, 2024 and 2023 was included \$132.3 million and \$183.2 million, respectively, of U.S. pension plan settlement losses net of tax. losses.

In March 2024, the company purchased a group annuity contract, with plan assets, for approximately \$195 million to transfer projected benefit obligations related to one of the company's U.S. defined benefit pension plans. This action resulted in a pre-tax settlement loss of \$132.3 million for the three six months ended March 31, 2024 June 30, 2024.

In March 2023, the company purchased a group annuity contract, with plan assets, for approximately \$265 million to transfer projected benefit obligations related to one of the company's U.S. defined benefit pension plans. This action resulted in a pre-tax settlement loss of \$183.2 million for the six months ended June 30, 2023.

Results of operations

Company results

Three months ended March 31, 2024 June 30, 2024 compared with the three months ended March 31, 2023 June 30, 2023

Revenue for the three months ended March 31, 2024 June 30, 2024 was \$487.8 million \$478.2 million compared with \$516.4 million \$476.8 million for the three months ended March 31, 2023 June 30, 2023, a decrease an increase of 5.5% 0.3% from the prior-year period. The decrease was primarily due to the timing of software license renewals within the Enterprise Computing Solutions segment. Foreign currency fluctuations had a 2 percentage-point positive negligible impact on revenue in the current period compared with the prior-year period.

Revenue from U.S. operations for the three months ended March 31, 2024 June 30, 2024 was \$212.3 million \$204.4 million, compared with \$201.0 million \$212.2 million for the three months ended March 31, 2023 June 30, 2023, an increase a decrease of 5.6% 3.7% from the prior-year period. Revenue from international operations for the three months ended March 31, 2024 June 30, 2024 was \$275.5 million \$273.8 million, compared with \$315.4 million \$264.6 million for the three months ended March 31, 2023 June 30, 2023, a decrease 12.7% an increase 3.5% from the prior-year period. Foreign currency had a 2 percentage-point positive negligible impact on international revenue in the three months ended March 31, 2024 June 30, 2024 compared with the three months ended March 31, 2023 June 30, 2023.

During the three months ended March 31, 2024 June 30, 2024, the company recognized net cost-reduction charges and other costs of \$6.3 million \$0.6 million. The net credit related to workforce reductions was \$0.7 million, principally related to severance costs, and was comprised of: (a) a credit of \$1.0 million for changes in estimates and (b) a charge of \$0.3 million. The company recorded charges of \$1.3 million comprised of \$1.2 million for net foreign currency losses related to exiting foreign countries and \$0.1 million for other expenses related to cost reduction efforts.

During the three months ended June 30, 2023, the company recognized net cost-reduction charges and other costs of \$3.5 million. The net charges related to workforce reductions were \$6.6 million \$2.1 million, principally related to severance costs, and were comprised of: (a) a charge of \$9.4 million \$3.9 million and (b) a credit of \$2.8 million for changes in estimates. The company recorded a net credit of \$0.3 million comprised of a net credit of \$0.8 million for changes in estimates related to other cost-reduction efforts and a charge of \$0.5 million for net foreign currency losses related to exiting foreign countries.

During the three months ended March 31, 2023, the company recognized net charges related to workforce reductions of \$0.7 million. These net charges were principally related to severance costs, and were comprised of: (a) a charge of \$2.6 million and (b) a credit of \$1.9 million \$1.8 million for changes in estimates. In addition, the company recorded a credit charges of \$3.5 million \$1.4 million comprised of \$1.3 million for professional fees and other expenses related to cost-reduction efforts and \$0.1 million for net foreign currency gains losses related to exiting foreign countries.

The charges (credits) were recorded in the following statement of income (loss) classifications:

	Three Months Ended March 31,
	Three Months Ended March 31,
	Three Months Ended March 31,
	Three Months Ended June 30,
	Three Months Ended June 30,
	Three Months Ended June 30,

2024
2024
2024

Cost of revenue
Cost of revenue
Cost of revenue
Selling, general and administrative
Selling, general and administrative
Selling, general and administrative
Research and development
Research and development
Research and development
Other (expense), net
Other (expense), net
Other (expense), net
Total
Total
Total

Gross profit and gross profit margin were \$136.0 million \$129.9 million and 27.9% 27.2% in the three months ended March 31, 2024 June 30, 2024, respectively, compared with \$159.0 million \$115.8 million and 30.8% 24.3% for the three months ended March 31, 2023 June 30, 2023, respectively. The decrease increase was primarily due to driven by the timing of software license renewals, partially offset by a benefit delivery improvements and an increase in higher-margin solutions from the resolution of a contractual dispute with a former client.

expansion and new scope for existing clients and new logo contracts.

Selling, general and administrative expense in the three months ended March 31, 2024 June 30, 2024 was \$112.2 million (23.0% \$101.4 million (21.2% of revenue) compared with \$102.9 million (19.9% \$110.3 million (23.1% of revenue) for the three months ended March 31, 2023 June 30, 2023. The increase decrease was primarily driven by higher cost-reduction charges lower professional services and increased stock compensation expense, lower cost reduction and other expenses.

Research and development expense for the three months ended March 31, 2024 June 30, 2024 and 2023 was \$6.1 million \$4.9 million and \$6.2 million \$5.4 million, respectively.

For the three months ended March 31, 2024 June 30, 2024, the company reported an operating profit of \$17.7 million \$23.6 million compared with an operating profit of \$49.9 million \$0.1 million in the three months ended March 31, 2023 June 30, 2023. The decrease increase was primarily driven by lower higher gross profit and increased lower selling, general and administrative expense as discussed above.

Interest expense for the three months ended March 31, 2024 June 30, 2024 and 2023 was \$7.9 million and \$7.6 million \$7.5 million, respectively.

Other (expense), net was expense of \$142.1 million \$9.4 million for the three months ended March 31, 2024 June 30, 2024 compared with expense of \$196.9 million \$16.7 million for the three months ended March 31, 2023 June 30, 2023. Other (expense), net for the three months ended March 31, 2024 and 2023 included \$132.3 million and \$183.2 million, respectively, of U.S. pension plan settlement losses. Additionally, other (expense), net for the three months ended March 31, 2024 includes a net gain of approximately \$14.9 million related to a favorable judgment received in a Brazilian services tax matter. See Note 6 of the Notes to Consolidated Financial Statements for details of other (expense), net.

The loss income before income taxes for the three months ended March 31, 2024 June 30, 2024 was \$132.3 million \$6.3 million compared with loss of \$154.6 million \$24.1 million for the three months ended March 31, 2023 June 30, 2023.

The provision for income taxes was \$17.0 million \$18.8 million for the three months ended March 31, 2024 June 30, 2024 compared with a provision of \$19.9 million \$15.4 million for the three months ended March 31, 2023 June 30, 2023. The change in the tax provision is a result of the geographic distribution of income as described below.

The company evaluates quarterly the realizability of its deferred tax assets by assessing its valuation allowance and by adjusting such amount, if necessary. The company records a tax provision or benefit for those international subsidiaries that do not have a full valuation allowance against their deferred tax assets. Any profit or loss recorded for the company's U.S. operations will have no provision or benefit associated with it due to the company's valuation allowance, except with respect to refundable tax credits and withholding taxes not creditable against future taxable income. As a result, the company's provision or benefit for taxes may vary significantly period to period depending on the geographic distribution of income.

The realization of the company's net deferred tax assets is primarily dependent on the ability to generate sustained taxable income in various jurisdictions. Judgment is required to estimate forecasted future taxable income, which may be impacted by future business developments, actual results, strategic operational and tax initiatives, legislative, and other economic factors and developments. Any increase or decrease in the valuation allowance would result in additional or lower income tax expense in that period and could have a significant impact on that period's earnings.

Net loss attributable to Unisys Corporation for the three months ended March 31, 2024 June 30, 2024 was \$149.5 million \$12.0 million, or \$2.18 \$0.17 per diluted share, compared with a loss of \$175.4 million \$40.0 million, or \$2.58 \$0.59 per diluted share, for the three months ended March 31, 2023 June 30, 2023.

Six months ended June 30, 2024 compared with the six months ended June 30, 2023

Revenue for the six months ended June 30, 2024 was \$966.0 million compared with \$993.2 million for the six months ended June 30, 2023, a decrease of 2.7% from the prior-year period. The decrease was primarily due to the timing of software license renewals. Foreign currency fluctuations had a 1 percentage-point positive impact on revenue in the current period compared with the prior-year period.

Revenue from U.S. operations for the six months ended June 30, 2024 was \$416.7 million, compared with \$413.2 million for the three months ended June 30, 2023, an increase of 0.8% from the prior-year period. Revenue from international operations for the six months ended June 30, 2024 was \$549.3 million, compared with \$580.0 million for the six months ended June 30, 2023, a decrease of 5.3% from the prior-year period. Foreign currency had a 1 percentage-point positive impact on international revenue in the six months ended June 30, 2024 compared with the six months ended June 30, 2023.

During the six months ended June 30, 2024, the company recognized net cost-reduction charges and other costs of \$6.9 million. The net charges related to workforce reductions were \$5.9 million, principally related to severance costs, and were comprised of: (a) a charge of \$9.7 million and (b) a credit of \$3.8 million for changes in estimates. The company recorded a net charge of \$1.0 million comprised of a charge of \$1.7 million for net

foreign currency losses related to exiting foreign countries and a net credit of \$0.7 million for changes in estimates related to other cost-reduction efforts.

During the six months ended June 30, 2023, the company recognized net cost-reduction charges and other costs of \$0.7 million. The net charges related to workforce reductions were \$2.8 million, principally related to severance costs, and were comprised

25

of: (a) a charge of \$6.5 million and (b) a credit of \$3.7 million for changes in estimates. In addition, the company recorded a net credit of \$2.1 million comprised of a credit of \$3.4 million for net foreign currency gains related to exiting foreign countries and a charge of \$1.3 million for professional fees and other expenses related to cost-reduction efforts.

The charges (credits) were recorded in the following statement of income (loss) classifications:

	Six Months Ended June 30,	
	2024	2023
Cost of revenue	\$ 1.4	\$ 3.4
Selling, general and administrative	2.7	0.5
Research and development	1.1	0.2
Other (expense), net	1.7	(3.4)
Total	\$ 6.9	\$ 0.7

Gross profit and gross profit margin were \$265.9 million and 27.5% in the six months ended June 30, 2024, respectively, compared with \$274.8 million and 27.7% in the six months ended June 30, 2023, respectively. The decrease was primarily due to the timing of software license renewals, partially offset by a benefit from the resolution of a contractual dispute with a former client, delivery modernization and efficiency initiatives.

Selling, general and administrative expense in the six months ended June 30, 2024 was \$213.6 million (22.1% of revenue) compared with \$213.2 million (21.5% of revenue) in the prior-year period.

Research and development expense for the six months ended June 30, 2024 and 2023 was \$11.0 million and \$11.6 million, respectively.

For the six months ended June 30, 2024, the company reported an operating profit of \$41.3 million compared with an operating profit of \$50.0 million for the prior-year period. The decrease was primarily driven by lower gross profit as discussed above.

Interest expense for the six months ended June 30, 2024 was \$15.8 million compared with \$15.1 million for the six months ended June 30, 2023.

Other (expense), net was expense of \$151.5 million for the six months ended June 30, 2024 compared with expense of \$213.6 million for the six months ended June 30, 2023. Other (expense), net for the six months ended June 30, 2024 and 2023 included \$132.3 million and \$183.2 million, respectively, of U.S. pension plan settlement losses. Additionally, other (expense), net for the six months ended June 30, 2024 included a net gain of approximately \$14.9 million related to a favorable judgment received in a Brazilian services tax matter. See Note 6 of the Notes to Consolidated Financial Statements for details of other (expense), net.

The loss before income taxes for the six months ended June 30, 2024 was \$126.0 million compared with a loss of \$178.7 million for the six months ended June 30, 2023. The loss for the six months ended June 30, 2024 and 2023 included \$132.3 million and \$183.2 million, respectively, of U.S. pension plan settlement losses.

The provision for income taxes was \$35.8 million for the six months ended June 30, 2024 compared with a provision of \$35.3 million for the six months ended June 30, 2023.

Net loss attributable to Unisys Corporation for the six months ended June 30, 2024 was \$161.5 million, or \$2.34 per diluted share, compared with a loss of \$215.4 million, or \$3.16 per diluted share, for the six months ended June 30, 2023. The loss for the three six months ended March 31, 2024 June 30, 2024 and 2023 included \$132.3 million and \$183.2 million, respectively, of U.S. pension plan settlement losses net of tax.

Segment results

The company's reportable segments are as follows:

- Digital Workplace Solutions (DWS), which provides modern and traditional workplace solutions;
- Cloud, Applications & Infrastructure Solutions (CA&I), which provides digital platform, applications, and infrastructure solutions; and
- Enterprise Computing Solutions (ECS), which provides solutions that harness secure, continuous high-intensity computing and enable digital services through software-defined operating environments.

The accounting policies of each segment are the same as those followed by the company as a whole. The company evaluates segment performance based on gross profit exclusive of the service cost component of postretirement income or expense, cost

26

reduction charges, amortization of purchased intangibles and unusual and nonrecurring items, which are included in other gross profit.

24

Three months ended **March 31, 2024** **June 30, 2024** compared with the three months ended **March 31, 2023** **June 30, 2023**

A summary of the company's operations by segment is presented below:

	Total Segments	Total Segments	DWS	CA&I	ECS	Total Segments	DWS	CA&I	ECS
Three Months Ended March 31, 2024									
Three Months Ended June 30, 2024									
Revenue									
Revenue									
Revenue									
Gross profit percent									
Gross profit percent									
	30.7 %	14.4 %	16.6 %	57.8 %	30.3 %	16.2 %	17.8 %	55.9 %	
Three Months Ended March 31, 2023									
Three Months Ended March 31, 2023									
Three Months Ended March 31, 2023									
Three Months Ended June 30, 2023									
Three Months Ended June 30, 2023									

Three Months Ended June 30, 2023

Revenue
Revenue
Revenue

Gross profit percent	Gross profit percent					Gross profit percent				
		35.4 %		11.9 %	13.0 %	66.7 %		28.2 %	13.6 %	16.9 % 54.1 %

DWS revenue was \$132.3 million \$132.1 million for the three months ended March 31, 2024 June 30, 2024, an increase a decrease of 1.0% 2.1% compared with the three months ended March 31, 2023 June 30, 2023. The decrease in revenue was primarily driven by lower discretionary volume with existing clients as compared to the prior-year period. Foreign currency fluctuations had a negligible impact on DWS revenue in the current period compared with the prior-year period. Gross profit percent was 16.2% in the current period compared with 13.6% in the year-ago period. The increase in gross profit was primarily driven by delivery modernization and efficiency initiatives as well as an increase in higher-margin solutions from expansion and new scope for existing clients and new logo contracts.

CA&I revenue was \$134.3 million for the three months ended June 30, 2024, an increase of 1.3% compared with the three months ended June 30, 2023. Foreign currency fluctuations had a negligible impact on CA&I revenue in the current period compared with the prior-year period. Gross profit percent was 17.8% in the current period compared with 16.9% in the prior-year period. The increase in gross profit was primarily driven by labor cost savings initiatives.

ECS revenue was \$137.5 million for the three months ended June 30, 2024, an increase of 2.2% compared with the three months ended June 30, 2023. Foreign currency fluctuations had a negligible impact on ECS revenue in the current period compared with the prior-year period. Gross profit percent was 55.9% in the current period compared with 54.1% in the prior-year period. The increase in revenue and gross profit was driven by the timing software license renewals and managed services growth.

Six months ended June 30, 2024 compared with the six months ended June 30, 2023

A summary of the company's operations by segment is presented below:

	Total Segments	DWS	CA&I	ECS
Six Months Ended June 30, 2024				
Revenue	\$ 812.2	\$ 264.4	\$ 263.3	\$ 284.5
Gross profit percent	30.5 %	15.3 %	17.2 %	56.9 %
Six Months Ended June 30, 2023				
Revenue	\$ 847.4	\$ 266.0	\$ 258.6	\$ 322.8
Gross profit percent	32.0 %	12.8 %	15.0 %	61.4 %

DWS revenue was \$264.4 million for the six months ended June 30, 2024, a decrease of 0.6% compared with the six months ended June 30, 2023. Foreign currency fluctuations had a 1 percentage-point positive impact on DWS revenue in the current period compared with the prior-year period. Gross profit percent was 14.4% 15.3% in the current period compared with 11.9% 12.8% in the year-ago prior-year period. The increase in gross profit was primarily driven by delivery modernization and efficiency initiatives.

CA&I revenue was \$129.0 million \$263.3 million for the three months six-months ended March 31, 2024 June 30, 2024, an increase of 2.4% 1.8% compared with the three six months ended March 31, 2023 June 30, 2023. Foreign currency fluctuations had a negligible impact on CA&I revenue in the current period compared with the prior-year period. Gross profit percent was 16.6% 17.2% in the current period compared with 13.0% 15.0% in the prior-year period. The increase in gross profit was primarily driven by labor cost savings initiatives.

ECS revenue was \$147.0 million \$284.5 million for the three six months ended March 31, 2024 June 30, 2024, a decline decrease of 21.9% 11.9% compared with the three six months ended March 31, 2023 June 30, 2023. Foreign currency fluctuations had a 3 2 percentage-point positive impact on ECS revenue in the current period compared with the prior-year period. Gross profit percent was 57.8% 56.9% in the current period compared with 66.7% 61.4% in the prior-year period. The decrease in revenue and gross profit was driven by the timing software license renewals.

Financial condition

The company's principal sources of liquidity are cash on hand, cash from operations and its revolving credit facility, discussed below. The company and certain international subsidiaries have access to uncommitted lines of credit from various banks. The company believes that it will have adequate sources of liquidity to meet its expected cash requirements for at least the next twelve months.

Cash and cash equivalents at March 31, 2024 June 30, 2024 were \$382.8 million \$344.9 million compared to \$387.7 million at December 31, 2023.

As of March 31, 2024 June 30, 2024, \$256.3 million \$236.7 million of cash and cash equivalents were held by the company's foreign subsidiaries and branches operating outside of the U.S. The company may not be able to readily transfer approximately one-quarter one-fifth of these funds out of the country in which they are located as a result of local restrictions, contractual or other legal arrangements or commercial considerations. Additionally, any transfers of these funds to the U.S. in the future may require the company to accrue or pay withholding or other taxes on a portion of the amount transferred.

During the three six months ended March 31, 2024 June 30, 2024, cash provided by operations was \$23.8 million \$26.5 million compared to cash provided of \$12.8 million \$55.3 million during the three six months ended March 31, 2023 June 30, 2023, primarily due to lower postretirement contributions, the timing of collections.

Cash used for investing activities during the three six months ended March 31, 2024 June 30, 2024 was \$18.8 million \$46.8 million compared to cash usage of \$11.5 million \$23.5 million during the three six months ended March 31, 2023 June 30, 2023. Net proceeds purchases of investments foreign exchange forward contracts were \$1.2 million \$5.6 million for the three six months ended March 31, 2024 June 30, 2024 compared with net proceeds of \$9.2 million \$15.0 million in the prior-year period. Proceeds from investments foreign exchange forward contracts and purchases of investments foreign exchange forward contracts represent derivative financial instruments used to reduce the company's currency exposure to market risks from changes in foreign currency exchange rates. In the current period, the investment in marketable software was \$13.2 million \$25.7 million compared with \$10.3 million \$21.3 million in the prior-year period, capital additions of properties were \$2.2 million \$7.3 million compared with \$7.3 million \$11.9 million in the prior-year period and capital additions of outsourcing assets were \$4.5 million \$8.1 million compared with \$2.7 million \$4.9 million in the prior-year period.

Cash used for financing activities during the three six months ended March 31, 2024 June 30, 2024 was \$7.7 million \$11.9 million compared to cash used of \$7.6 million \$11.0 million during the three six months ended March 31, 2023 June 30, 2023.

In March 2024, the company purchased a group annuity contract, with plan assets, for approximately \$195 million to transfer projected benefit obligations related to approximately 3,800 retirees of one of the company's U.S. defined benefit pension plans. This action resulted in a pre-tax settlement loss of \$132.3 million for the three six months ended March 31, 2024 June 30, 2024. After considering this most recent group annuity contract purchase, the company has successfully reduced its global defined benefit pension obligations since December 2020 by \$2.2 billion, including \$1.5 billion in the U.S.

The company will continue to evaluate opportunities for additional reduction of its global defined benefit pension obligations in future periods depending on overall market conditions. Due to the company's significant postretirement plans accumulated other comprehensive losses, future group annuity contract purchases could result in material non-cash settlement losses.

At the end of each year, the company estimates its future cash contributions to its U.S. qualified defined benefit pension plans based on year-end pension data and assumptions. In 2023, the company made cash contributions of \$42.4 million to its worldwide defined benefit pension plans. Based on current legislation, global regulations, recent interest rates and expected returns, the company estimates future cash contributions of

approximately \$20 million in 2024, primarily for its international defined benefit pension plans. For the ~~three~~ ~~six~~ months ended ~~March 31, 2024~~ ~~June 30, 2024~~ and 2023, the company made cash contributions of ~~\$6.4 million~~ ~~\$10.3 million~~ and ~~\$14.5 million~~ ~~\$28.4 million~~, respectively. The company estimates that cash contributions to its U.S. qualified defined benefit pension plans will begin in 2025, increasing the total estimated contributions for the company's U.S. and non-U.S. defined benefit pension plans to approximately ~~\$110 million~~ ~~\$95 million~~ in 2025. If the company is not able to generate sufficient cash flows from operations, we may need to obtain additional funding in order to make these contributions. Any material deterioration in the value of the company's U.S. qualified defined benefit pension plan assets, as well as changes in pension legislation, volatility in the capital markets, discount rate changes, asset return changes, or changes in economic or demographic trends, could require the company to make cash contributions to its U.S. qualified defined benefit pension plans in different amounts and on a different schedule than previously contemplated.

At ~~March 31, 2024~~ ~~June 30, 2024~~, total debt was ~~\$498.4 million~~ ~~\$496.4 million~~ compared to \$504.2 million at December 31, 2023.

28

The company has a secured revolving credit facility (the Amended and Restated ABL Credit Facility), which matures on October 29, 2025, and provides for revolving loans and letters of credit up to an aggregate amount of \$145.0 million (with a limit on letters of credit of \$40.0 million), with an accordion feature provision allowing for the aggregate amount available under the credit facility to be increased up to \$175.0 million upon the satisfaction of certain specified conditions. Availability under the credit facility is subject to a borrowing base calculated by reference to the company's receivables. At ~~March 31, 2024~~ ~~June 30, 2024~~, the company had no borrowings and \$7.0 million of letters of credit outstanding. Availability under the facility was ~~\$43.4 million~~ ~~\$58.5 million~~ net of letters of credit issued. Any borrowings under the facility will be subject to variable interest rates.

The Amended and Restated ABL Credit Facility is subject to a springing maturity, under which the Amended and Restated ABL Credit Facility will immediately mature 91 days prior to any date on which contributions to pension funds in the United States in an amount in excess of \$100.0 million are required to be paid unless the company is able to meet certain conditions, including that the company has the liquidity (as defined in the Amended and Restated ABL Credit Facility) to cash settle the amount of such pension payments, no default or event of default has occurred under the Amended and Restated ABL Credit Facility, the company's liquidity is above \$130.0 million and the company is in compliance with the then applicable fixed charge coverage ratio on a pro forma basis.

The Amended and Restated ABL Credit Facility is guaranteed by Unisys Holding Corporation, Unisys NPL, Inc. and Unisys AP Investment Company I, each of which is a U.S. corporation that is directly or indirectly owned by the company (the subsidiary guarantors). The facility is secured by the assets of the company and the subsidiary guarantors, other than certain excluded assets, under a security agreement entered into by the company and the subsidiary guarantors in favor of JPMorgan Chase Bank, N.A., as agent for the lenders under the credit facility.

The company is required to maintain a minimum fixed charge coverage ratio if the availability under the Amended and Restated ABL Credit Facility falls below the greater of 10% of the lenders' commitments under the facility and \$14.5 million.

The Amended and Restated ABL Credit Facility contains customary representations and warranties, including, but not limited to, that there has been no material adverse change in the company's business, properties, operations or financial condition. The Amended and Restated ABL Credit Facility includes restrictions on the ability of the company and its subsidiaries to, among other things, incur other debt or liens, dispose of assets and make acquisitions, loans and investments, repurchase its equity, and prepay other debt. These restrictions are subject to several important limitations and exceptions. Events of default include non-payment, failure to comply with covenants, materially incorrect representations and warranties, change of control and default under other debt aggregating at least \$50.0 million, subject to relevant cure periods, as applicable.

At ~~March 31, 2024~~ ~~June 30, 2024~~, the company has met all covenants and conditions under its various lending and funding agreements. For at least the next 12 months, the company expects to continue to meet these covenants and conditions.

From time to time, the company may explore a variety of additional debt and equity sources to fund its liquidity and capital needs.

26

The company may, from time to time, redeem, tender for, or repurchase its securities in the open market or in privately negotiated transactions depending upon availability, market conditions and other factors.

The company does not have any off-balance sheet arrangements that are material or reasonably likely to become material to its financial condition or results of operations.

Critical accounting policies and estimates

There have been no significant changes to the company's critical accounting policies and estimates as reported in its Annual Report on Form 10-K for the year ended December 31, 2023.

29

Item 3. Quantitative and Qualitative Disclosures About Market Risk

There has been no material change in the company's assessment of its sensitivity to market risk since its disclosure in its Annual Report on Form 10-K for the year ended December 31, 2023.

Item 4. Controls and Procedures

Evaluation of Disclosure Controls and Procedures

As of the end of the period covered by this Quarterly Report, management performed, with the participation of the Chief Executive Officer (CEO) and the Chief Financial Officer (CFO), an evaluation of the effectiveness of the company's disclosure controls and procedures as defined in Rules 13a-15(e) and 15d-15(e) of the Securities Exchange Act of 1934, as amended (the Exchange Act). In designing and evaluating the disclosure controls and procedures, management recognized that any controls and procedures, no matter how well designed and operated, can provide only reasonable assurance of achieving the desired control objectives. Based upon that evaluation, the CEO and the CFO concluded that, as of March 31, 2024 June 30, 2024, the company's disclosure controls and procedures were effective to provide reasonable assurance that information required to be disclosed in our Exchange Act reports is recorded, processed, summarized and reported within the time periods specified by the U.S. Securities and Exchange Commission (SEC), and that such information is accumulated and communicated to management, including the CEO and CFO, as appropriate, to allow timely decisions regarding required disclosure.

Changes in Internal Control Over Financial Reporting

There have been no changes in our internal control over financial reporting during the quarter ended March 31, 2024 June 30, 2024, that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.

27 30

Part II - OTHER INFORMATION

Item 1. Legal Proceedings

Information with respect to legal proceedings is set forth in Note 14 of the Notes to Consolidated Financial Statements, and such information is incorporated herein by reference.

Item 1A. Risk Factors

There have been no material changes to the “Risk Factors” in Part I, Item 1A of the company’s Annual Report on Form 10-K for the year ended December 31, 2023.

Item 2. Unregistered Sales of Equity Securities and Use of Proceeds and Issuer Purchases of Equity Securities

None

Item 5. Other Information

During the three months ended March 31, 2024 June 30, 2024, none of our directors or officers (as defined in Rule 16a-1(f) of the Securities Exchange Act of 1934, as amended) adopted or terminated a Rule 10b5-1 trading arrangement or non-Rule 10b5-1 trading arrangement (as such terms are defined in Item 408 408(a) of Regulation S-K of the Securities Act of 1933 1933, as amended).

28

Item 6. Exhibits

See Exhibit Index

29 31

EXHIBIT INDEX

Exhibit Number	Description
10.1	Form of Executive Severance Letter Agreement by and between Unisys Corporation and each of its executive officers
10.2	Form of Executive Employment Agreement by and between Unisys Corporation and each of its executive officers
31.1	Certification of Peter A. Altabef, Chief Executive Officer, pursuant to Rule 13a-14(a) or Rule 15d-14(a) of the Securities Exchange Act of 1934, as amended
31.2	Certification of Debra McCann, Chief Financial Officer, pursuant to Rule 13a-14(a) or Rule 15d-14(a) of the Securities Exchange Act of 1934, as amended
32.1	Certification of Peter A. Altabef, Chief Executive Officer, pursuant to Rule 13a-14(b) or Rule 15d-14(b) of the Securities Exchange Act of 1934, as amended, and Section 906 of the Sarbanes-Oxley Act of 2002, 18 U.S.C. Section 1350
32.2	Certification of Debra McCann, Chief Financial Officer, pursuant to Rule 13a-14(b) or Rule 15d-14(b) of the Securities Exchange Act of 1934, as amended, and Section 906 of the Sarbanes-Oxley Act of 2002, 18 U.S.C. Section 1350
101	The following financial information from Unisys Corporation's Quarterly Report on Form 10-Q for the quarter ended March 31, 2024 June 30, 2024 formatted in Inline XBRL (Extensible Business Reporting Language) includes: (i) the Consolidated Statements of Income (Loss), (ii) the Consolidated Statements of Comprehensive Income (Loss), (iii) the Consolidated Balance Sheets, (iv) the Consolidated Statements of Cash Flows, (v) the Consolidated Statements of Equity (Deficit), and (vi) Notes to Consolidated Financial Statements
104	Cover page Interactive Data File (formatted as Inline XBRL and contained in Exhibit 101)
	30 32

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

UNISYS CORPORATION

Date: **May 8, 2024** **August 6, 2024**

By: /s/ Debra McCann

Debra McCann

Executive Vice President and Chief Financial Officer
(Principal Financial Officer)

By: /s/ David Brown

David Brown

Vice President, Chief Accounting Officer and Corporate
Controller
(Principal Accounting Officer)

Exhibit 10.1

Name

Street Address

City, State Zip Code

Dear ,

As an elected officer of Unisys Corporation (the “Company”), you are a valued contributor to its success. The Compensation and Human Resources Committee of the Board of Directors, in consultation with its executive compensation advisor and based on their recommendations, has determined to offer to you the severance benefits described below in this letter agreement (this “Agreement”) if your employment is terminated as set forth in this Agreement.

1. **Certain Defined Terms.** In addition to terms defined elsewhere herein, the following terms have the following meanings when used in this Agreement with initial capital letters:

(a) “**Annual Base Salary**” means your annual base salary rate, exclusive of bonuses, commissions and other incentive pay, as in effect immediately preceding your Termination Date (but prior to taking into account any reduction that constitutes Good Reason).

(b) “**Annual Bonus**” means your target bonus under the Company’s Executive Variable Compensation Plan or any successor plan, as in effect immediately preceding your Termination Date (but prior to taking into account any reduction in your Annual Base Salary that constitutes Good Reason).

(c) “**Board**” means the Board of Directors of the Company.

(d) “**Cause**” means:

(i) your willful and continued failure to perform substantially, or your willful and continued taking of actions substantially inconsistent with, your duties with the Company or one of its affiliates (other than any such failure resulting from incapacity due to physical or mental illness), after a written demand for substantial performance is delivered to you by the Board or the Chief Executive Officer of the Company which specifically identifies the manner in which the Board or Chief Executive Officer believes that you have not substantially performed, or have taken actions substantially inconsistent with, your duties, or

(ii) you willfully engaging in illegal conduct or gross misconduct which is materially and demonstrably injurious to the Company.

For purposes of this provision, no act or failure to act, on your part, shall be considered “willful” unless it is done, or omitted to be done, by you in bad faith or without reasonable belief that your action or omission was in the best interests of the Company. Any act, or failure to act, based upon authority given pursuant to a resolution duly adopted by the Board or upon the instructions of the Chief Executive Officer or a senior officer of the Company or based upon the advice of counsel for the Company shall be conclusively presumed to be done, or omitted to be done, by you in good faith and in the best interests of the Company. The cessation of your employment shall not be deemed to be for Cause unless and until there shall have been delivered to you a copy of a resolution duly

adopted by the affirmative vote of not less than three-quarters of the entire membership of the Board at a meeting of the Board called and held

for such purpose (after reasonable notice is provided to you and you are given an opportunity, together with counsel, to be heard before the Board), finding that, in the good faith opinion of the Board, you are guilty of the conduct described in subparagraph (i) or (ii) above, and specifying the particulars thereof in detail.

(e) “COBRA” means the Consolidated Omnibus Budget Reconciliation Act of 1986, as amended.

(f) “Disability” means your absence from your duties with the Company on a full-time basis for 180 consecutive business days as a result of incapacity due to mental or physical illness which is determined to be total and permanent by a physician selected by the Company or its insurers and acceptable to you or your legal representative.

(g) “Good Reason” means, the occurrence of any of the following without your written consent:

(i) a material diminution in your authority, duties or responsibilities with the Company;

(ii) a material diminution of your Annual Base Salary (exclusive of bonuses, commissions and other incentive pay); or

(iii) the Company's requiring you to be based at any office or location that is a material change from which you previously performed services, which for this purpose a material change shall be deemed to be an office or location that is more than fifty (50) miles from the office or location from which you previously performed services.

Notwithstanding the foregoing, for you to be able to terminate your employment with the Company on account of Good Reason, you must provide notice of the occurrence of the event constituting Good Reason and your desire to terminate your employment with the Company on account of such occurrence within ninety (90) days following the initial existence of the condition constituting Good Reason, and the Company must have a period of thirty (30) days following receipt of such notice to cure the condition. If the Company does not cure the event constituting Good Reason within such thirty (30) day period, your Termination Date shall be the day immediately following the end of such thirty (30) day period, unless the Company provides for an earlier Termination Date.

(h) “Termination Date” means the last day of your employment with the Company.

2. Compensation Upon Termination: Subject to the provisions of Section 4 hereof, in the event a termination either (1) by the Company for any reason other than on account of Cause, death or Disability or (2) by you for Good Reason as described above, the Company shall provide you with the following, provided that you execute and do not revoke the Release (as defined in Section 4):

(a) An amount equal to the sum of (i) your Annual Base Salary and (ii) your Annual Bonus (the “Severance Payment”). The Severance Payment shall be paid in substantially equal installments on the Company's regular payroll dates occurring during the twelve (12) month period following your Termination Date. Except if delay is required pursuant to Section 14 below, the payments will commence within sixty (60) days after your Termination Date, and each successive installment shall be paid on successive payroll dates thereafter for the remainder of such twelve (12) month period. Any payments

not paid during the sixty (60) day period shall be paid in a lump sum on the date that the installment payments commence in accordance with the immediately preceding sentence.

(b) For up to twelve (12) months following your Termination Date (the “Continuation Period”), you (and where applicable, your spouse and eligible dependents) shall continue to be eligible to receive the medical, dental and vision coverages under the Company plans in which you were participating immediately prior to your Termination Date, in accordance with the terms of the applicable plan documents and subject to such changes to the terms of such plans as the Company determines shall apply to employees of the Company, generally; provided, that in order to receive such coverage for the Continuation Period, you shall be required to pay to the Company, at the same time that premium payments are due for the month, the full monthly premium required by the Company under such plans for continued group healthcare continuation coverage under COBRA and the Company will reimburse to you an amount equal to the monthly payment for such COBRA coverage, less (x) the amount that you would have been required to pay for such coverage if you had been employed by the Company at such time and (y) applicable deductions and withholdings. In the event that either (I) you obtain full-time employment during the Continuation Period and are eligible for coverage under your new employer’s plans, in which case you will notify the Company, or (II) you cease to pay the applicable monthly premium, the Continuation Period shall automatically terminate and the Company shall have no further obligations under this Section 2(b). Except if delay is required pursuant to Section 14 below, the reimbursements will commence within sixty (60) days after your Termination Date and each successive reimbursement shall be paid within thirty (30) days following the date such COBRA payment is due. Any reimbursements not paid during the sixty (60) day period shall be paid in a lump sum on the date that the reimbursements commence in accordance with the immediately preceding sentence. The COBRA continuation period shall run simultaneously with the Continuation Period.

In addition, you shall be entitled to (i) any accrued, but unpaid, Annual Base Salary as of your Termination Date, (ii) any accrued, but unused, vacation as of your Termination Date and (iii) any accrued or owing but not yet paid vested benefits under the plans and programs in which you were participating as of your Termination Date, in accordance with the governing terms of such plans and programs (collectively, the “Accrued Benefits”); provided, that you shall not be entitled to receive severance benefits under any other Company severance plan, agreement or offer letter. Except as otherwise provided under the terms of the applicable benefit plans or programs, the Accrued Benefits will be paid within thirty (30) days following the Termination Date. To the extent that you are entitled to any benefits under any other Agreements between you and the Company, including as a result of a Change of Control (as defined in any such Agreement), you shall not be entitled to any benefits hereunder.

3. Termination on Account of Disability, Death, Cause or Voluntarily Without Good Reason.

(a) Termination on Account of Disability. If the Company determines in good faith that your Disability has occurred during your employment by the Company, the Company may give to you written notice in accordance with Section 13 of this Agreement of its intention to terminate your employment. In such event, your employment with the Company shall terminate effective on the 30th day after your receipt of such notice if, within the 30 days after such receipt, you shall not have returned to full-time performance of your duties with the Company. Upon such termination, you shall be entitled to receive disability benefits under any disability program maintained by the Company, if any, under which you are covered, and you shall not receive any benefits pursuant to Section 2 hereof. However, you shall receive any Accrued Benefits, which shall be paid to you within thirty (30) days following the Termination Date, except as otherwise provided under the terms of the applicable benefit plans or programs.

(b) Termination on Account of Death. Notwithstanding anything in this Agreement to the contrary, if your employment terminates on account of death, your beneficiary shall be entitled to receive death benefits under any death benefit program maintained by the Company, if any, under which you are covered, and you shall not receive any benefits pursuant to Section 2 hereof. In addition, your beneficiary shall receive any Accrued Benefits, which shall be paid to your beneficiary within thirty (30) days following the Termination Date, except as otherwise provided under the terms of the applicable benefit plans or programs.

(c) Termination on Account of Cause. Notwithstanding anything in this Agreement to the contrary, if your employment terminates by the Company on account of Cause, you shall not receive any benefits pursuant to Section 2 hereof. However, you shall

receive any Accrued Benefits, which shall be paid to you within thirty (30) days following the Termination Date, except as otherwise provided under the terms of the applicable benefit plans or programs.

(d) Termination on Account of Voluntary Resignation Without Good Reason. Notwithstanding anything in this Agreement to the contrary, if your employment terminates on account of your resignation for no reason or any reason other than on account of Good Reason, you shall not receive any benefits pursuant to Section 2 hereof. However, you shall receive any Accrued Benefits, which shall be paid to you within thirty (30) days following the Termination Date, except as otherwise provided under the terms of the applicable benefit plans or programs.

4. **Release.** Notwithstanding the foregoing, no payments under Section 2 of this Agreement shall be made unless you execute, and do not revoke, the Company's standard written release, the current version of which is substantially in the form attached hereto as Annex A (the "Release"), of any and all claims against the Company and all related parties with respect to all matters arising out of your employment by the Company (other than entitlements under the terms of this Agreement) or a termination thereof.

5. **Conduct After Termination.**

(a) For a period of twelve (12) months from and after the termination of your employment for any reason:

(i) You shall not engage in or become employed as a business owner, employee, agent, representative or consultant in any activity which is in competition with any line of business of the Company (or its subsidiaries or affiliates) existing as of your termination date, except with the express prior written consent of the Board; provided, however, you shall be deemed not to be in competition for purposes of Section 5 of this Agreement (w) if you are an employee of or a consultant to an entity a unit of which is in competition with the Company, provided that it can be demonstrated to the reasonable satisfaction of the Board that procedures are in place to assure that any unit that is in competition with the Company and any director, officer, employee, consultant or other representative of such unit cannot directly or indirectly avail itself or themselves of your services, (x) if you are an employee of or a consultant to an entity that provides consulting services to other entities, one or more of which are in competition with the Company, provided that it can be demonstrated to the reasonable satisfaction of the Board that procedures are in place to assure that no entity that is in competition with the Company nor any director, officer, employee, consultant or other representative of such unit can directly or indirectly avail itself or themselves of your services, (y) if you invest in securities which are listed for trading on a national exchange or NASDAQ and your investment does not exceed 1% of the issued and outstanding

shares of stock or (z) if you acquire an ownership interest in a non-public company, provided that such ownership represents a passive investment;

(ii) You shall not negatively comment publicly or privately about the Company (or its subsidiaries or affiliates), any of its products, services or other businesses, its present or past Board of Directors, its officers, or its employees, nor shall you in any way discuss the circumstances of your termination of employment, except that (u) you may participate, cooperate, or give truthful testimony in any action, investigation, or proceeding with, or provide information to, any court, governmental agency or legislative body, any self-regulatory organization, and/or pursuant to the Sarbanes-Oxley Act, (v) you may make comments about the circumstances of your termination with the prior written approval of the Company, (w) you may respond publicly to any untrue public comment made by the Company, (x) you may discuss the circumstances of your termination with your attorneys, financial and tax advisers, members of your family and any prospective employer, provided that you take all necessary steps to assure that each such person does not, as a result of these discussions, make any such negative comment prohibited under this Agreement, (y) accept any U.S. Securities and Exchange Commission award. Notwithstanding Associate's preexisting obligations with respect to Unisys's confidential information, pursuant to the federal Defend Trade Secrets Act, Associate cannot be held criminally or civilly liable under any federal or state trade secret law for disclosing a trade secret if that disclosure is made: (i) in confidence to a federal, state, or local government official, either directly or indirectly, or to any attorney, and for the sole purpose of reporting or investigating a suspected violation of law; or (ii) in a complaint or other document filed in a lawsuit or similar proceeding, provided that filing is made under seal and (z) you may make

comments to an arbitrator or court for the purpose of determining or enforcing your rights under this Agreement or any entitlement under any agreement, plan, award, policy or program with or sponsored by the Company (or any of its subsidiaries or affiliates);

(iii) You shall not, directly or indirectly, induce or attempt to induce any employee of the Company (or any of its subsidiaries or affiliates) to render services for any other person, firm or business entity, except that you will be permitted to give recommendations, if requested, for employees seeking employment outside of the Company;

(iv) The Company (and its subsidiaries and affiliates) agrees not to negatively comment publicly or privately about you or the circumstances of your termination of employment, except (u) the Company may give truthful testimony before a court or governmental agency, (v) the Company may make comments about the circumstances of your termination with your prior written approval, (w) the Company may respond publicly to any untrue public comment made by you, (x) the Company may discuss the circumstances of your termination with its attorneys and its financial and tax advisers, provided that it takes reasonable steps to assure that each such person does not, as a result of the Company's discussions with them, make any such negative comment prohibited under this Agreement, (y) the Company may make comments to an arbitrator or court for the purpose of determining its rights under this Agreement or any agreement, plan, award, policy or program with or sponsored by the Company (or any of its subsidiaries or affiliates) and (z) the Company may make such disclosures as are required by law or regulation.

(b) From and after the termination of your employment for any reason, you shall not use, furnish or divulge to any other person, firm or business entity any confidential information relating to the Company's business (or that of any of its subsidiaries or affiliates), or any trade secrets, processes, contracts or arrangements involved in any such business, except (i) when required to do so by a court of law, by any governmental agency having supervisory authority over the business of the Company or by any administrative or legislative body (including a committee thereof) with apparent jurisdiction to order you to divulge, disclose or make accessible such information, in each case with advance written notice to the Company in sufficient time to allow the Company to challenge the disclosure of such information if it so chooses, (ii) to an attorney as necessary to enforce your rights under this Agreement, or any other agreement, plan, policy, award or program with or sponsored by the Company or (iii) after such information becomes known to the public or within the relevant industry to which such confidential information pertains.

(c) In the event that you should materially breach your obligations under this Section 5, (i) the Company shall have the right, in addition to any other legal or equitable remedies, to terminate any payments due you under Section 2 and (ii) you agree that you shall repay to the Company any payments previously made to you under Section 2.

(d) Exception for Certain States and Jurisdictions. The obligations in Section a (i) shall not apply during any period of time in which you work or reside in California, North Dakota, Washington D.C., or any state or other jurisdiction in which they are prohibited by applicable law. The obligations in Section a (i) and (iii) shall not apply during any period of time in which you work or reside in California.

6. No Mitigation Obligation. You shall not be required to mitigate the amount of any payment or benefit provided for in this Agreement by seeking other employment or otherwise, nor shall the amount of any payment or benefit provided for herein be reduced by any compensation earned by other employment or otherwise except as set forth in Section 2(b) above. For avoidance of doubt, all compensation, including any payment or benefit provided for in this Agreement, is paid pursuant to Company policy, including the Executive Clawback Policy for Recoupment of Erroneously Awarded Compensation.

7. Cooperation. At the Company's request, you agree, to the extent permitted by law, to assist, consult with, and cooperate with the Company in any litigation, investigation, administrative procedures, or legal proceedings or inquiries that involve the Company, either now existing or which may hereafter be instituted by or against the Company, including, but not limited to, engaging in interviews related to the Company's investigations, appearing upon the Company's reasonable request as a witness and/or consultant in connection with any litigation, investigation, administrative procedures, or legal proceedings or inquiries, and meeting in advance with the Company and its representatives to prepare for any such appearance or any appearance by you at any such proceeding compelled by law. In addition, at the Company's request, you agree to provide information regarding your ownership of the Company's securities to the extent such information is required to be disclosed by the Company pursuant to any law or regulation. To the extent

permitted by applicable law, the Company will reimburse you for the reasonable attorney's fees and reasonable out-of-pocket expenses, if any, that you incur in connection with any such cooperation; provided, that such counsel is selected by the Company or approved by the Company.

8. **Employment Rights.** Nothing expressed or implied in this Agreement will create any right or duty on your part or on the part of the Company to have you remain in the employment of the Company or any subsidiary at any time.

9. **Withholding of Taxes.** All amounts payable under this Agreement to you are subject to applicable tax withholding requirements and the Company may withhold from any amounts payable under this Agreement all federal, state, city or other taxes as the Company is required to withhold pursuant to any applicable law, regulation or ruling.

10. **Term of Agreement.** This Agreement shall continue in full force and effect for the duration of your employment with the Company, unless terminated at any earlier time by mutual agreement between you and the Company; provided, however, that after the termination of your employment during the term of this Agreement, this Agreement shall remain in effect until all of the obligations of the parties hereunder are satisfied or have expired.

11. **Successors and Binding Agreement.**

(a) The Company will require any successor (whether direct or indirect, by purchase, merger, consolidation, reorganization or otherwise) to all or substantially all of the business or assets of the Company expressly to assume and agree to perform this Agreement in the same manner and to the same extent the Company would be required to perform if no such succession had taken place. This Agreement will be binding upon and inure to the benefit of the Company and any successor to the Company, including without limitation any persons acquiring directly or indirectly all or substantially all of the business or assets of the Company whether by purchase, merger, consolidation, reorganization or otherwise (and such successor will thereafter be deemed the "Company" for the purposes of this Agreement), but will not otherwise be assignable, transferable or delegable by the Company.

(b) This Agreement will inure to the benefit of and be enforceable by your personal or legal representatives, executors, administrators, successors, heirs, distributees and legatees. Except with respect to the Employment Agreement, this Agreement will supersede the provisions of any employment, severance or other agreement or offer letter between you and the Company that relate to payments on account of the termination of your employment, and such provisions in such other agreements will be null and void.

(c) This Agreement is personal in nature and neither of the parties hereto will, without the consent of the other, assign, transfer or delegate this Agreement or any rights or obligations hereunder except as expressly provided in Sections 11(a) and 11(b). Without limiting the generality or effect of the foregoing, your right to receive payments hereunder will not be assignable, transferable or delegable, whether by pledge, creation of a security interest, or otherwise, other than by a transfer by your will or by the laws of descent and distribution and, in the event of any attempted assignment or transfer contrary to this Section 11(c), the Company will have no liability to pay any amount so attempted to be assigned, transferred or delegated.

12. **Dispute Resolution.** In the event of any dispute relating to the termination of your employment, or this Agreement, other than a dispute in which the primary relief sought is an equitable remedy such as an injunction, and unless prohibited by applicable law, the parties shall be required to have the dispute, controversy or claim settled by alternative dispute resolution conducted by JAMS (or, if JAMS is not available, another mutually agreeable alternative dispute resolution organization), in the city of your principal place of employment. Any award entered by JAMS (or such other organization) shall be final, binding and nonappealable, and judgment may be entered thereon by either party in accordance with applicable law in any court of competent jurisdiction. This Section 12 shall be specifically enforceable. JAMS (or such other organization) shall have no authority to modify any provision of this Agreement. In the event of a dispute, each party shall be responsible for its own expenses (including attorneys' fees) relating to the conduct of the arbitration, and the parties shall share equally the fees of JAMS. THE PARTIES IRREVOCABLY WAIVE ANY RIGHT TO TRIAL BY JURY AS TO ALL CLAIMS HEREUNDER

13. **Notices.** For all purposes of this Agreement, all communications, including without limitation notices, consents, requests or approvals, required or permitted to be given hereunder will be in writing and will be deemed to have been duly given when hand delivered or dispatched by electronic facsimile transmission (with receipt thereof orally confirmed), or five (5) business days after having been mailed by United States registered or certified mail, return receipt requested, postage prepaid, or three (3) business days after having been sent by a nationally recognized overnight courier service such as FedEx or UPS, addressed to the Company (to the attention of the Secretary of the Company) at its principal executive office and to you at your principal residence, or to such other address as any party may have furnished to the other in writing and in accordance herewith, except that notices of changes of address will be effective only upon receipt.

14. **Section 409A of the Code.**

(a) **Interpretation.** Notwithstanding the other provisions hereof, this Agreement is intended to comply with the requirements of section 409A of the Internal Revenue Code of 1986, as amended (the "Code"), to the extent applicable, and this Agreement shall be interpreted to avoid any penalty sanctions under section 409A of the Code. Accordingly, all provisions herein, or incorporated by reference, shall be construed and interpreted to comply with section 409A of the Code and, if necessary, any such provision shall be deemed amended to comply with section 409A of the Code and regulations thereunder. If any payment or benefit cannot be provided or made at the time specified herein without incurring sanctions under section 409A of the Code, then such benefit or payment shall be provided in full at the earliest time thereafter when such sanctions will not be imposed. All payments to be made upon a termination of employment under this Agreement may only be made upon a "separation from service" under section 409A of the Code. For purposes of section 409A of the Code, each payment made under this Agreement shall be treated as a separate payment and the right to a series of installment payments under this Agreement shall be treated as a right to a series of separate payments. In no event may you, directly or indirectly, designate the calendar year of payment, and, unless a delay is required pursuant to Section 14(b) below, if any payment under this Agreement constitutes deferred compensation subject to the requirements of section 409A of the Code is payable within the sixty (60) day period following your Termination Date and such sixty (60) day period spans two (2) calendar years, such payment shall be made in the second calendar year.

(b) **Payment Delay.** Notwithstanding any provision to the contrary in this Agreement, if on the date of your termination of employment, you are a "specified employee" (as such term is defined in section 409A(a)(2)(B)(i) of the Code and its corresponding regulations) as determined in the sole discretion of the Company in accordance with the Company's "specified employee" determination policy, then all severance benefits payable to you under this Agreement that constitute deferred compensation subject to the requirements of section 409A of the Code shall be postponed for a period of six (6) months following your termination of employment with the Company. The postponed amounts shall be paid to you in a lump sum on the first business day after the date that is six (6) months following your termination of employment with the Company. If you die during such six-month period and prior to payment of the postponed amounts hereunder, the amounts delayed on account of section 409A of the Code shall be paid to the personal representative of your estate within seventy-five (75) days after your death.

(c) **Reimbursements.** To the maximum extent permitted under section 409A of the Code, the monthly reimbursements pursuant to Section 2(b) of this Agreement are intended to qualify for the exception from deferred compensation as a medical benefit provided in accordance with the requirements of section 409A of the Code and Treas. Reg. §1.409A-1(b)(9)(v)(B). All reimbursements provided under

this Agreement shall be made or provided in accordance with the requirements of section 409A of the Code, including, where applicable, the requirement that (i) any reimbursement is for expenses incurred during your lifetime (or during a shorter period of time specified in this Agreement), (ii) the amount of expenses eligible for reimbursement during a calendar year may not affect the expenses eligible for reimbursement in any other calendar year, (iii) the reimbursement of an eligible expense will be made on or before the last day of the taxable year following the year in which the expense is incurred, and (iv) the right to reimbursement is not subject to liquidation or exchange for another benefit.

(d) No action or failure to act pursuant to this Section shall subject the Company or any subsidiary or affiliate thereof to any claim, liability or expense, and none of the Company nor any subsidiary or affiliate thereof shall have any obligation to indemnify or otherwise protect you from the obligation to pay any taxes pursuant to section 409A of the Code.

15. **Governing Law.** The validity, interpretation, construction and performance of this Agreement will be governed by and construed in accordance with the substantive laws of the Commonwealth of Pennsylvania, without giving effect to the principles of conflict of laws of such State.

16. **Validity.** If any provision of this Agreement or the application of any provision hereof to any person or circumstances is held invalid, unenforceable or otherwise illegal, the remainder of this Agreement and the application of such provision to any other person or circumstances will not be affected, and the provision so held to be invalid, unenforceable or otherwise illegal will be reformed to the extent (and only to the extent) necessary to make it enforceable, valid or legal.

17. **Miscellaneous.** No provision of this Agreement may be modified, waived or discharged unless such waiver, modification or discharge is agreed to in writing signed by you and the Company. No waiver by either party hereto at any time of any breach by the other party hereto or compliance with any condition or provision of this Agreement to be performed by such other party will be deemed a waiver of similar or dissimilar provisions or conditions at the same or at any prior or subsequent time. No agreements or representations, oral or otherwise, expressed or implied with respect to the subject matter hereof have been made by either party that are not set forth expressly in this Agreement. References to Sections are to references to Sections of this Agreement. Any reference in this Agreement to a provision of a statute, rule or regulation will also include any successor provision thereto.

18. **Counterparts.** This Agreement may be executed in one or more counterparts, each of which will be deemed to be an original but all of which together will constitute one and the same agreement.

Sincerely,
UNISYS CORPORATION

By: _____
Name: _____
Title: _____

Accepted and agreed to by:

[NAME OF EXECUTIVE]

ANNEX A

FORM OF RELEASE

GENERAL RELEASE

1. I, _____, agree that I have been allowed at least twenty-one (21) days to consider the meaning and effect of this Release (this "Release") and that this Release constitutes written notice that I have been advised to consult with an attorney prior to executing this Release. You agree that any modifications, material or otherwise, made to this agreement do not restart or affect in any manner the original at least twenty-one (21) calendar day consideration period.

2. I acknowledge that I have seven (7) days from the day I sign this Release to revoke my acceptance of this Release and this Release shall not become effective or enforceable until this revocation period has expired. To the extent the Release purports to release claims pursuant to the Minnesota Human Rights Act, I acknowledge that I have fifteen (15) days from the day I sign this

Release to revoke my acceptance of this Release and this Release shall not become effective or enforceable until the sixteenth (16th) day after the day I have signed and returned it, provided that I have not revoked this Release during the Revocation Period.

3. I acknowledge that all amounts payable pursuant to the letter agreement dated as of _____, 20__ (the "Agreement") that I have entered into with Unisys Corporation (the "Company") are subject to applicable tax withholdings. In addition, I acknowledge that I am solely responsible for all taxes that may result from my receipt of the amounts payable and benefits to be provided to me under the Agreement, and neither the Company nor any of its affiliates makes or has made any representation, warranty or guarantee of any federal, state or local tax consequences to me of my receipt of any payment or benefit hereunder, including, but not limited to, under Section 409A of the Internal Revenue Code of 1986, as amended.

4. In consideration for the payments to me by the Company under the Agreement and other good and valuable consideration, which I acknowledge are adequate and satisfactory to me, and intending to be legally bound, I knowingly and voluntarily hereby release the Company, its shareholders, directors, officers, employees, agents, benefit plans, attorneys, affiliates, parents, subsidiaries, predecessors, successors, assigns, and all persons acting by, through, under or in concert with any of them (collectively, "Released Parties"), from any and all rights, causes of action, suits, debts, claims and demands in law or in equity (collectively, "Claims"), known or unknown, that I or which my heirs, executors or administrators may have now or in the future may arise based on, arising out of or relating to my employment with the Company or the termination thereof for any and all reasons. Said release includes, but is not limited to, any Claims which I may have against any of the Released Parties based upon Title VII of the Civil Rights Act of 1964, 42 U.S.C. § 2000e et seq., as amended, the Civil Rights Act of 1866, 42 U.S.C. § 1981, as amended (including, but not limited to, 42 U.S.C. § 1981a), the Americans with Disabilities Act of 1990, 42 U.S.C. § 12101 et seq., as amended, the Age Discrimination in Employment Act, 29 U.S.C. § 621 et seq., as amended, including the Older Workers Benefit Protection Act ("OWBPA"); the Employee Retirement Income Security Act of 1974, 29 U.S.C. § 1001 et seq., as amended, the Family Medical Leave Act, 29 U.S.C. § 2601 et seq., as amended, any applicable state laws identified on Schedule 1 hereto (to the greatest extent such release is permissible under applicable law), as well as any Claims for breach of any employment contract or agreement (written, oral, or implied), wrongful discharge, breach of the covenant of good faith and fair dealing, promissory and/or equitable estoppel, tort claims of any nature, and any Claims which may have been asserted under the common law

or any other federal, state or local law, as well as all claims for counsel fees and costs. This Release covers claims that I know about and those that I may not know about up through the date of this Release. Notwithstanding the generality of the foregoing, I am not releasing or waiving any rights I may have: (i) under COBRA; (ii) to my own vested accrued employee benefits under Unisys's health, welfare, or retirement benefit plans as of the last date of employment; (iii) to benefits and/or the right to seek benefits under applicable workers' compensation and/or unemployment compensation statutes; (iv) to pursue claims which by law cannot be waived by signing this Agreement and/or which may arise after the execution of this Agreement; (v) to enforce this Agreement; and/or (vi) to challenge the validity of this Agreement.

5. I acknowledge that, by reason of the position which I held within Unisys that I have become familiar with highly confidential and/or proprietary information relating to the business of Unisys such as various customer lists, sales and marketing strategies and plans, bids, projections, costs, financial data, personnel information developments, improvements, processes, methods, tools and customer relationships. I further recognize that the business of Unisys is highly competitive, and that Unisys has a legitimate business interest in preserving any and all trade secrets and other highly confidential and/or proprietary information that I may have acquired from Unisys, which are essential to the continued success of Unisys, and that Unisys will suffer irreparable harm should such confidential information be utilized by a competitor. I further acknowledge that all such confidential and/or proprietary information and trade secrets acquired through my employment are owned and shall continue to be owned by Unisys.

6. I agree that I will not, at any time, whether during my term of employment or thereafter, disclose to any unauthorized person, firm or corporation any information I acquired in confidence through my employment with Unisys, it being understood that all such confidential and/or proprietary information constitutes trade secrets that are material to the successful conduct of Unisys and belong exclusively to Unisys. By way of example and not limitation, such confidential and/or proprietary information and trade secrets include any and all information, not otherwise available to the public, concerning: (i) marketing plans, business plans, strategies, forecasts, unpublished financial statements, budgets, bids, projections and costs; (ii) personnel information; (iii) customer lists, customer and

supplier transaction histories, identities, contacts, volumes, characteristics, agreements and prices; (iv) information regarding promotional, operational, program management, sales, marketing, research and development techniques, methods and reports and (v) other trade secrets. I specifically acknowledge that such confidential and/or proprietary information and trade secrets have commercial value to Unisys, the unauthorized disclosure of which could be detrimental to the interests of Unisys, whether or not such information is specifically identified as "Confidential" and/or "Proprietary" information by Unisys. Provided, however, that the restrictions of this paragraph shall not extend to any information or materials that are either known to the public or that can be derived, compiled or learned by a third party without significant effort or expense. Nothing in this Release, any other agreement between Unisys and myself, or any other policies of Unisys shall prohibit or restrict me or my attorneys from: (a) making any disclosure of relevant and necessary information or documents in any action, investigation, or proceeding relating to this Release, or as required by law or legal process, including with respect to possible violations of the law; (b) participating, cooperating, or testifying in any action, investigation, or proceeding with, or providing information to, any governmental agency or legislative body, any self-regulatory organization, and/or pursuant to the Sarbanes-Oxley Act; or (c) accepting any U.S. Securities and Exchange Commission awards. Notwithstanding my preexisting obligations with respect to Unisys's confidential information, pursuant to the federal Defend Trade Secrets Act, I understand that I cannot be held criminally or civilly liable under any federal or state trade secret law for disclosing a trade secret if that disclosure is made: (i) in confidence to a federal, state, or local government official, either directly or indirectly, or to any attorney,

and for the sole purpose of reporting or investigating a suspected violation of law; or (ii) in a complaint or other document filed in a lawsuit or similar proceeding, provided that filing is made under seal.

7. I acknowledge that the restrictions contained in the foregoing paragraphs 5 and 6, in view of the nature of the work performed by Unisys, are reasonable and necessary in order to protect the legitimate interests of Unisys, and that any violation thereof may result in irreparable injuries to Unisys, and I therefore acknowledge that, in the event of any violation of any of these restrictions, Unisys may be entitled to obtain from any court of competent jurisdiction preliminary and permanent injunctive relief as well as damages and an equitable accounting of all earnings, profits and other benefits arising from such violation, which rights shall be cumulative and in addition to any other rights or remedies to which Unisys may be entitled.

8. Nothing in this Release shall prohibit or restrict me, Unisys, or their respective attorneys from: (i) filing or disclosing any facts necessary to receive unemployment insurance, Medicaid, or other public benefits to which I am entitled; (ii) making any disclosure of relevant and necessary information or documents in connection with any charge, action, investigation, or proceeding relating to this Release or as required by law or legal process; (iii) initiating, testifying, assisting, complying with a subpoena from, or participating in any manner with an investigation conducted by a self-regulatory authority or a government agency or entity, including without limitation, the U.S. Department of Labor, the National Labor Relations Board, the U.S. Department of Justice, the U.S. Securities and Exchange Commission, the U.S. Commodities Futures Trading Commission, the Financial Industry Regulatory Authority, the Occupational Safety and Health Administration, the U.S. Congress, any other federal, state, or local government agency or commission, and any agency Inspector General (collectively, the "Regulators"), or from making other disclosures that are protected under the whistleblower provisions of federal, state, or local law or regulation; to the extent permitted by law, upon receipt of any subpoena, court order or other legal process compelling the disclosure of any such information or documents, I shall give prompt written notice to Unisys so as to permit Unisys to protect its interests in confidentiality to the fullest extent possible. I do not need the prior authorization of Unisys to engage in conduct protected by this paragraph, and I do not need to notify Unisys that I have engaged in such conduct. This Release does not limit my right to receive an award from any Regulator that provides awards for providing information relating to a potential violation of the law. I recognize and agree that, in connection with any such activity outlined above, I must inform the Regulators, my attorney, a court or a government official that the information I am providing is confidential. Despite the foregoing, I am not permitted to reveal to any third-party, including any governmental, law enforcement, or regulatory authority, information I came to learn during the course of my employment with Unisys that is protected from disclosure by any applicable privilege, including but not limited to the attorney-client privilege and/or attorney work product doctrine. Unisys does not waive any applicable privileges or the right to continue to protect its privileged attorney-client information, attorney work product, and other privileged information.

9. If in connection with any investigation, government inquiry, threatened litigation, or filed litigation involving Unisys, I am called upon to assist Unisys; to provide evidence; or to testify in any manner, I agree to reasonably cooperate fully with Unisys in connection

with any matter arising out of or related to my former employment. If requested by Unisys, I agree to be present and participate in the trial of any such matter. I will, to the extent permitted by applicable law, be reimbursed for my reasonable costs and expenses for any time spent assisting Unisys in this regard.

10. In the event that, any one or more provisions (or portion thereof) of this Release is held to be invalid, unlawful or unenforceable for any reason, the invalid, unlawful or unenforceable provision (or portion thereof) shall be construed or modified so as to provide the Released Parties with the maximum protection that is valid, lawful and enforceable, consistent with my intent in entering into this Release. If such provision (or portion thereof) cannot be construed or modified so as to be valid, lawful and enforceable, that provision (or portion thereof) shall be construed as narrowly as possible and shall be severed from the remainder of this Release (or provision), and the remainder shall remain in effect and be construed as broadly as possible, as if such invalid, unlawful or unenforceable provision (or portion thereof) had never been contained in this Release.

11. This Release shall be construed and enforced under and in accordance with the laws of the Commonwealth of Pennsylvania.

THE COMPANY HEREBY ADVISES YOU THAT YOU HAVE AT LEAST TWENTY-ONE (21) CALENDAR DAYS TO REVIEW THIS RELEASE AND HEREBY ADVISES YOU TO CONSULT WITH AN ATTORNEY PRIOR TO EXECUTION OF THIS RELEASE.

YOU AGREE THAT ANY MODIFICATIONS, MATERIAL OR OTHERWISE, MADE TO THIS RELEASE DO NOT RESTART OR AFFECT IN ANY MANNER THE ORIGINAL AT LEAST TWENTY-ONE (21) CALENDAR DAY CONSIDERATION PERIOD.

HAVING ELECTED TO EXECUTE THIS RELEASE, TO FULFILL THE PROMISES AND TO RECEIVE THE CONSIDERATION IN ACCORDANCE WITH THE AGREEMENT REFERENCES IN PARAGRAPH 3 ABOVE, YOU FREELY AND KNOWINGLY, AND AFTER DUE CONSIDERATION, ENTER INTO THIS RELEASE INTENDING TO WAIVE, SETTLE AND RELEASE ALL CLAIMS YOU HAVE OR MIGHT HAVE AGAINST RELEASEES AS SET FORTH IN THIS AGREEMENT.

I, _____, do hereby knowingly and voluntarily enter into this agreement as of the dates set forth below.

Executed this _____ day of _____, 20_____.

Agreed: _____

NAME OF EXECUTIVE

SCHEDULE 1

By entering into this Separation Agreement And General Release ("Agreement"), the individual identified in the signature block of the Agreement ("Employee") acknowledges and agrees that the release set forth in the Agreement extends to include, but is not limited to, the laws of any state in which Employee performed work for Unisys, or that otherwise might apply to Employee's employment with Unisys, or the termination thereof (each to the extent applicable, and as amended from time to time):

Alabama	Alabama Age Discrimination in Employment Act Alabama Unlawful Practices related to Opposition of Employer under Section 25-1-28 of the Alabama Code Alabama Whistleblower Protection Law Alabama Pay Equity Law Retaliatory or Constructive Discharge and for co-employer liability under Sections 25-5-11 and 25-5-11.1 of the Alabama Code.
Alaska	Alaska Human Rights Law Alaska Family and Medical Leave Law Alaska Occupational Safety and Health Law Alaska Uniform Contribution Among Tortfeasors Act
Arizona	Arizona Civil Rights Act Arizona Employment Protection Act Arizona Occupational Safety and Health Law Arizona Right to Work Act
Arkansas	Arkansas Civil Rights Act of 1993 Arkansas Equal Pay Law Arkansas Minimum Wage Act Arkansas Wage Payment Laws Arkansas Uniform Contribution Among Tortfeasors Act
California	California Family Rights Act California Fair Employment and Housing Act California Civil Code California Labor Code (except as prohibited by law) Unruh Civil Rights Act California Fair Pay Act California Pregnancy Disability Leave Law California WARN Act

Colorado	<p>Colorado Anti-Discrimination Act</p> <p>Colorado Equal Pay Law</p> <p>Colorado Law Prohibiting Discrimination by Labor Organization</p> <p>Colorado Whistleblower Law</p> <p>Colorado Maternity Leave Law</p> <p>Colorado Healthy Families and Workplaces</p> <p>Colorado Minimum Wage Law</p> <p>Colorado Minimum Wage Order No. 32</p> <p>Colorado Labor Peace Act</p>
Connecticut	<p>Connecticut Fair Employment Practices Act</p> <p>Connecticut Human Rights and Opportunities Act</p> <p>Connecticut Family and Medical Leave Law</p> <p>Connecticut General Statute Paid Sick Leave</p> <p>Connecticut Whistleblower Law</p> <p>Connecticut Free Speech Law</p> <p>Connecticut WARN Law</p> <p>Connecticut Human Rights and Opportunities Act</p> <p>Connecticut Minimum Wage and Overtime Law</p> <p>Connecticut Equal Pay Act</p> <p>Connecticut Maximum Hours and Overtime Law (provided, however, that nothing in this Agreement shall be construed as a release of disputed wages as a condition to receive wages conceded to be due).</p>
Delaware	<p>Delaware Discrimination in Employment Act</p> <p>Delaware Handicapped Persons Employment Protection Act</p> <p>Delaware Persons with Disabilities Employment Protections Act</p> <p>Delaware Whistleblower's Act</p> <p>Delaware Wage Payment and Collection Act</p> <p>Delaware Fair Employment Practices Act (provided, however, that nothing in this agreement shall be construed as a requirement for or condition to any payment due under the Wage Payment and Collection Act).</p>
District of Columbia	<p>D.C. Human Rights Act</p> <p>D.C. Prohibition of Discrimination on the Basis of Tobacco Use Act</p> <p>D.C. Whistleblower Protection Act for Employees of D.C. Contractors</p> <p>D.C. Family and Medical Leave Act</p> <p>D.C. Parental Leave Act</p> <p>D.C. Employee Sick Leave Provision of Paid Leave</p> <p>D.C. Displaced Workers Protection Act</p> <p>D.C. Wage Payment and Collection Law</p> <p>D.C. Minimum Wage Act</p>

Florida	Florida Civil Rights Act Florida Omnibus AIDS Act Florida Wage Discrimination Law Florida Educational Equity Act Florida Discrimination Against Military Personnel Law Florida Workers Compensation Act Retaliation Provision Florida Fair Housing Act Florida False Claims Act Florida Whistleblower Act Florida Whistle-blower's Act Florida Minimum Wage Act
Georgia	Georgia Fair Employment Practices Act Georgia Equal Pay Act Georgia Age Discrimination in Employment Law Georgia Equal Employment for Persons with Disabilities Code Georgia Right to Arbitration for Sex Discrimination Claims Claims Arising under the Georgia Constitution.
Hawaii	Hawaii Fair Employment Practices Act Hawaii Discriminatory Practices Law Hawaii Equal Pay Law Hawaii Civil Rights Act Hawaii Whistleblowers' Protection Act Hawaii Dislocated Workers Law Hawaii Family Leave Law Hawaii Occupational Safety and Health Law
Idaho	Idaho Fair Employment Practices Act Idaho Civil Rights Law Idaho Human Rights Act Idaho Equal Pay Law Idaho Minimum Wage Law Idaho Wage Payment Law

Illinois	<ul style="list-style-type: none"> Illinois Human Rights Act Illinois Equal Pay Laws Illinois Whistleblower Act IL Wages for Women and Minors Act Illinois Religious Freedom Restoration Act Illinois Family Military Leave Act Illinois WARN Act Illinois Right to Privacy in the Workplace Act Illinois Union Employee Health and Benefits Protection Act Illinois Employment Contract Act Illinois Dispute Act Illinois Victims' Economic Security and Safety Act IL Nursing Mothers in the Workplace Act Cook County Human Rights Ordinance (if applicable) Chicago Human Rights Ordinance (if applicable)
Indiana	<ul style="list-style-type: none"> Indiana Civil Rights Law Indiana Age Discrimination Law Indiana Employment Discrimination Against Disabled Persons Law Indiana Equal Pay Law Indiana Military Leave and Re-Employment Rights Indiana Off Duty Use of Tobacco by Employees Law Indiana Whistleblower Protections for Employees of Private Employer that is Under Public Contract Indiana Military Family Leave Act Indiana Minimum Wage Law Indiana Wage Payment and Wage Claims Act Indiana Occupational Safety and Health Law Indiana Blacklisting Statute
Iowa	<ul style="list-style-type: none"> Iowa Civil Rights Act Iowa Law Related to Military Leave/Re-Employment Rights Iowa Minimum Wage Law Iowa Wage Payment Collection Law Iowa WARN Act
Kansas	<ul style="list-style-type: none"> Kansas Act Against Discrimination Kansas Equal Pay Law Kansas Age Discrimination in Employment Act Kansas Discrimination Against Military Personnel Act Kansas Discrimination Against Victims of Domestic Violence or Sexual Assault Act Kansas Whistleblower Protection Laws Kansas Minimum Wage and Maximum Hours Law Kansas WARN Act

Kentucky	Kentucky Civil Rights Act Kentucky Equal Opportunities Act Kentucky Wage Discrimination Because of Sex Law Kentucky Law Regarding Military Leave and Re-Employment Rights Kentucky Equal Pay Act Kentucky Leave of Absence to Adopt a Child Law Kentucky Minimum Wage Law Kentucky Occupational Safety and Health Law Kentucky Workers' Compensation Act Retaliation Provision
Louisiana	Louisiana Employment Discrimination Law Louisiana Whistleblower Protection Laws Louisiana Family and Medical Leave Laws Louisiana Payment of Employees Law Louisiana Workers' Compensation Act Retaliation Provision Louisiana General Tort Provision
Maine	Maine Human Rights Act Maine Equal Pay Law Maine Civil Rights Act Maine Protection from Harassment Law Maine Sexual Harassment Policies Law Maine Whistleblowers' Protection Act Maine Family Medical Leave Act Maine Family Sick Leave Law Maine Labor and Industry Earned Paid Leave Maine Wage Law Maine WARN Laws
Maryland	Maryland Anti-Discrimination Law Maryland Fair Employment Practices Act Maryland Reasonable Accommodations for Disabilities Due to Pregnancy Act Maryland Deployment of Family Members in the Armed Forces Act Maryland Equal Pay for Equal Work Law Maryland Medical Information Discrimination Law Maryland Maternity Leave Law Maryland Healthy Working Families Act Maryland Wage Payment and Collection Law Maryland Wage and Hour Law Maryland WARN Laws Maryland Occupational Safety and Health Act

<p>Massachusetts</p>	<p>Massachusetts Law Prohibiting Unlawful Discrimination</p> <p>Massachusetts Equal Pay Law, except for claims that cannot be waived related to inquiry or discussion of wages</p> <p>Massachusetts Right to be Free from Sexual Harassment Law</p> <p>Massachusetts Age Discrimination Law</p> <p>Massachusetts Equal Rights Law</p> <p>Massachusetts Equal Rights for the Elderly and Disabled Law</p> <p>Massachusetts Civil Rights Law</p> <p>Massachusetts False Claims Act</p> <p>Massachusetts Family and Medical Leave Laws and Small Necessities Act</p> <p>Massachusetts Earned Sick Time</p> <p>Massachusetts Labor and Industry Privacy Law</p> <p>By entering into this Agreement, you acknowledge that your release and waiver includes any future claims against the Company under Mass. Gen. Laws ch. 149, § 148 - the Massachusetts Wage Act. These claims include, but are not limited to, failure to pay earned wages, failure to pay overtime, failure to pay earned commissions, failure to timely pay wages, failure to pay accrued vacation or holiday pay, failure to furnish appropriate pay stubs, claims for improper wage deductions, and claims for failing to provide proper check-cashing facilities.</p>
<p>Michigan</p>	<p>Elliott-Larsen Civil Rights Act</p> <p>Michigan Persons with Disabilities Civil Rights Act</p> <p>Michigan Whistleblowers' Protection Act</p> <p>Michigan Minimum Wage Law</p> <p>Michigan Equal Pay Law</p> <p>Michigan Paid Medical Leave Act</p> <p>Michigan Payment of Wages and Fringe Benefits Law</p> <p>Sales Representatives Commission Act</p> <p>Michigan WARN Laws</p> <p>Bullard-Plawecki Employee Right to Know Act</p> <p>Social Security Number Privacy Act</p> <p>Internet Privacy Protection Act</p> <p>Michigan Occupational Safety and Health Act</p>

Minnesota	<p>Minnesota Human Rights Act</p> <p>Minnesota Equal Pay for Equal Work Law</p> <p>Minnesota Age Discrimination Statute</p> <p>Minnesota Nonwork Activities Law</p> <p>Minnesota Whistleblower Protection Law</p> <p>Minnesota Parenting Leave Act</p> <p>Minnesota Wage Law</p> <p>Minnesota WARN Laws</p> <p>Minnesota Personnel Record Access Laws</p> <p>Minnesota Whistleblowers' Protection Retaliation Provision</p> <p>Notwithstanding any conflicting terms of the Agreement (if applicable), if you were employed by the Company in Minnesota, then with respect to claims under the Minnesota Human Rights Act, you are provided fifteen calendar days after signing this Agreement to revoke it. To be effective, this revocation must be in writing and either (a) hand-delivered to the Company within fifteen calendar days of signing; or (b) sent by certified mail, return receipt requested, to the Company with a postmark within fifteen calendar days of signing. If this Agreement is revoked, you will not be entitled to the Severance Package described by the Agreement.</p>
Mississippi	<p>Mississippi Employment Protection Act</p> <p>Mississippi Military Leave/Re-Employment Rights Statute</p> <p>Mississippi Wage Law</p>
Missouri	<p>Missouri Human Rights Act</p> <p>Missouri Equal Pay for Women Act</p> <p>Missouri Minimum Wage Law</p> <p>Missouri Wage Payment Law</p> <p>Missouri Service Letter Statute</p>
Montana	<p>Montana Human Rights Act</p> <p>Montana Equal Pay Law</p> <p>Montana Wrongful Discharge from Employment Act</p> <p>Montana Maternity Leave Act</p> <p>Montana Wage Payment Law</p> <p>Montana Minimum Wage and Overtime Compensation Act</p> <p>Montana Limitation on Hours for Certain Employees</p> <p>Montana Blacklisting Statutes</p> <p>You agree that your termination was for good cause as defined by Montana Law.</p>

Nebraska	Nebraska Fair Employment Practices Act Nebraska Discrimination in Employment Act Nebraska Equal Pay Law Nebraska Laws Against Discrimination of Military Personnel Nebraska AIDS Discrimination Act Nebraska Genetic Information and Testing Law Nebraska Family Military Leave Nebraska Wage and Hour Act Waivable Claims under the Nebraska Wage Payment and Collection Act
Nevada	Nevada Fair Employment Practices Act (including age and sexual harassment claims, claims related to false pretenses, blacklisting, grafting, kickbacks, or lie detectors) Nevada Paid Leave
New Hampshire	New Hampshire Law Against Discrimination New Hampshire Whistleblowers' Protection Act New Hampshire Minimum Wage Law New Hampshire Protective Legislation Law New Hampshire Unemployment Compensation Prohibition Against Discrimination Law New Hampshire Uniform Trade Secrets Act New Hampshire Safety and Health of Employees Law New Hampshire Protective Legislation Law Non-Compete and Non-Piracy Sections
New Jersey	New Jersey Law Against Discrimination New Jersey Equal Pay Act New Jersey Civil Rights Law New Jersey Security and Financial Empowerment Act New Jersey Conscientious Employee Protection Act New Jersey Family Leave Act New Jersey Earned Sick Leave New Jersey Wage and Hour Law New Jersey WARN Laws New Jersey Workers' Compensation Law Retaliation Provisions
New Mexico	New Mexico Human Rights Act New Mexico Re-Employment of Persons in Armed Forces Act New Mexico Fraud Against Taxpayers Act New Mexico Promoting Financial Independence for Victims of Domestic Abuse Act New Mexico Employee Privacy Act

New York	New York State Human Rights Law New York Off Duty Conduct Law Activities Discrimination Law New York City Humans Rights Law (if applicable) New York City Commission on Human Rights Law (if applicable) New York City Earned Sick Time Act (if applicable) New York Wage Hour and Wage Payment Law New York Minimum Wage Law New York WARN New York Equal Pay Law New York State Civil Rights Law New York Family Leave Law New York Sick Leave Law New York State Worker Adjustment and Retraining Notification Act New York Workers' Compensation Law Retaliation Provisions
North Carolina	North Carolina Equal Employment Practices Act North Carolina Persons with Disabilities Protection Act North Carolina Civil Rights Law North Carolina Lawful Products Use Law North Carolina Hemoglobin/Genetic Information Anti-Discrimination Law North Carolina Retaliatory Employment Discrimination Act North Carolina Leave for Parent Involvement in Schools Law
North Dakota	North Dakota Human Rights Act North Dakota Equal Pay Law North Dakota Age Discrimination Law North Dakota Whistleblower Law North Dakota Wage and Hour Law North Dakota Wage Collection Law
Ohio	Ohio Civil Rights Act Ohio Equal Pay Act Ohio Whistleblowers' Protection Statute Ohio Pregnancy Discrimination/Maternity Leave Act Ohio Wage Payment Law Ohio Minimum Fair Wage Standards Act Ohio Miscellaneous Labor Provisions Ohio Workers' Compensation Retaliation Law Ohio Constitution

Oklahoma	<p>Oklahoma Anti-Discrimination Act</p> <p>Oklahoma Discriminatory Wages Law</p> <p>Oklahoma Genetic Nondiscrimination in Employment Act</p> <p>Oklahoma General Anti-Retaliation Law</p> <p>You acknowledge that this waiver is not a restraint as contemplated by Okla. Stat. Ann. tit. 40, § 199(B)(2), Oklahoma Law Governing Wages and Working Conditions, Oklahoma Minimum Wage Act, the Retaliation and Discrimination provision of the Oklahoma Administrative Workers' Compensation Act, and the Standards for Workplace Drug and Alcohol Testing Act.</p>
Oregon	<p>Oregon Anti-Discrimination Law</p> <p>Oregon Fair Employment Practices Act</p> <p>Oregon Unlawful Discrimination Against Persons with Disabilities Law</p> <p>Oregon Genetic Screening Law</p> <p>Unlawful Discrimination Against Injured Workers Law</p> <p>Oregon Unlawful Discrimination for Service in Uniformed Service Law</p> <p>Oregon Leave of Absence for State Service Law</p> <p>Oregon Military Family Leave Act</p> <p>Oregon Sick Leave</p> <p>Oregon Whistleblower Law</p> <p>Oregon Initiating or Aiding Administrative, Criminal, or Civil Proceeding Law</p> <p>Oregon Family Leave Act</p> <p>Oregon Hours of Labor and Wage Payment Law</p> <p>Oregon Minimum Wage Law</p> <p>Oregon WARN Act</p>
Pennsylvania	<p>Pennsylvania Human Relations Act</p> <p>Pennsylvania Equal Pay Law</p> <p>Pennsylvania Whistleblower Law</p> <p>Pennsylvania Pregnancy Guidelines of the Human Relations Comm.</p>

Rhode Island	<p>Rhode Island Fair Employment Practices Act</p> <p>Rhode Island Civil Rights Act</p> <p>Rhode Island Equal Pay Act</p> <p>Rhode Island Civil Rights of People with Disabilities Act</p> <p>Rhode Island Discrimination Based on Genetic Testing Law</p> <p>Rhode Island AIDS Discrimination Law</p> <p>Employment Discrimination Provision of Rhode Island Victim's Bill of Rights</p> <p>Rhode Island Military Family Relief Act</p> <p>Rhode Island Whistleblowers' Protection Act</p> <p>Rhode Island Parental and Family Medical Leave Act</p> <p>Rhode Island Healthy and Safe Families and Workplaces Act</p> <p>Rhode Island Minimum Wage Act</p> <p>Rhode Island Wage Payment Law</p>
South Carolina	<p>South Carolina Human Affairs Law</p> <p>South Carolina Bill of Rights for Handicapped Persons Law</p> <p>South Carolina Military Re-Employment Rights Law</p> <p>South Carolina 's Unlawful Discrimination Against Union Members Law</p> <p>South Carolina Whistleblower Law</p> <p>South Carolina Workers' Compensation Retaliation Provision</p> <p>South Carolina Consumer Protection Code Wrongful Termination Provision</p> <p>South Carolina's Unlawful Termination of an Employee Replaced by an Authorized Alien Law</p> <p>South Carolina's Wrongful Demotion or Termination of an Employee for Complying with a Subpoena or Serving on a Jury Law</p> <p>South Carolina's Personnel Action Based on Use of Tobacco Products Outside of Workplace Prohibited Law</p>
South Dakota	<p>South Dakota Human Relations Act</p> <p>South Dakota Equal Pay Law</p> <p>South Dakota Genetic Information Bias Law</p> <p>South Dakota Wage Retaliation Law</p> <p>South Dakota Minimum Wage Law</p>
Tennessee	<p>Tennessee Human Rights Act</p> <p>Tennessee Equal Pay Law</p> <p>Tennessee Leave for Adoption, Pregnancy, Childbirth and Infant Nursing Law</p> <p>Tennessee Wage Protection Act</p> <p>Tennessee WARN Act</p> <p>Tennessee Occupational Safety and Health Act</p>

Texas	Texas Commission on Human Rights Act Texas Equal Pay Law Texas Employment Discrimination Law Texas Disability Discrimination Law Texas State Wage Payment and Work Hour Laws Texas Payday Law Texas Minimum Wage Act
Utah	Utah Antidiscrimination Act Utah Genetic Testing Privacy Act Utah Occupational Safety and Health Act Utah Employment Relations and Collective Bargaining Act Utah Right to Work Law Utah Drug and Alcohol Testing Act Utah Protection of Activities in Private Vehicles Act Utah Employment Selection Procedures Act Utah's Local Government Entity/Drug-Free Workplace Policies Act
Vermont	Vermont Fair Employment Practices Act Vermont Genetic Testing Discrimination Law Vermont Whistleblower Laws Vermont Parental and Family Leave Act Vermont Earned Sick Time Vermont Occupational Safety and Health Act Vermont Minimum Wage Law Vermont Wage Law
Virginia	Virginians with Disabilities Act Virginia Human Rights Act Virginia Equal Pay Act Virginia Genetic Testing Law Virginia Right-to-Work Law Virginia Occupational Safety and Health Act Virginia Fraud Against Taxpayers Act Virginia Right to Work Law
Washington	Washington Law Against Discrimination Washington Age Discrimination Law Washington Equal Pay Law Washington Sex Discrimination Law Washington Family Leave Act Washington Family Care Act Washington Genetic Testing Protection Law Washington Whistleblower Protection Law Washington Wage, Hour, and Working Conditions Law Washington Wage Payment Law

West Virginia	West Virginia Human Rights Act West Virginia Equal Pay Act West Virginia's Prohibition Against Discrimination for Jury Duty Summons West Virginia Parental Leave Act West Virginia Minimum Wage Law West Virginia Workers' Compensation Act Retaliation Provisions West Virginia Consumer Credit and Protection Act Retaliation Provision Notwithstanding any conflicting terms of the Agreement (if applicable), if you were employed by the Company in West Virginia, then you are provided a minimum of 21 days in which to consider this Agreement, and are provided a 7 day revocation period under Section 77-6-1.1 – 77-6-8.1 of West Virginia's Human Rights Commission Bias Rules.
Wisconsin	Wisconsin Fair Employment Act Wisconsin AIDS Testing Discrimination Law Wisconsin Personnel Records Statute Wisconsin Family and Medical Leave Act Wisconsin Minimum Wage Law Wisconsin Wage Payments, Claims and Collections Law Wisconsin WARN Act Wisconsin Cessation of Health Care Benefits Law Wisconsin Employment Peace Act
Wyoming	Wyoming Fair Employment Practices Act Wyoming Equal Pay Law Wyoming Whistleblower Act Wyoming Minimum Wage Law Wyoming Occupational Health and Safety Act

Exhibit 10.2

EMPLOYMENT AGREEMENT

AGREEMENT by and between Unisys Corporation, a Delaware corporation (the "Company") and xxx (the "Executive"), dated as of xxx.

The Company has determined that it is in the best interests of the Company and its stockholders to assure that the Company will have the continued dedication of the Executive, notwithstanding the possibility, threat or occurrence of a Change of Control (as defined below) of the Company. The Company believes it is imperative to diminish the inevitable distraction of the Executive by virtue of the personal uncertainties and risks created by a pending or threatened Change of Control and to encourage the Executive's full attention and dedication to the Company currently and in the event of any

threatened or pending Change of Control, and to provide the Executive with compensation and benefits arrangements upon a Change of Control which ensure that the compensation and benefits expectations of the Executive will be satisfied and which are competitive with those of other corporations. Therefore, in order to accomplish these objectives, the Company is entering into the Employment Agreement with Executive, dated as of the date set forth above (the "Agreement").

NOW, THEREFORE, IT IS HEREBY AGREED AS FOLLOWS:

1. Certain Definitions.

(a) The "Effective Date" shall mean the first date during the Change of Control Period (as defined in Section 1(b)) on which a Change of Control (as defined in Section 2) occurs. Anything in this Agreement to the contrary notwithstanding, if a Change of Control occurs and if the Executive's employment with the Company is terminated within the twelve (12) month period prior to the date on which the Change of Control occurs, and if it is reasonably demonstrated by the Executive that such termination of employment (i) was at the request of a third party who has taken steps reasonably calculated to effect a Change of Control or (ii) otherwise arose in connection with or anticipation of a Change of Control, then for all purposes of this Agreement the "Effective Date" shall mean the date immediately prior to the date of such termination of employment.

(b) The "Change of Control Period" shall mean the period commencing on the date hereof and ending on the third anniversary of the date hereof; provided, however, that commencing on the date one year after the date hereof, and on each annual anniversary of such date (such date and each annual anniversary thereof shall be hereinafter referred to as the "Renewal Date"), unless previously terminated, the Change of Control Period shall be automatically extended so as to terminate three years from such Renewal Date, unless at least 60 days prior to the Renewal Date the Company shall give notice to the Executive that the Change of Control Period shall not be so extended.

2. Change of Control. For the purpose of this Agreement, a "Change of Control" shall mean:

(a) The date on which occurs the acquisition by any individual, entity or group (within the meaning of Section 13(d)(3) or 14(d)(2) of the Securities Exchange Act of 1934, as amended (the "Exchange Act")) (a "Person") of beneficial ownership (within the meaning of Rule 13d-3 promulgated under the Exchange Act) of 30% or more of the combined voting power of the then

outstanding voting securities of the Company entitled to vote (the "Outstanding Company Voting Securities"); provided, however, that for purposes of this subsection (a), the following acquisitions shall not constitute a Change of Control: (i) any acquisition directly from the Company, (ii) any acquisition by the Company, (iii) any acquisition by any employee benefit plan (or related trust) sponsored or maintained by the Company or any corporation controlled by the Company or (iv) any acquisition by any corporation pursuant to a transaction which complies with clauses (i), (ii) and (iii) of subsection (c) of this Section 2; or

(b) The date a majority of the members of the Board of Directors of the Company (the "Incumbent Board") is replaced during any 12-month period by directors whose appointment or election is not endorsed by the Incumbent Board; provided, however, that any individual becoming a director subsequent to the date hereof whose election, or nomination for election by the Company's stockholders, was approved by a vote of at least a majority of the directors then comprising the Incumbent Board shall be considered as though such individual were a member of the Incumbent Board, but excluding, for

this purpose, any such individual whose initial assumption of office occurs as a result of an actual or threatened election contest with respect to the election or removal of directors or other actual or threatened solicitation of proxies or consents by or on behalf of a Person other than the Incumbent Board; or

(c) Consummation of a merger or consolidation, or sale or other disposition of all or substantially all of the assets, of the Company (a "Business Combination"), in each case, unless, following such Business Combination, (i) all or substantially all of the individuals and entities who were the beneficial owners, respectively, of the then outstanding total fair market value of the shares of common stock of the Company (the "Outstanding Company Common Stock") and the Outstanding Company Voting Securities immediately prior to such Business Combination beneficially own, directly or indirectly, more than 50% of, respectively, the then outstanding shares of common stock and the combined voting power of the then outstanding voting securities entitled to vote generally in the election of directors, as the case may be, of the corporation resulting from such Business Combination (including, without limitation, a corporation which as a result of such transaction owns the Company or all or substantially all of the Company's assets either directly or through one or more subsidiaries) in substantially the same proportions as their ownership, immediately prior to such Business Combination of the Outstanding Company Common Stock and Outstanding Company Voting Securities, as the case may be, (ii) no Person (excluding any corporation resulting from such Business Combination or any employee benefit plan (or related trust) of the Company or such corporation resulting from such Business Combination) beneficially owns, directly or indirectly, 30% or more of, respectively, the then outstanding shares of common stock of the corporation resulting from such Business Combination or the combined voting power of the then outstanding voting securities of such corporation except to the extent that such ownership existed prior to the Business Combination and (iii) at least a majority of the members of the board of directors of the corporation resulting from such Business Combination were members of the Incumbent Board at the time of the execution of the initial agreement, or of the action of the Board of Directors of the Company (the "Board"), providing for such Business Combination.

3. Employment Period. The Company hereby agrees to continue the Executive in its employ, and the Executive hereby agrees to remain in the employ of the Company subject to the terms and

2

conditions of this Agreement, for the period commencing on the Effective Date and ending on the third anniversary of such date (the "Employment Period").

4. Terms of Employment.

(a) Position and Duties.

(i) During the Employment Period, (A) the Executive's position (including status, offices, titles and reporting requirements), authority, duties and responsibilities shall be at least commensurate in all material respects with the most significant of those held, exercised and assigned at any time during the 120-day period immediately preceding the Effective Date and (B) the Executive's services shall be performed at the location where the Executive was employed immediately preceding the Effective Date or any office or location less than 50 miles from such location.

(ii) During the Employment Period, and excluding any periods of vacation and sick leave to which the Executive is entitled, the Executive agrees to devote reasonable attention and time during normal business hours to

the business and affairs of the Company and, to the extent necessary to discharge the responsibilities assigned to the Executive hereunder, to use the Executive's reasonable best efforts to perform faithfully and efficiently such responsibilities. During the Employment Period it shall not be a violation of this Agreement for the Executive to (A) serve on corporate, civic or charitable boards or committees, (B) deliver lectures, fulfill speaking engagements or teach at educational institutions and (C) manage personal investments, so long as such activities do not significantly interfere with the performance of the Executive's responsibilities as an employee of the Company in accordance with this Agreement. It is expressly understood and agreed that to the extent that any such activities have been conducted by the Executive prior to the Effective Date, the continued conduct of such activities (or the conduct of activities similar in nature and scope thereto) subsequent to the Effective Date shall not thereafter be deemed to interfere with the performance of the Executive's responsibilities to the Company.

(b) Compensation.

(i) **Base Salary.** During the Employment Period, the Executive shall receive an annual base salary ("Annual Base Salary"), which shall be paid at a monthly rate, at least equal to twelve times the highest monthly base salary paid or payable, including any base salary which has been earned but deferred, to the Executive by the Company and its affiliated companies in respect of the twelve-month period immediately preceding the month in which the Effective Date occurs. During the Employment Period, the Annual Base Salary shall be reviewed no more than 12 months after the last salary increase awarded to the Executive prior to the Effective Date and thereafter at least annually. Any increase in Annual Base Salary shall not serve to limit or reduce any other obligation to the Executive under this Agreement. Annual Base Salary shall not be reduced after any such increase and the term Annual Base Salary as utilized in this Agreement shall refer to Annual Base Salary as so increased. As used in this Agreement, the term "affiliated companies" shall include any company controlled by, controlling or under common control with the Company.

3

(ii) **Annual Bonus.** In addition to Annual Base Salary, the Executive shall be awarded, for each fiscal year ending during the Employment Period, an annual bonus (the "Annual Bonus") in cash at least equal to the Executive's highest bonus under the Company's Executive Variable Compensation Plan, or any comparable bonus or retention amount under any predecessor or successor plan or retention agreement, for the last three full fiscal years prior to the Effective Date (annualized in the event that the Executive was not employed by the Company for the whole of such fiscal year) (the "Recent Annual Bonus"). Each such Annual Bonus shall be paid on or after January 1 of the fiscal year next following the fiscal year for which the Annual Bonus is awarded, but not later than March 15 of such fiscal year, unless the Executive shall elect to defer the receipt of such Annual Bonus in accordance with the terms of the applicable deferred compensation plan.

(iii) **Incentive, Savings and Retirement Plans.** During the Employment Period, the Executive shall be entitled to participate in all incentive, savings and retirement plans, practices, policies and programs applicable generally to other peer executives of the Company and its affiliated companies, but in no event shall such plans, practices, policies and programs provide the Executive with incentive opportunities (measured with respect to both regular and special incentive opportunities, to the extent, if any, that such distinction is applicable), savings opportunities and

retirement benefit opportunities, in each case, less favorable, in the aggregate, than the most favorable of those provided by the Company and its affiliated companies for the Executive under such plans, practices, policies and programs as in effect at any time during the 120-day period immediately preceding the Effective Date or if more favorable to the Executive, those provided generally at any time after the Effective Date to other peer executives of the Company and its affiliated companies.

(iv) Welfare Benefit Plans. During the Employment Period, the Executive and/or the Executive's family, as the case may be, shall be eligible for participation in and shall receive all benefits under welfare benefit plans, practices, policies and programs provided by the Company and its affiliated companies (including, without limitation, medical, prescription, dental, disability, employee life, group life, accidental death and travel accident insurance plans and programs) to the extent applicable generally to other peer executives of the Company and its affiliated companies, but in no event shall such plans, practices, policies and programs provide the Executive with benefits which are less favorable, in the aggregate, than the most favorable of such plans, practices, policies and programs in effect for the Executive at any time during the 120-day period immediately preceding the Effective Date or, if more favorable to the Executive, those provided generally at any time after the Effective Date to other peer executives of the Company and its affiliated companies.

(v) Expenses. During the Employment Period, the Executive shall be entitled to receive prompt reimbursement for all reasonable expenses incurred by the Executive in accordance with the most favorable policies, practices and procedures of the Company and its affiliated companies in effect for the Executive at any time during the 120-day period immediately preceding the Effective Date or, if more favorable to the Executive, as in effect generally at any time thereafter with respect to other peer executives of the Company and its affiliated companies.

4

(vi) Fringe Benefits. During the Employment Period, the Executive shall be entitled to fringe benefits, including, without limitation, tax and financial planning services, payment of club dues, and, if applicable, use of an automobile and payment of related expenses, in accordance with the most favorable plans, practices, programs and policies of the Company and its affiliated companies in effect for the Executive at any time during the 120-day period immediately preceding the Effective Date or, if more favorable to the Executive, as in effect generally at any time thereafter with respect to other peer executives of the Company and its affiliated companies.

(vii) Office and Support Staff. During the Employment Period, the Executive shall be entitled to an office or offices of a size and with furnishings and other appointments, and to exclusive personal secretarial and other assistance, at least equal to the most favorable of the foregoing provided to the Executive by the Company and its affiliated companies at any time during the 120-day period immediately preceding the Effective Date or, if more favorable to the Executive, as provided generally at any time thereafter with respect to other peer executives of the Company and its affiliated companies.

(viii) Vacation. During the Employment Period, the Executive shall be entitled to paid vacation in accordance with the most favorable plans, policies, programs and practices of the Company and its affiliated companies as in effect for the Executive at any time during the 120-day period immediately preceding the Effective Date or, if more

favorable to the Executive, as in effect generally at any time thereafter with respect to other peer executives of the Company and its affiliated companies.

5. Termination of Employment.

(a) Death or Disability. The Executive's employment shall terminate automatically upon the Executive's death during the Employment Period. If the Company determines in good faith that the Disability of the Executive has occurred during the Employment Period (pursuant to the definition of Disability set forth below), it may give to the Executive written notice in accordance with Section 12(b) of this Agreement of its intention to terminate the Executive's employment. In such event, the Executive's employment with the Company shall terminate effective on the 30th day after receipt of such notice by the Executive (the "Disability Effective Date"), provided that, within the 30 days after such receipt, the Executive shall not have returned to full-time performance of the Executive's duties. For purposes of this Agreement, "Disability" shall mean the absence of the Executive from the Executive's duties with the Company on a full-time basis for 180 consecutive business days as a result of incapacity due to mental or physical illness which is determined to be total and permanent by a physician selected by the Company or its insurers and acceptable to the Executive or the Executive's legal representative.

(b) Cause. The Company may terminate the Executive's employment during the Employment Period for Cause. For purposes of this Agreement, "Cause" shall mean:

(i) the willful and continued failure of the Executive to perform substantially the Executive's duties with the Company or one of its affiliates (other than any such failure resulting from incapacity due to physical or mental illness), after a written demand for substantial performance is delivered to the Executive by the Board or the Chief Executive Officer of the Company which specifically identifies the manner in which the Board or

5

Chief Executive Officer believes that the Executive has not substantially performed the Executive's duties, or

(ii) the willful engaging by the Executive in illegal conduct or gross misconduct which is materially and demonstrably injurious to the Company.

For purposes of this provision, no act or failure to act, on the part of the Executive, shall be considered "willful" unless it is done, or omitted to be done, by the Executive in bad faith or without reasonable belief that the Executive's action or omission was in the best interests of the Company. Any act, or failure to act, based upon authority given pursuant to a resolution duly adopted by the Board or upon the instructions of the Chief Executive Officer or a senior officer of the Company or based upon the advice of counsel for the Company shall be conclusively presumed to be done, or omitted to be done, by the Executive in good faith and in the best interests of the Company. The cessation of employment of the Executive shall not be deemed to be for Cause unless and until there shall have been delivered to the Executive a copy of a resolution duly adopted by the affirmative vote of not less than three-quarters of the entire membership of the Board at a meeting of the Board called and held for such purpose (after reasonable notice is provided to the Executive and the Executive is given an opportunity, together with counsel, to be heard before the Board), finding that, in the good faith opinion of the Board, the Executive is guilty of the conduct described in subparagraph (i) or (ii) above, and specifying the particulars thereof in detail.

(c) **Good Reason.** The Executive's employment may be terminated by the Executive for Good Reason. For purposes of this Agreement, "Good Reason" shall mean, without the Executive's written consent, the occurrence of any of the following on, or within the two year period following, the occurrence of a Change of Control:

(i) a material diminution in Executive's authority, duties or responsibilities as compared to those in effect immediately prior to the occurrence of the Change of Control;

(ii) a material diminution in the Executive's Annual Base Salary, as in effect immediately prior to the occurrence of the Change of Control;

(iii) the Company's requiring the Executive to be based at any office or location that is a material change from which the Executive was required to perform services immediately prior to the date of the Change of Control, which for this purpose a material change shall be deemed to be an office or location that is more than fifty (50) miles from the office or location in which the Executive was required to perform services immediately prior to the date of the Change of Control; or

(iv) any other action or inaction by the Company that constitutes a material breach of this Agreement.

Notwithstanding the foregoing, the Executive shall not be eligible to resign for Good Reason unless and until the Executive has provided written notice to the Company of the occurrence of the event constituting Good Reason, which notice must occur within ninety (90) days following the initial existence of the condition constituting Good Reason, and the Company has a period of thirty (30) days following receipt of such notice to cure the condition. If the Company does not cure the condition constituting Good Reason within such thirty (30) day period, the Date of

6

Termination shall be the day immediately following the end of such thirty (30) day Company cure period, unless the Company provides for an earlier Date of Termination.

(d) **Notice of Termination.** Any termination by the Company for Cause, or by the Executive for Good Reason, shall be communicated by Notice of Termination to the other party hereto given in accordance with Section 12(b) of this Agreement. For purposes of this Agreement, a "Notice of Termination" means a written notice which (i) indicates the specific termination provision in this Agreement relied upon, (ii) to the extent applicable, sets forth in reasonable detail the facts and circumstances claimed to provide a basis for termination of the Executive's employment under the provision so indicated and (iii) if the Date of Termination (as defined below) is other than the date of receipt of such notice, specifies the termination date (which date shall be not more than thirty days after the giving of such notice). The failure by the Company to set forth in the Notice of Termination any fact or circumstance which contributes to a showing of Cause shall not waive any right of the Executive or the Company, respectively, hereunder or preclude the Executive or the Company, respectively, from asserting such fact or circumstance in enforcing the Executive's or the Company's rights hereunder. If the Executive resigns for Good Reason, the Executive will be deemed to have provided the Notice of Termination on the day immediately following the end of the Company's thirty (30) day cure period if the Company has not cured the condition constituting Good Reason as provided in Section 5(c) above, unless prior to such date the Executive has revoked such Notice of Termination.

(e) Date of Termination. "Date of Termination" means (i) if the Executive's employment is terminated by the Company for Cause, the date of receipt of the Notice of Termination or any later date specified therein, as the case may be, (ii) if the Executive's resignation is on account of Good Reason, the Executive's Date of Termination shall be as provided in Section 5(c) above, unless the Company provides for an earlier Date of Termination, (iii) if the Executive's employment is terminated by the Company other than for Cause or Disability, the Date of Termination shall be the date on which the Company notifies the Executive of such termination or any later date specified therein, as the case may be, and (iv) if the Executive's employment is terminated by reason of death or Disability, the Date of Termination shall be the date of death of the Executive or the Disability Effective Date, as the case may be.

6. Obligations of the Company upon Termination.

(a) Good Reason; Other Than for Cause, Death or Disability. If, during the Employment Period, the Company shall terminate the Executive's employment other than for death, Cause or Disability or the Executive shall terminate employment for Good Reason, then, if Executive executes and does not revoke a Release (as defined in Section 6(v)) within the time period required by the Company, Executive shall receive the following:

(i) unless delay is required pursuant to Section 13(b) below, the Company shall pay to the Executive in a lump sum in cash within 75 days after the Date of Termination the aggregate of the following amounts:

A. the sum of (1) the Executive's Annual Base Salary through the Date of Termination to the extent not theretofore paid or deferred, (2) the product of (x) the higher of (I) the Recent Annual Bonus and (II) the Annual Bonus paid or payable, including any bonus or portion thereof which has been earned but deferred (and annualized for any fiscal year consisting of less than twelve full months or during

7

which the Executive was employed for less than twelve full months), for the most recently completed fiscal year during the Employment Period, if any (such higher amount being referred to as the "Highest Annual Bonus") and (y) a fraction, the numerator of which is the number of days in the current fiscal year through the Date of Termination, and the denominator of which is 365 and (3) any accrued vacation pay, to the extent not theretofore paid (the sum of the amounts described in clauses (1), (2), and (3) shall be hereinafter referred to as the "Accrued Obligations"; provided, however, that any such amounts that Executive shall have previously elected to defer shall not be paid in a lump sum in cash but shall instead be credited to the Executive's account under the relevant deferred compensation plan and paid to the Executive in accordance with the terms of such plan); and

B. the amount equal to the product of (1) two and (2) the sum of (x) the Executive's Annual Base Salary and (y) the Highest Annual Bonus;

C. an amount equal to the value of the monthly premium cost that the Company would have had to pay to continue Executive and/or the Executive's family in the plans, programs, practices and policies described in Section 4(b)(iv) of this Agreement (other than continuation of health benefits) if the Executive's employment had not been terminated for the two year period following Executive's Date of Termination; provided, that if the Executive is eligible for a death benefit under any Unisys death benefit only plan in accordance with the terms of such plan, no premium will be payable to the Executive for such benefit.

(ii) for a period of up to two years following Executive's Date of Termination, Executive and Executive's spouse and eligible dependents, shall continue to be eligible to receive health benefits coverage under Company health plans described in Section 4(b)(iv) of this Agreement in accordance with the terms of the applicable plan documents, at the same premium rates as may be charged from time to time for employees of the Company generally, as if Executive had continued in employment with the Company during such period; provided, that in order to receive such continued coverage at such rates, Executive shall be required to pay to the Company at the same time that premium payments are due for the month an amount equal to the full monthly premium required by the Company under such plans for such coverage (in accordance with payment instructions from the Company), and the Company shall reimburse to Executive, within 60 days following the date such monthly premium payment is due, an amount equal to the monthly premium payment, less the amount that Executive would have been required to pay for such coverage if Executive had remained employed by the Company at such time (the "Health Payment"). The period of continuation of group health plan coverage under section 4980B ("COBRA") of the Internal Revenue Code of 1986, as amended (the "Code") (the "COBRA Period") runs concurrently during the period for which the Health Payment is paid to Executive. The Health Payment during the COBRA Period is intended to qualify for the exception for deferred compensation as a medical benefit provided in accordance with the requirements of Section 409A of the Code and Treas. Reg. §1.409A-1(b)(9)(v)(B). If Executive does not pay the applicable monthly premium for a particular month at any time during the two year period, no further Health Payment will be paid to Executive. For purposes of determining eligibility (but not the time of commencement of benefits) of the Executive for retiree benefits

pursuant to such health plans, the Executive shall be considered to have remained employed until two years after the Date of Termination and to have retired on the last day of such period, if permitted by the applicable plan;

(iii) the Company shall, at its sole expense as actually incurred by Executive, provide the Executive with reasonable outplacement services directly related to the termination of Executive's employment with the Company, the provider of which shall be selected by the Executive in his sole discretion, provided that such outplacement service coverage shall not extend beyond the last day of the second taxable year of Executive following the taxable year of Executive in which the termination of employment occurred; and

(iv) to the extent not theretofore paid or provided, in accordance with the terms of the relevant plans, programs, policies or practices or contracts or agreements, the Company shall timely pay or provide to the Executive any other amounts or benefits required to be paid or provided or which the Executive is eligible to receive under any such plan, program, policy or practice or contract or agreement of the Company and its affiliated companies (such other amounts and benefits shall be hereinafter referred to as the "Other Benefits").

If the Executive becomes entitled to the severance benefits provided in this Section 6(a) as a result of Section 1(a) of this Agreement and Executive's termination prior to the Change of Control was for a reason under this Section 6(a), (A) the cash severance benefits payable to the Executive under clause 6(a)(i) shall be reduced by the amount payable to Executive on account of Executive's termination prior to the Change of Control and, unless delay is required pursuant to Section 13(b) below, shall be paid to Executive within 75 days following the date of the Change of Control if the Change of

Control constitutes a change in the ownership or effective control of the Company, or in the ownership of a substantial portion of the assets of the Company, within the meaning of Section 409A(a)(2)(A)(v) of the Code and its corresponding regulations (a "409A Change of Control"), or if the Change of Control does not constitute a 409A Change of Control, such amounts shall be paid to Executive within 75 days following the first anniversary of the Executive's Date of Termination; (B) severance benefits provided pursuant to clause 6(a)(ii) shall only be applicable if the period provided in clause 6(a)(ii) is longer than that provided to Executive on Executive's Date of Termination, and in such event, the period of time such severance benefits are provided shall be extended to reflect the additional period provided in clause 6(a)(ii) as measured from Executive's Date of Termination; (C) severance benefits provided in clause 6(a)(iii) shall apply as of the date of the Change of Control, provided that the measurement period for purposes of Section 409A of the Code commences on the Executive's Date of Termination; and (D) the Other Benefits shall be payable in accordance with the terms of the applicable plans, programs, policies or practices or contracts or agreements.

(b) Death. If the Executive's employment is terminated by reason of the Executive's death during the Employment Period, this Agreement shall terminate without further obligations to the Executive's legal representatives under this Agreement, other than for payment of Accrued Obligations and the timely payment or provision of Other Benefits. Accrued Obligations shall be paid to the Executive's estate or beneficiary, as applicable, in a lump sum in cash within 75 days following the Date of Termination. With respect to the provision of Other Benefits, the term

9

Other Benefits as utilized in this Section 6(b) shall include, without limitation, and the Executive's estate and/or beneficiaries shall be entitled to receive, benefits at least equal to the most favorable benefits provided by the Company and affiliated companies to the estates and beneficiaries of peer executives of the Company and such affiliated companies under such plans, programs, practices and policies relating to death benefits, if any, as in effect with respect to other peer executives and their beneficiaries at any time during the 120-day period immediately preceding the Effective Date or, if more favorable to the Executive's estate and/or the Executive's beneficiaries, as in effect on the date of the Executive's death with respect to other peer executives of the Company and its affiliated companies and their beneficiaries.

(c) Disability. If the Executive's employment is terminated by reason of the Executive's Disability during the Employment Period, this Agreement shall terminate without further obligations to the Executive, other than for payment of Accrued Obligations and the timely payment or provision of Other Benefits. Unless delay is required pursuant to Section 13(b) below, Accrued Obligations shall be paid to the Executive in a lump sum in cash within 75 days following the Date of Termination. With respect to the provision of Other Benefits, the term Other Benefits as utilized in this Section 6(c) shall include, and the Executive shall be entitled after the Disability Effective Date to receive, disability and other benefits at least equal to the most favorable of those generally provided by the Company and its affiliated companies to disabled executives and/or their families in accordance with such plans, programs, practices and policies relating to disability, if any, as in effect generally with respect to other peer executives and their families at any time during the 120-day period immediately preceding the Effective Date or, if more favorable to the Executive and/or the Executive's family, as in effect at any time thereafter generally with respect to other peer executives of the Company and its affiliated companies and their families.

(d) Cause; Other than for Good Reason. If the Executive's employment shall be terminated for Cause during the Employment Period, this Agreement shall terminate without further obligations to the Executive other than the obligation to

pay to the Executive (x) his Annual Base Salary through the Date of Termination, and (y) Other Benefits, in each case to the extent not theretofore paid or deferred. If the Executive voluntarily terminates employment during the Employment Period, excluding a termination for Good Reason, this Agreement shall terminate without further obligations to the Executive, other than for Accrued Obligations and the timely payment or provision of Other Benefits. In such case, unless delay is required pursuant to Section 13(b) below, all Accrued Obligations shall be paid to the Executive in a lump sum in cash within 75 days following the Date of Termination.

(e) Release. Notwithstanding the foregoing, no payments under this Section 6 of this Agreement shall be made unless Executive executes, and does not revoke, the Company's standard written release, the current version of which is substantially in the form attached hereto as Annex A (the "Release"), of any and all claims against the Company and all related parties with respect to all matters arising out of Executive's employment by the Company (other than entitlements under the terms of this Agreement) or a termination thereof.

7. Non-exclusivity of Rights. Nothing in this Agreement shall prevent or limit the Executive's continuing or future participation in any plan, program, policy or practice provided by the Company or any of its affiliated companies and for which the Executive may qualify, nor,

10

subject to Section 12(f), shall anything herein limit or otherwise affect such rights as the Executive may have under any contract or agreement with the Company or any of its affiliated companies. Amounts which are vested benefits or which the Executive is otherwise entitled to receive under any plan, policy, practice or program of or any contract or agreement with the Company or any of its affiliated companies at or subsequent to the Date of Termination shall be payable in accordance with such plan, policy, practice or program or contract or agreement except as explicitly modified by this Agreement.

8. Full Settlement. The Company's obligation to make the payments provided for in this Agreement and otherwise to perform its obligations hereunder shall not be affected by any set-off, counterclaim, recoupment, defense or other claim, right or action which the Company may have against the Executive or others. In no event shall the Executive be obligated to seek other employment or take any other action by way of mitigation of the amounts payable to the Executive under any of the provisions of this Agreement and such amounts shall not be reduced whether or not the Executive obtains other employment. The Company agrees to pay as incurred, to the full extent permitted by law, all legal fees and expenses which the Executive may reasonably incur as a result of any contest (regardless of the outcome thereof) by the Company, the Executive or others of the validity or enforceability of, or liability under, any provision of this Agreement or any guarantee of performance thereof (including as a result of any contest by the Executive about the amount of any payment pursuant to this Agreement), plus in each case interest on any delayed payment at the applicable Federal rate provided for in Section 7872(f)(2)(A) of the Code.

9. Certain Reductions in Payments.

(a) Anything in this Agreement to the contrary notwithstanding, in the event Grant Thornton LLP or such other accounting firm as shall be designated by the Company prior to the Effective Date (the "Accounting Firm") shall determine that receipt of all payments or distributions by the Company or its affiliated companies in the nature of compensation to or for the Executive's benefit, whether paid or payable pursuant to this Agreement or otherwise (a "Payment") would subject

the Executive to the excise tax under Section 4999 of the Code, the Accounting Firm shall determine whether to reduce any of the Payments paid or payable pursuant to this Agreement (the "Agreement Payments") to the Reduced Amount (as defined below). The Agreement Payments shall be reduced to the Reduced Amount only if the Accounting Firm determines that the Executive would have a greater Net After-Tax Receipt (as defined below) of aggregate Payments if the Executive's Agreement Payments were reduced to the Reduced Amount. If such a determination is not made by the Accounting Firm, the Executive shall receive all Agreement Payments to which the Executive is entitled under this Agreement.

(b) If the Accounting Firm determines that aggregate Agreement Payments should be reduced to the Reduced Amount, the Company shall promptly give the Executive notice to that effect and a copy of the detailed calculation thereof. All determinations made by the Accounting Firm under this Section 9 shall be binding upon the Company and the Executive and shall be made within 60 days of a termination of the Executive's employment. The reduction of the amounts payable hereunder, if applicable, shall be made by reducing the payments and benefits under the following sections in the following order: Section 6(a)(i)(B); Section 6(a)(iii); Section 6(a)(i)(C); Section 6(a)(ii). All fees and expenses of the Accounting Firm shall be borne solely by the Company.

11

(c) As a result of the uncertainty in the application of Section 4999 of the Code at the time of the initial determination by the Accounting Firm hereunder, it is possible that amounts will have been paid or distributed by the Company to or for the benefit of the Executive pursuant to this Agreement which should not have been so paid or distributed ("Overpayment") or that additional amounts which will have not been paid or distributed by the Company to or for the benefit of the Executive pursuant to this Agreement could have been so paid or distributed ("Underpayment"), in each case, consistent with the calculation of the Reduced Amount hereunder. In the event that the Accounting Firm, based upon the assertion of a deficiency by the Internal Revenue Service against either the Company or the Executive which the Accounting Firm believes has a high probability of success determines that an Overpayment has been made, the Executive shall pay any such Overpayment to the Company together with interest at the applicable federal rate provided for in Section 7872(f)(2)(A) of the Code; provided, however, that no amount shall be payable by the Executive to the Company if and to the extent such payment would not either reduce the amount on which the Executive is subject to tax under Section 1 and Section 4999 of the Code or generate a refund of such taxes. In the event that the Accounting Firm, based upon controlling precedent or substantial authority, determines that an Underpayment has occurred, any such Underpayment shall be promptly paid by the Company to or for the benefit of the Executive together with interest at the applicable federal rate provided for in Section 7872(f)(2)(A) of the Code.

(d) For purposes hereof, the following terms have the meanings set forth below:

(i) "Reduced Amount" shall mean the greatest amount of Agreement Payments that can be paid that would not result in the imposition of the excise tax under Section 4999 of the Code if the Accounting Firm determines to reduce Agreement Payments pursuant to Section 9(a).

(ii) "Net After-Tax Receipt" shall mean the present value (as determined in accordance with Sections 280G(b)(2)(A)(ii) and 280G(d)(4) of the Code) of a Payment net of all taxes imposed on the Executive with respect thereto under Sections 1 and 4999 of the Code and under applicable state and local laws, determined by applying the highest marginal rate under Section 1 of the Code and under state and local laws which applied to the Executive's

taxable income for the immediately preceding taxable year, or such other rate(s) as the Executive certifies, in the Executive's sole discretion, as likely to apply to him in the relevant tax year(s).

(e) Compliance with Company Policy. For avoidance of doubt, all compensation, including any payment or benefit provided for in this Agreement, is paid pursuant to Company policy, including the Executive Clawback Policy for Recoupment of Erroneously Awarded Compensation.

10. Confidential Information. The Executive shall hold in a fiduciary capacity for the benefit of the Company all secret or confidential information, knowledge or data relating to the Company or any of its affiliated companies, and their respective businesses, which shall have been obtained by the Executive during the Executive's employment by the Company or any of its affiliated companies and which shall not be or become public knowledge (other than by acts by the Executive or representatives of the Executive in violation of this Agreement). After termination of the Executive's employment with the Company, the Executive shall not, without the prior written consent of the Company or as may otherwise be required by law or legal

12

process, communicate or divulge any such information, knowledge or data to anyone other than the Company and those designated by it. Further, pursuant to the Federal Defend Trade Secrets Act, the Executive cannot be held criminally or civilly liable under any federal or state trade secret law for disclosing a trade secret if that disclosure is made: (i) in confidence to a federal, state, or local government official, either directly or indirectly, or to any attorney, and for the sole purpose of reporting or investigating a suspected violation of law; or (ii) in a complaint or other document filed in a lawsuit or similar proceeding, provided that filing is made under seal. In no event shall an asserted violation of the provisions of this Section 10 constitute a basis for deferring or withholding any amounts otherwise payable to the Executive under this Agreement.

11. Successors.

(a) This Agreement is personal to the Executive and without the prior written consent of the Company shall not be assignable by the Executive otherwise than by will or the laws of descent and distribution. This Agreement shall inure to the benefit of and be enforceable by the Executive's legal representatives.

(b) This Agreement shall inure to the benefit of and be binding upon the Company and its successors and assigns.

(c) The Company will require any successor (whether direct or indirect, by purchase, merger, consolidation or otherwise) to all or substantially all of the business and/or assets of the Company to assume expressly and agree to perform this Agreement in the same manner and to the same extent that the Company would be required to perform it if no such succession had taken place. As used in this Agreement, "Company" shall mean the Company as hereinbefore defined and any successor to its business and/or assets as aforesaid which assumes and agrees to perform this Agreement by operation of law, or otherwise.

12. Miscellaneous.

(a) This Agreement shall be governed by and construed in accordance with the laws of the State of Delaware, without reference to principles of conflict of laws. The captions of this Agreement are not part of the provisions hereof and

shall have no force or effect. This Agreement may not be amended or modified otherwise than by a written agreement executed by the parties hereto or their respective successors and legal representatives.

(b) All notices and other communications hereunder shall be in writing and shall be given by hand delivery to the other party or by registered or certified mail, return receipt requested, postage prepaid, addressed as follows:

If to the Executive:

Name

Address

Address

If to the Company:

801 Lakeview Drive, Suite 100

Blue Bell, PA 19422

Attention: General Counsel

13

or to such other address as either party shall have furnished to the other in writing in accordance herewith. Notice and communications shall be effective when actually received by the addressee.

(c) The invalidity or unenforceability of any provision of this Agreement shall not affect the validity or enforceability of any other provision of this Agreement.

(d) The Company may withhold from any amounts payable under this Agreement such Federal, state, local or foreign taxes as shall be required to be withheld pursuant to any applicable law or regulation.

(e) The Executive's or the Company's failure to insist upon strict compliance with any provision of this Agreement or the failure to assert any right the Executive or the Company may have hereunder, including, without limitation, the right of the Executive to terminate employment for Good Reason pursuant to Section 5(c)(i)-(v) of this Agreement, shall not be deemed to be a waiver of such provision or right or any other provision or right of this Agreement.

(f) The Executive and the Company acknowledge that, except as may otherwise be provided under any other written agreement between the Executive and the Company, the employment of the Executive by the Company is "at will" and, subject to Section 1(a) hereof, prior to the Effective Date, the Executive's employment and/or this Agreement may be terminated by either the Executive or the Company at any time prior to the Effective Date, in which case the Executive shall have no further rights under this Agreement. From and after the Effective Date this Agreement shall supersede any other agreement between the parties with respect to the subject matter hereof.

13. Compliance with Section 409A of the Code.

(a) Notwithstanding the other provisions hereof, this Agreement is intended to comply with the requirements of Section 409A of the Code, to the extent applicable, and this Agreement shall be interpreted to avoid any penalty sanctions under Section 409A of the Code. Accordingly, all provisions herein, or incorporated by reference, shall be construed and

interpreted to comply with Section 409A and, if necessary, any such provision shall be deemed amended to comply with Section 409A of the Code and regulations thereunder. All payments to be made upon a termination of employment under this Agreement may only be made upon a "separation from service" under Section 409A of the Code. If any payment or benefit cannot be provided or made at the time specified herein without incurring sanctions under Section 409A of the Code, then such benefit or payment shall be provided in full at the earliest time thereafter when such sanctions will not be imposed. For purposes of Section 409A of the Code, each payment made under this Agreement shall be treated as a separate payment. In no event may Executive, directly or indirectly, designate the calendar year of any payment to be made under this Agreement. If the period to review and revoke the Release begins in one calendar year and ends in the next calendar year, the payment will be made in the second calendar year on a date determined by the Company if the payment is nonqualified deferred compensation subject to Section 409A of the Code.

(b) Notwithstanding any provision to the contrary in this Agreement, if on the date of Executive's separation from service, Executive is a "specified employee" (as such term is defined in Section 409A(a)(2)(B)(i) of the Code and its corresponding regulations) as determined in the sole discretion of the Company (or any successor thereto) in accordance with the

14

Company's (or any successor's) "specified employee" determination policy, then all severance benefits payable to Executive under this Agreement that are deemed as deferred compensation subject to the requirements of Section 409A of the Code shall be postponed for a period of six months following Executive's separation from service with the Company (or any successor thereto). The postponed amounts shall be paid to Executive in a lump sum on the first business day after the date that is six months following Executive's separation from service with the Company (or any successor thereto). If Executive dies during such six-month period and prior to payment of the postponed amounts hereunder, the amounts delayed on account of Section 409A of the Code shall be paid to the personal representative of Executive's estate within 75 days after Executive's death.

(c) All reimbursements provided under this Agreement that are provided under a nonqualified deferred compensation plan within the meaning of Section 409A of the Code and Treas. Reg. §1.409A-1(a) shall be made or provided in accordance with the requirements of Section 409A of the Code and Treas. Reg. §1.409A-3(i)(1)(iv).

(d) Notwithstanding anything herein to the contrary, if Executive is entitled to severance benefits prior to the Change of Control in a form other than in a lump sum, the severance benefits payable under this Agreement in the form of a lump sum shall only be paid in a lump sum if the Change of Control qualifies as a 409A Change of Control and the Executive's Date of Termination occurs within the two year period following the date of the 409A Change of Control. If the Change of Control does not qualify as a 409A Change of Control or Executive's Date of Termination is after the second anniversary of the 409A Change of Control, the severance benefits payable under this Agreement will be payable in the same form as the severance benefits that were payable to Executive for periods prior to a Change of Control.

IN WITNESS WHEREOF, the Executive has hereunto set the Executive's hand and the Company has caused these presents to be executed in its name on its behalf, all as of the day and year first above written.

Dated: _____, 20__

NAME OF EXECUTIVE

UNISYS CORPORATION

Dated: _____, 20__

By: _____
Ruchi Kulhari
Senior Vice President,
Chief Human Resources Officer

15

ANNEX A

FORM OF RELEASE

GENERAL RELEASE

1. I, _____, agree that I have been allowed at least twenty-one (21) days to consider the meaning and effect of this Release (this "Release") and that this Release constitutes written notice that I have been advised to consult with an attorney prior to executing this Release. You agree that any modifications, material or otherwise, made to this agreement do not restart or affect in any manner the original at least twenty-one (21) calendar day consideration period.
2. I acknowledge that I have seven (7) days from the day I sign this Release to revoke my acceptance of this Release and this Release shall not become effective or enforceable until this revocation period has expired. To the extent the Release purports to release claims pursuant to the Minnesota Human Rights Act, I acknowledge that I have fifteen (15) days from the day I sign this Release to revoke my acceptance of this Release and this Release shall not become effective or enforceable until the sixteenth (16th) day after the day I have signed and returned it, provided that I have not revoked this Release during the Revocation Period.
3. I acknowledge that all amounts payable pursuant to the letter agreement dated as of _____, 20__ (the "Agreement") that I have entered into with Unisys Corporation (the "Company") are subject to applicable tax withholdings. In addition, I acknowledge that I am solely responsible for all taxes that may result from my receipt of the amounts payable and benefits to be provided to me under the Agreement, and neither the Company nor any of its affiliates makes or has made any representation, warranty or guarantee of any federal, state or local tax consequences to me of my receipt of any payment or benefit hereunder, including, but not limited to, under Section 409A of the Internal Revenue Code of 1986, as amended.
4. In consideration for the payments to me by the Company under the Agreement and other good and valuable consideration, which I acknowledge are adequate and satisfactory to me, and intending to be legally bound, I knowingly and voluntarily hereby release the Company, its shareholders, directors, officers, employees, agents, benefit plans, attorneys, affiliates, parents, subsidiaries, predecessors, successors, assigns, and all persons acting by, through, under or in concert with any of them (collectively, "Released Parties"), from any and all rights, causes of action, suits, debts, claims and demands in law or in equity (collectively, "Claims"), known

or unknown, that I or which my heirs, executors or administrators may have now or in the future may arise based on, arising out of or relating to my employment with the Company or the termination thereof for any and all reasons. Said release includes, but is not limited to, any Claims which I may have against any of the Released Parties based upon Title VII of the Civil Rights Act of 1964, 42 U.S.C. § 2000e et seq., as amended, the Civil Rights Act of 1866, 42 U.S.C. § 1981, as amended (including, but not limited to, 42 U.S.C. § 1981a), the Americans with Disabilities Act of 1990, 42 U.S.C. § 12101 et seq., as amended, the Age Discrimination in Employment Act, 29 U.S.C. § 621 et seq., as amended, including the Older Workers Benefit Protection Act ("OWBPA"); the Employee Retirement Income Security Act of 1974, 29 U.S.C. § 1001 et seq., as amended, the Family Medical Leave Act, 29 U.S.C. § 2601 et seq., as amended, any applicable state laws identified on Schedule 1 hereto (to the greatest extent such release is permissible under applicable law), as well as any Claims for breach of any employment contract or agreement (written, oral, or implied), wrongful discharge, breach of the covenant of good faith and fair dealing, promissory and/or equitable estoppel, tort claims of any nature, and any Claims which may have been asserted under the common law or any other federal, state or local law, as well as all claims for counsel fees and costs. This Release covers claims that I know about and those that I may not know about up through the date of this Release.

Notwithstanding the generality of the foregoing, I am not releasing or waiving any rights I may have: (i) under COBRA; (ii) to my own vested accrued employee benefits under Unisys's health, welfare, or retirement benefit plans as of the last date of employment; (iii) to benefits and/or the right to seek benefits under applicable workers' compensation and/or unemployment compensation statutes; (iv) to pursue claims which by law cannot be waived by signing this Agreement and/or which may arise after the execution of this Agreement; (v) to enforce this Agreement; and/or (vi) to challenge the validity of this Agreement.

5. I acknowledge that, by reason of the position which I held within Unisys that I have become familiar with highly confidential and/or proprietary information relating to the business of Unisys such as various customer lists, sales and marketing strategies and plans, bids, projections, costs, financial data, personnel information developments, improvements, processes, methods, tools and customer relationships. I further recognize that the business of Unisys is highly competitive, and that Unisys has a legitimate business interest in preserving any and all trade secrets and other highly confidential and/or proprietary information that I may have acquired from Unisys, which are essential to the continued success of Unisys, and that Unisys will suffer irreparable harm should such confidential information be utilized by a competitor. I further acknowledge that all such confidential and/or proprietary information and trade secrets acquired through my employment are owned and shall continue to be owned by Unisys.

6. I agree that I will not, at any time, whether during my term of employment or thereafter, disclose to any unauthorized person, firm or corporation any information I acquired in confidence through my employment with Unisys, it being understood that all such confidential and/or proprietary information constitutes trade secrets that are material to the successful conduct of Unisys and belong exclusively to Unisys. By way of example and not limitation, such confidential and/or proprietary information and trade secrets include any and all information, not otherwise available to the public, concerning: (i) marketing plans, business plans, strategies, forecasts, unpublished financial statements, budgets, bids, projections and costs; (ii) personnel information; (iii) customer lists, customer and supplier transaction histories, identities, contacts, volumes, characteristics, agreements and prices; (iv) information regarding promotional, operational, program management, sales, marketing, research and development techniques, methods and reports and (v) other trade secrets. I specifically acknowledge that such confidential and/or proprietary information and trade secrets have commercial value to Unisys, the unauthorized disclosure of which could be detrimental to the interests of Unisys, whether or not such information is specifically identified as "Confidential" and/or "Proprietary" information by Unisys. Provided, however, that the restrictions of this paragraph shall not extend to any information or materials that are either known to the public or that can be derived, compiled or learned by a third party without significant effort or expense. Nothing in this Release, any other agreement between Unisys and

myself, or any other policies of Unisys shall prohibit or restrict me or my attorneys from: (a) making any disclosure of relevant and necessary information or documents in any action, investigation, or proceeding relating to this Release, or as required by law or legal process, including with respect to possible violations of the law; (b) participating, cooperating, or testifying in any action, investigation, or proceeding with, or providing information to, any governmental agency or legislative body, any self-regulatory organization, and/or pursuant to the Sarbanes-Oxley Act; or (c) accepting any U.S. Securities and Exchange Commission awards. Notwithstanding my preexisting obligations with respect to Unisys's confidential information, pursuant to the federal Defend Trade Secrets Act, I understand that I cannot be held criminally or civilly liable under any federal or state trade secret law for disclosing a trade secret if that disclosure is made: (i) in confidence to a federal, state, or local government official, either directly or indirectly, or to any attorney, and for the sole purpose of reporting or investigating a suspected violation of law; or (ii) in a complaint or other document filed in a lawsuit or similar proceeding, provided that filing is made under seal.

17

7. I acknowledge that the restrictions contained in the foregoing paragraphs 5 and 6, in view of the nature of the work performed by Unisys, are reasonable and necessary in order to protect the legitimate interests of Unisys, and that any violation thereof may result in irreparable injuries to Unisys, and I therefore acknowledge that, in the event of any violation of any of these restrictions, Unisys may be entitled to obtain from any court of competent jurisdiction preliminary and permanent injunctive relief as well as damages and an equitable accounting of all earnings, profits and other benefits arising from such violation, which rights shall be cumulative and in addition to any other rights or remedies to which Unisys may be entitled.

8. Nothing in this Release shall prohibit or restrict me, Unisys, or their respective attorneys from: (i) filing or disclosing any facts necessary to receive unemployment insurance, Medicaid, or other public benefits to which I am entitled; (ii) making any disclosure of relevant and necessary information or documents in connection with any charge, action, investigation, or proceeding relating to this Release or as required by law or legal process; (iii) initiating, testifying, assisting, complying with a subpoena from, or participating in any manner with an investigation conducted by a self-regulatory authority or a government agency or entity, including without limitation, the U.S. Department of Labor, the National Labor Relations Board, the U.S. Department of Justice, the U.S. Securities and Exchange Commission, the U.S. Commodities Futures Trading Commission, the Financial Industry Regulatory Authority, the Occupational Safety and Health Administration, the U.S. Congress, any other federal, state, or local government agency or commission, and any agency Inspector General (collectively, the "Regulators"), or from making other disclosures that are protected under the whistleblower provisions of federal, state, or local law or regulation; to the extent permitted by law, upon receipt of any subpoena, court order or other legal process compelling the disclosure of any such information or documents, I shall give prompt written notice to Unisys so as to permit Unisys to protect its interests in confidentiality to the fullest extent possible. I do not need the prior authorization of Unisys to engage in conduct protected by this paragraph, and I do not need to notify Unisys that I have engaged in such conduct. This Release does not limit my right to receive an award from any Regulator that provides awards for providing information relating to a potential violation of the law. I recognize and agree that, in connection with any such activity outlined above, I must inform the Regulators, my attorney, a court or a government official that the information I am providing is confidential. Despite the foregoing, I am not permitted to reveal to any third-party, including any governmental, law enforcement, or regulatory authority, information I came to learn during the course of my employment with Unisys that is protected from disclosure by any applicable privilege, including but not limited to the attorney-client privilege and/or attorney work product doctrine. Unisys does not waive any applicable privileges or the right to continue to protect its privileged attorney-client information, attorney work product, and other privileged information.

9. If in connection with any investigation, government inquiry, threatened litigation, or filed litigation involving Unisys, I am called upon to assist Unisys; to provide evidence; or to testify in any manner, I agree to reasonably cooperate fully with Unisys in connection

with any matter arising out of or related to my former employment. If requested by Unisys, I agree to be present and participate in the trial of any such matter. I will, to the extent permitted by applicable law, be reimbursed for my reasonable costs and expenses for any time spent assisting Unisys in this regard.

10. In the event that, any one or more provisions (or portion thereof) of this Release is held to be invalid, unlawful or unenforceable for any reason, the invalid, unlawful or unenforceable provision (or portion thereof) shall be construed or modified so as to provide the Released Parties with the maximum protection that is valid, lawful and enforceable, consistent with my intent in entering into this Release. If such provision (or portion thereof) cannot be construed or modified so as to be valid, lawful and enforceable, that provision (or portion thereof) shall be construed as narrowly as possible and shall be severed from the remainder of this Release (or provision), and the remainder shall remain in effect and be

18

construed as broadly as possible, as if such invalid, unlawful or unenforceable provision (or portion thereof) had never been contained in this Release.

11. This Release shall be construed and enforced under and in accordance with the laws of the Commonwealth of Pennsylvania.

THE COMPANY HEREBY ADVISES YOU THAT YOU HAVE AT LEAST TWENTY-ONE (21) CALENDAR DAYS TO REVIEW THIS RELEASE AND HEREBY ADVISES YOU TO CONSULT WITH AN ATTORNEY PRIOR TO EXECUTION OF THIS RELEASE.

YOU AGREE THAT ANY MODIFICATIONS, MATERIAL OR OTHERWISE, MADE TO THIS RELEASE DO NOT RESTART OR AFFECT IN ANY MANNER THE ORIGINAL AT LEAST TWENTY-ONE (21) CALENDAR DAY CONSIDERATION PERIOD.

HAVING ELECTED TO EXECUTE THIS RELEASE, TO FULFILL THE PROMISES AND TO RECEIVE THE CONSIDERATION IN ACCORDANCE WITH THE AGREEMENT REFERENCES IN PARAGRAPH 3 ABOVE, YOU FREELY AND KNOWINGLY, AND AFTER DUE CONSIDERATION, ENTER INTO THIS RELEASE INTENDING TO WAIVE, SETTLE AND RELEASE ALL CLAIMS YOU HAVE OR MIGHT HAVE AGAINST RELEASEES AS SET FORTH IN THIS AGREEMENT.

I, _____, do hereby knowingly and voluntarily enter into this agreement as of the dates set forth below.

Executed this _____ day of _____, 20____.

Agreed: _____

NAME OF EXECUTIVE

19

SCHEDULE 1

By entering into this Separation Agreement And General Release (“Agreement”), the individual identified in the signature block of the Agreement (“Employee”) acknowledges and agrees that the release set forth in the Agreement extends to include, but is not limited to, the laws of any state in which Employee performed work for Unisys, or that otherwise might apply to Employee’s employment with Unisys, or the termination thereof (each to the extent applicable, and as amended from time to time):

Alabama	Alabama Age Discrimination in Employment Act Alabama Unlawful Practices related to Opposition of Employer under Section 25-1-28 of the Alabama Code Alabama Whistleblower Protection Law Alabama Pay Equity Law Retaliatory or Constructive Discharge and for co-employer liability under Sections 25-5-11 and 25-5-11.1 of the Alabama Code.
Alaska	Alaska Human Rights Law Alaska Family and Medical Leave Law Alaska Occupational Safety and Health Law Alaska Uniform Contribution Among Tortfeasors Act
Arizona	Arizona Civil Rights Act Arizona Employment Protection Act Arizona Occupational Safety and Health Law Arizona Right to Work Act
Arkansas	Arkansas Civil Rights Act of 1993 Arkansas Equal Pay Law Arkansas Minimum Wage Act Arkansas Wage Payment Laws Arkansas Uniform Contribution Among Tortfeasors Act
California	California Family Rights Act California Fair Employment and Housing Act California Civil Code California Labor Code (except as prohibited by law) Unruh Civil Rights Act California Fair Pay Act California Pregnancy Disability Leave Law California WARN Act

Colorado	<p>Colorado Anti-Discrimination Act</p> <p>Colorado Equal Pay Law</p> <p>Colorado Law Prohibiting Discrimination by Labor Organization</p> <p>Colorado Whistleblower Law</p> <p>Colorado Maternity Leave Law</p> <p>Colorado Healthy Families and Workplaces</p> <p>Colorado Minimum Wage Law</p> <p>Colorado Minimum Wage Order No. 32</p> <p>Colorado Labor Peace Act</p>
Connecticut	<p>Connecticut Fair Employment Practices Act</p> <p>Connecticut Human Rights and Opportunities Act</p> <p>Connecticut Family and Medical Leave Law</p> <p>Connecticut General Statute Paid Sick Leave</p> <p>Connecticut Whistleblower Law</p> <p>Connecticut Free Speech Law</p> <p>Connecticut WARN Law</p> <p>Connecticut Human Rights and Opportunities Act</p> <p>Connecticut Minimum Wage and Overtime Law</p> <p>Connecticut Equal Pay Act</p> <p>Connecticut Maximum Hours and Overtime Law (provided, however, that nothing in this Agreement shall be construed as a release of disputed wages as a condition to receive wages conceded to be due).</p>
Delaware	<p>Delaware Discrimination in Employment Act</p> <p>Delaware Handicapped Persons Employment Protection Act</p> <p>Delaware Persons with Disabilities Employment Protections Act</p> <p>Delaware Whistleblower's Act</p> <p>Delaware Wage Payment and Collection Act</p> <p>Delaware Fair Employment Practices Act (provided, however, that nothing in this agreement shall be construed as a requirement for or condition to any payment due under the Wage Payment and Collection Act).</p>
District of Columbia	<p>D.C. Human Rights Act</p> <p>D.C. Prohibition of Discrimination on the Basis of Tobacco Use Act</p> <p>D.C. Whistleblower Protection Act for Employees of D.C. Contractors</p> <p>D.C. Family and Medical Leave Act</p> <p>D.C. Parental Leave Act</p> <p>D.C. Employee Sick Leave Provision of Paid Leave</p> <p>D.C. Displaced Workers Protection Act</p> <p>D.C. Wage Payment and Collection Law</p> <p>D.C. Minimum Wage Act</p>

Florida	Florida Civil Rights Act Florida Omnibus AIDS Act Florida Wage Discrimination Law Florida Educational Equity Act Florida Discrimination Against Military Personnel Law Florida Workers Compensation Act Retaliation Provision Florida Fair Housing Act Florida False Claims Act Florida Whistleblower Act Florida Whistle-blower's Act Florida Minimum Wage Act
Georgia	Georgia Fair Employment Practices Act Georgia Equal Pay Act Georgia Age Discrimination in Employment Law Georgia Equal Employment for Persons with Disabilities Code Georgia Right to Arbitration for Sex Discrimination Claims Claims Arising under the Georgia Constitution.
Hawaii	Hawaii Fair Employment Practices Act Hawaii Discriminatory Practices Law Hawaii Equal Pay Law Hawaii Civil Rights Act Hawaii Whistleblowers' Protection Act Hawaii Dislocated Workers Law Hawaii Family Leave Law Hawaii Occupational Safety and Health Law
Idaho	Idaho Fair Employment Practices Act Idaho Civil Rights Law Idaho Human Rights Act Idaho Equal Pay Law Idaho Minimum Wage Law Idaho Wage Payment Law

Illinois	<ul style="list-style-type: none"> Illinois Human Rights Act Illinois Equal Pay Laws Illinois Whistleblower Act IL Wages for Women and Minors Act Illinois Religious Freedom Restoration Act Illinois Family Military Leave Act Illinois WARN Act Illinois Right to Privacy in the Workplace Act Illinois Union Employee Health and Benefits Protection Act Illinois Employment Contract Act Illinois Dispute Act Illinois Victims' Economic Security and Safety Act IL Nursing Mothers in the Workplace Act Cook County Human Rights Ordinance (if applicable) Chicago Human Rights Ordinance (if applicable)
Indiana	<ul style="list-style-type: none"> Indiana Civil Rights Law Indiana Age Discrimination Law Indiana Employment Discrimination Against Disabled Persons Law Indiana Equal Pay Law Indiana Military Leave and Re-Employment Rights Indiana Off Duty Use of Tobacco by Employees Law Indiana Whistleblower Protections for Employees of Private Employer that is Under Public Contract Indiana Military Family Leave Act Indiana Minimum Wage Law Indiana Wage Payment and Wage Claims Act Indiana Occupational Safety and Health Law Indiana Blacklisting Statute
Iowa	<ul style="list-style-type: none"> Iowa Civil Rights Act Iowa Law Related to Military Leave/Re-Employment Rights Iowa Minimum Wage Law Iowa Wage Payment Collection Law Iowa WARN Act
Kansas	<ul style="list-style-type: none"> Kansas Act Against Discrimination Kansas Equal Pay Law Kansas Age Discrimination in Employment Act Kansas Discrimination Against Military Personnel Act Kansas Discrimination Against Victims of Domestic Violence or Sexual Assault Act Kansas Whistleblower Protection Laws Kansas Minimum Wage and Maximum Hours Law Kansas WARN Act

Kentucky	Kentucky Civil Rights Act Kentucky Equal Opportunities Act Kentucky Wage Discrimination Because of Sex Law Kentucky Law Regarding Military Leave and Re-Employment Rights Kentucky Equal Pay Act Kentucky Leave of Absence to Adopt a Child Law Kentucky Minimum Wage Law Kentucky Occupational Safety and Health Law Kentucky Workers' Compensation Act Retaliation Provision
Louisiana	Louisiana Employment Discrimination Law Louisiana Whistleblower Protection Laws Louisiana Family and Medical Leave Laws Louisiana Payment of Employees Law Louisiana Workers' Compensation Act Retaliation Provision Louisiana General Tort Provision
Maine	Maine Human Rights Act Maine Equal Pay Law Maine Civil Rights Act Maine Protection from Harassment Law Maine Sexual Harassment Policies Law Maine Whistleblowers' Protection Act Maine Family Medical Leave Act Maine Family Sick Leave Law Maine Labor and Industry Earned Paid Leave Maine Wage Law Maine WARN Laws
Maryland	Maryland Anti-Discrimination Law Maryland Fair Employment Practices Act Maryland Reasonable Accommodations for Disabilities Due to Pregnancy Act Maryland Deployment of Family Members in the Armed Forces Act Maryland Equal Pay for Equal Work Law Maryland Medical Information Discrimination Law Maryland Maternity Leave Law Maryland Healthy Working Families Act Maryland Wage Payment and Collection Law Maryland Wage and Hour Law Maryland WARN Laws Maryland Occupational Safety and Health Act

Massachusetts	<p>Massachusetts Law Prohibiting Unlawful Discrimination</p> <p>Massachusetts Equal Pay Law, except for claims that cannot be waived related to inquiry or discussion of wages</p> <p>Massachusetts Right to be Free from Sexual Harassment Law</p> <p>Massachusetts Age Discrimination Law</p> <p>Massachusetts Equal Rights Law</p> <p>Massachusetts Equal Rights for the Elderly and Disabled Law</p> <p>Massachusetts Civil Rights Law</p> <p>Massachusetts False Claims Act</p> <p>Massachusetts Family and Medical Leave Laws and Small Necessities Act</p> <p>Massachusetts Earned Sick Time</p> <p>Massachusetts Labor and Industry Privacy Law</p> <p>By entering into this Agreement, you acknowledge that your release and waiver includes any future claims against the Company under Mass. Gen. Laws ch. 149, § 148 - the Massachusetts Wage Act. These claims include, but are not limited to, failure to pay earned wages, failure to pay overtime, failure to pay earned commissions, failure to timely pay wages, failure to pay accrued vacation or holiday pay, failure to furnish appropriate pay stubs, claims for improper wage deductions, and claims for failing to provide proper check-cashing facilities.</p>
Michigan	<p>Elliott-Larsen Civil Rights Act</p> <p>Michigan Persons with Disabilities Civil Rights Act</p> <p>Michigan Whistleblowers' Protection Act</p> <p>Michigan Minimum Wage Law</p> <p>Michigan Equal Pay Law</p> <p>Michigan Paid Medical Leave Act</p> <p>Michigan Payment of Wages and Fringe Benefits Law</p> <p>Sales Representatives Commission Act</p> <p>Michigan WARN Laws</p> <p>Bullard-Plawecki Employee Right to Know Act</p> <p>Social Security Number Privacy Act</p> <p>Internet Privacy Protection Act</p> <p>Michigan Occupational Safety and Health Act</p>

Minnesota	<p>Minnesota Human Rights Act</p> <p>Minnesota Equal Pay for Equal Work Law</p> <p>Minnesota Age Discrimination Statute</p> <p>Minnesota Nonwork Activities Law</p> <p>Minnesota Whistleblower Protection Law</p> <p>Minnesota Parenting Leave Act</p> <p>Minnesota Wage Law</p> <p>Minnesota WARN Laws</p> <p>Minnesota Personnel Record Access Laws</p> <p>Minnesota Whistleblowers' Protection Retaliation Provision</p> <p>Notwithstanding any conflicting terms of the Agreement (if applicable), if you were employed by the Company in Minnesota, then with respect to claims under the Minnesota Human Rights Act, you are provided fifteen calendar days after signing this Agreement to revoke it. To be effective, this revocation must be in writing and either (a) hand-delivered to the Company within fifteen calendar days of signing; or (b) sent by certified mail, return receipt requested, to the Company with a postmark within fifteen calendar days of signing. If this Agreement is revoked, you will not be entitled to the Severance Package described by the Agreement.</p>
Mississippi	<p>Mississippi Employment Protection Act</p> <p>Mississippi Military Leave/Re-Employment Rights Statute</p> <p>Mississippi Wage Law</p>
Missouri	<p>Missouri Human Rights Act</p> <p>Missouri Equal Pay for Women Act</p> <p>Missouri Minimum Wage Law</p> <p>Missouri Wage Payment Law</p> <p>Missouri Service Letter Statute</p>
Montana	<p>Montana Human Rights Act</p> <p>Montana Equal Pay Law</p> <p>Montana Wrongful Discharge from Employment Act</p> <p>Montana Maternity Leave Act</p> <p>Montana Wage Payment Law</p> <p>Montana Minimum Wage and Overtime Compensation Act</p> <p>Montana Limitation on Hours for Certain Employees</p> <p>Montana Blacklisting Statutes</p> <p>You agree that your termination was for good cause as defined by Montana Law.</p>

Nebraska	Nebraska Fair Employment Practices Act Nebraska Discrimination in Employment Act Nebraska Equal Pay Law Nebraska Laws Against Discrimination of Military Personnel Nebraska AIDS Discrimination Act Nebraska Genetic Information and Testing Law Nebraska Family Military Leave Nebraska Wage and Hour Act Waivable Claims under the Nebraska Wage Payment and Collection Act
Nevada	Nevada Fair Employment Practices Act (including age and sexual harassment claims, claims related to false pretenses, blacklisting, grafting, kickbacks, or lie detectors) Nevada Paid Leave
New Hampshire	New Hampshire Law Against Discrimination New Hampshire Whistleblowers' Protection Act New Hampshire Minimum Wage Law New Hampshire Protective Legislation Law New Hampshire Unemployment Compensation Prohibition Against Discrimination Law New Hampshire Uniform Trade Secrets Act New Hampshire Safety and Health of Employees Law New Hampshire Protective Legislation Law Non-Compete and Non-Piracy Sections
New Jersey	New Jersey Law Against Discrimination New Jersey Equal Pay Act New Jersey Civil Rights Law New Jersey Security and Financial Empowerment Act New Jersey Conscientious Employee Protection Act New Jersey Family Leave Act New Jersey Earned Sick Leave New Jersey Wage and Hour Law New Jersey WARN Laws New Jersey Workers' Compensation Law Retaliation Provisions
New Mexico	New Mexico Human Rights Act New Mexico Re-Employment of Persons in Armed Forces Act New Mexico Fraud Against Taxpayers Act New Mexico Promoting Financial Independence for Victims of Domestic Abuse Act New Mexico Employee Privacy Act

New York	New York State Human Rights Law New York Off Duty Conduct Law Activities Discrimination Law New York City Humans Rights Law (if applicable) New York City Commission on Human Rights Law (if applicable) New York City Earned Sick Time Act (if applicable) New York Wage Hour and Wage Payment Law New York Minimum Wage Law New York WARN New York Equal Pay Law New York State Civil Rights Law New York Family Leave Law New York Sick Leave Law New York State Worker Adjustment and Retraining Notification Act New York Workers' Compensation Law Retaliation Provisions
North Carolina	North Carolina Equal Employment Practices Act North Carolina Persons with Disabilities Protection Act North Carolina Civil Rights Law North Carolina Lawful Products Use Law North Carolina Hemoglobin/Genetic Information Anti-Discrimination Law North Carolina Retaliatory Employment Discrimination Act North Carolina Leave for Parent Involvement in Schools Law
North Dakota	North Dakota Human Rights Act North Dakota Equal Pay Law North Dakota Age Discrimination Law North Dakota Whistleblower Law North Dakota Wage and Hour Law North Dakota Wage Collection Law
Ohio	Ohio Civil Rights Act Ohio Equal Pay Act Ohio Whistleblowers' Protection Statute Ohio Pregnancy Discrimination/Maternity Leave Act Ohio Wage Payment Law Ohio Minimum Fair Wage Standards Act Ohio Miscellaneous Labor Provisions Ohio Workers' Compensation Retaliation Law Ohio Constitution

Oklahoma	<p>Oklahoma Anti-Discrimination Act</p> <p>Oklahoma Discriminatory Wages Law</p> <p>Oklahoma Genetic Nondiscrimination in Employment Act</p> <p>Oklahoma General Anti-Retaliation Law</p> <p>You acknowledge that this waiver is not a restraint as contemplated by Okla. Stat. Ann. tit. 40, § 199(B)(2), Oklahoma Law Governing Wages and Working Conditions, Oklahoma Minimum Wage Act, the Retaliation and Discrimination provision of the Oklahoma Administrative Workers' Compensation Act, and the Standards for Workplace Drug and Alcohol Testing Act.</p>
Oregon	<p>Oregon Anti-Discrimination Law</p> <p>Oregon Fair Employment Practices Act</p> <p>Oregon Unlawful Discrimination Against Persons with Disabilities Law</p> <p>Oregon Genetic Screening Law</p> <p>Unlawful Discrimination Against Injured Workers Law</p> <p>Oregon Unlawful Discrimination for Service in Uniformed Service Law</p> <p>Oregon Leave of Absence for State Service Law</p> <p>Oregon Military Family Leave Act</p> <p>Oregon Sick Leave</p> <p>Oregon Whistleblower Law</p> <p>Oregon Initiating or Aiding Administrative, Criminal, or Civil Proceeding Law</p> <p>Oregon Family Leave Act</p> <p>Oregon Hours of Labor and Wage Payment Law</p> <p>Oregon Minimum Wage Law</p> <p>Oregon WARN Act</p>
Pennsylvania	<p>Pennsylvania Human Relations Act</p> <p>Pennsylvania Equal Pay Law</p> <p>Pennsylvania Whistleblower Law</p> <p>Pennsylvania Pregnancy Guidelines of the Human Relations Comm.</p>
Rhode Island	<p>Rhode Island Fair Employment Practices Act</p> <p>Rhode Island Civil Rights Act</p> <p>Rhode Island Equal Pay Act</p> <p>Rhode Island Civil Rights of People with Disabilities Act</p> <p>Rhode Island Discrimination Based on Genetic Testing Law</p> <p>Rhode Island AIDS Discrimination Law</p> <p>Employment Discrimination Provision of Rhode Island Victim's Bill of Rights</p> <p>Rhode Island Military Family Relief Act</p> <p>Rhode Island Whistleblowers' Protection Act</p> <p>Rhode Island Parental and Family Medical Leave Act</p> <p>Rhode Island Healthy and Safe Families and Workplaces Act</p> <p>Rhode Island Minimum Wage Act</p> <p>Rhode Island Wage Payment Law</p>

South Carolina	South Carolina Human Affairs Law South Carolina Bill of Rights for Handicapped Persons Law South Carolina Military Re-Employment Rights Law South Carolina 's Unlawful Discrimination Against Union Members Law South Carolina Whistleblower Law South Carolina Workers' Compensation Retaliation Provision South Carolina Consumer Protection Code Wrongful Termination Provision South Carolina's Unlawful Termination of an Employee Replaced by an Authorized Alien Law South Carolina's Wrongful Demotion or Termination of an Employee for Complying with a Subpoena or Serving on a Jury Law South Carolina's Personnel Action Based on Use of Tobacco Products Outside of Workplace Prohibited Law
South Dakota	South Dakota Human Relations Act South Dakota Equal Pay Law South Dakota Genetic Information Bias Law South Dakota Wage Retaliation Law South Dakota Minimum Wage Law
Tennessee	Tennessee Human Rights Act Tennessee Equal Pay Law Tennessee Leave for Adoption, Pregnancy, Childbirth and Infant Nursing Law Tennessee Wage Protection Act Tennessee WARN Act Tennessee Occupational Safety and Health Act
Texas	Texas Commission on Human Rights Act Texas Equal Pay Law Texas Employment Discrimination Law Texas Disability Discrimination Law Texas State Wage Payment and Work Hour Laws Texas Payday Law Texas Minimum Wage Act
Utah	Utah Antidiscrimination Act Utah Genetic Testing Privacy Act Utah Occupational Safety and Health Act Utah Employment Relations and Collective Bargaining Act Utah Right to Work Law Utah Drug and Alcohol Testing Act Utah Protection of Activities in Private Vehicles Act Utah Employment Selection Procedures Act Utah's Local Government Entity/Drug-Free Workplace Policies Act

Vermont	Vermont Fair Employment Practices Act Vermont Genetic Testing Discrimination Law Vermont Whistleblower Laws Vermont Parental and Family Leave Act Vermont Earned Sick Time Vermont Occupational Safety and Health Act Vermont Minimum Wage Law Vermont Wage Law
Virginia	Virginians with Disabilities Act Virginia Human Rights Act Virginia Equal Pay Act Virginia Genetic Testing Law Virginia Right-to-Work Law Virginia Occupational Safety and Health Act Virginia Fraud Against Taxpayers Act Virginia Right to Work Law
Washington	Washington Law Against Discrimination Washington Age Discrimination Law Washington Equal Pay Law Washington Sex Discrimination Law Washington Family Leave Act Washington Family Care Act Washington Genetic Testing Protection Law Washington Whistleblower Protection Law Washington Wage, Hour, and Working Conditions Law Washington Wage Payment Law
West Virginia	West Virginia Human Rights Act West Virginia Equal Pay Act West Virginia's Prohibition Against Discrimination for Jury Duty Summons West Virginia Parental Leave Act West Virginia Minimum Wage Law West Virginia Workers' Compensation Act Retaliation Provisions West Virginia Consumer Credit and Protection Act Retaliation Provision Notwithstanding any conflicting terms of the Agreement (if applicable), if you were employed by the Company in West Virginia, then you are provided a minimum of 21 days in which to consider this Agreement, and are provided a 7 day revocation period under Section 77-6-1.1 – 77-6-8.1 of West Virginia's Human Rights Commission Bias Rules.

Wisconsin	Wisconsin Fair Employment Act Wisconsin AIDS Testing Discrimination Law Wisconsin Personnel Records Statute Wisconsin Family and Medical Leave Act Wisconsin Minimum Wage Law Wisconsin Wage Payments, Claims and Collections Law Wisconsin WARN Act Wisconsin Cessation of Health Care Benefits Law Wisconsin Employment Peace Act
Wyoming	Wyoming Fair Employment Practices Act Wyoming Equal Pay Law Wyoming Whistleblower Act Wyoming Minimum Wage Law Wyoming Occupational Health and Safety Act

Exhibit 31.1

CERTIFICATION

I, Peter A. Altabef, certify that:

1. I have reviewed this quarterly report on Form 10-Q of Unisys Corporation;
2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;
3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;
4. The registrant's other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:
 - a. Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

b. Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

c. Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and d. Disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting; and

5. The registrant's other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions):

a. All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information; and b. Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.

Date: May 8, 2024 August 6, 2024

	/s/ Peter A. Altabef
Name:	Peter A. Altabef
Title:	Chair and Chief Executive Officer

Exhibit 31.2

CERTIFICATION

I, Debra McCann, certify that:

1. I have reviewed this quarterly report on Form 10-Q of Unisys Corporation;
2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;
3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;
4. The registrant's other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:
 - a. Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

b. Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

c. Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and d. Disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting; and

5. The registrant's other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions):

a. All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information; and b. Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.

Date: May 8, 2024 August 6, 2024

/s/ Debra McCann
Name: Debra McCann
Title: Executive Vice President and Chief Financial Officer

Exhibit 32.1

CERTIFICATION OF PERIODIC REPORT

I, Peter A. Altabef, Chair and Chief Executive Officer of Unisys Corporation (the "Company"), certify, pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, 18 U.S.C. Section 1350, that:

(1) the Quarterly Report on Form 10-Q of the Company for the quarterly period ended March 31, 2024 June 30, 2024 (the "Report") fully complies with the requirements of Section 13(a) or Section 15(d) of the Securities Exchange Act of 1934 (15 U.S.C. 78m); and

(2) the information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

Date: May 8, 2024 August 6, 2024

/s/ Peter A. Altabef
Peter A. Altabef
Chair and Chief Executive Officer

A signed original of this written statement required by Section 906 has been provided to the Company and will be retained by the Company and furnished to the Securities and Exchange Commission or its staff upon request.

Exhibit 32.2

CERTIFICATION OF PERIODIC REPORT

I, Debra McCann, Executive Vice President and Chief Financial Officer of Unisys Corporation (the "Company"), certify, pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, 18 U.S.C. Section 1350, that:

(1) the Quarterly Report on Form 10-Q of the Company for the quarterly period ended **March 31, 2024** **June 30, 2024** (the "Report") fully complies with the requirements of Section 13(a) or Section 15(d) of the Securities Exchange Act of 1934 (15 U.S.C. 78m); and

(2) the information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

Date: **May 8, 2024** **August 6, 2024**

/s/ Debra McCann

Debra McCann

Executive Vice President and Chief Financial Officer

A signed original of this written statement required by Section 906 has been provided to the Company and will be retained by the Company and furnished to the Securities and Exchange Commission or its staff upon request.

DISCLAIMER

THE INFORMATION CONTAINED IN THE REFINITIV CORPORATE DISCLOSURES DELTA REPORT™ IS A COMPARISON OF TWO FINANCIALS PERIODIC REPORTS. THERE MAY BE MATERIAL ERRORS, OMISSIONS, OR INACCURACIES IN THE REPORT INCLUDING THE TEXT AND THE COMPARISON DATA AND TABLES. IN NO WAY DOES REFINITIV OR THE APPLICABLE COMPANY ASSUME ANY RESPONSIBILITY FOR ANY INVESTMENT OR OTHER DECISIONS MADE BASED UPON THE INFORMATION PROVIDED IN THIS REPORT. USERS ARE ADVISED TO REVIEW THE APPLICABLE COMPANY'S ACTUAL SEC FILINGS BEFORE MAKING ANY INVESTMENT OR OTHER DECISIONS.

©2024, Refinitiv. All rights reserved. Patents Pending.